US20120016004A1 - Compositions for inhibiting gene expression and uses thereof - Google Patents

Compositions for inhibiting gene expression and uses thereof Download PDF

Info

Publication number
US20120016004A1
US20120016004A1 US13/038,924 US201113038924A US2012016004A1 US 20120016004 A1 US20120016004 A1 US 20120016004A1 US 201113038924 A US201113038924 A US 201113038924A US 2012016004 A1 US2012016004 A1 US 2012016004A1
Authority
US
United States
Prior art keywords
oligonucleotide
seq
based compound
oligonucleotides
stranded rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/038,924
Inventor
Sudhir Agrawal
Ekambar Kandimalla
Mallikarjuna Putta
Tao Lan
Lakshmi Bhagat
Daqing Wang
Dong Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aceragen Inc
Original Assignee
Idera Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idera Pharmaceuticals Inc filed Critical Idera Pharmaceuticals Inc
Priority to US13/038,924 priority Critical patent/US20120016004A1/en
Assigned to IDERA PHARMACEUTICALS, INC reassignment IDERA PHARMACEUTICALS, INC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AGRAWAL, SUDHIR, BHAGAT, LAKSHMI, KANDIMALLA, EKAMBAR, LAN, TAO, PUTTA, MALLIKARJUNA, WANG, DAQING, YU, DONG
Assigned to IDERA PHARMACEUTICALS, INC reassignment IDERA PHARMACEUTICALS, INC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AGRAWAL, SUDHIR, BHAGAT, LAKSHMI, KANDIMALLA, EKAMBAR, LAN, TAO, PUTTA, MALLIKARJUNA, WANG, DAQING, YU, DONG
Publication of US20120016004A1 publication Critical patent/US20120016004A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C12N2310/152—Nucleic acids forming more than 2 strands, e.g. TFOs on a single-stranded target, e.g. fold-back TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers

Definitions

  • the present invention relates to compounds, compositions, and methods of use for the inhibition of gene expression and/or activity or for diagnosing, treating and/or preventing diseases and/or conditions that respond to the inhibition of gene expression and/or activity.
  • RNAi RNA inhibition
  • Zamecnik & Stephenson published the first demonstration of using antisense oligonucleotides as a means to inhibit translation of viral proteins (Zemecnik and Stephenson (1978) Proc. Natl. Acad. Sci. 75: 285-288), there has been great interest in utilizing oligonucleotide-based compounds to inhibit expression of genes. These initial efforts utilized single-stranded, unmodified oligodeoxyribonucleotides or oligoribonucleotides (Agrawal et al. (1992) Ann. NY Acad. Sci.
  • oligodoexyribonucleotides that incorporated nuclease-resistant phosphorothioate and/or methylphosphonate linkages (Agrawal et. al (1988) Proc. Natl. Acad. Sci. 85:7079-7083; Metelev & Agrawal U.S. Pat. No. 5,652,355; Metelev & Agrawal U.S. Pat. No. 6,143,881; Matsukura et al. (1987) Proc. Natl. Acad. Sci. 84:7706).
  • Ribozymes form stem loop structures and bind to an RNA target to mediate its cleavage directly (Cech, T. (1990) Ann. Rev. Biochem. 59:543). Ribozymes selectively bind to target-RNA and catalyze a transesterification or a hydrolysis reaction to cleave specific phosphodiester linkages in single-stranded RNA. If introduced into cells, ribozymes have the potential to bind to target-mRNA and inhibit translation of such mRNA.
  • RNA-interfering technologies (e.g. short interfering-RNA (siRNA), microRNA (miRNA), DNA-directed-RNAi (ddRNAi), and single-stranded RNAi (ssRNAi)) in mammalian systems.
  • RNAi refers to the process of post-transcriptional inhibition of gene expression using short oligonucleotides that are designed to hybridize to specific mRNA targets (Fire et al. (1998) Nature 391:806-811; Zamore et al. (2000) Cell, 101:25-33).
  • RNA-induced silencing complex RISC is thought to be present in cells to catalytically break down specific mRNA molecules.
  • ssRNAi single-stranded RNAi
  • RNAi technologies are able to selectively bind to target mRNA, such molecules have also been recognized to induce non-specific immune stimulation through interaction with TLR3 (Kleinman et al., (2008) Nature 452:591-597; De Veer et. al. (2005) Immun. Cell Bio. 83:224-228; Kariko et al. (2004) J. Immunol. 172:6545-6549).
  • This non-specific immune activation has raised questions as to the utility of RNAi technologies as pharmaceutical agents.
  • each of the antisense-based technologies has been used with some success, as a result of being based on oligonucleotides, each of these technologies has the inherent problem of being unstable in vivo and having the potential to produce off-target effects, for example unintended immune stimulation (Agrawal & Kandimalla (2004) Nature Biotech. 22:1533-1537).
  • these oligonucleotides appear to have the additional issue of inefficient, in vivo delivery to cells (Medarova et. al (2007) Nature Med. 13:372-377).
  • antisense oligonucleotide drug candidates only one such compound has been approved as a drug by the FDA. This antisense compound was approved for treating CMV, but has never been marketed as a product. Additionally, no ribozyme or siRNA drug candidate has yet been approved by the FDA.
  • RNA/DNA hybrid molecule (Metelev at al. (1994) Bioorg. Med. Chem. Lett. 4:2929-2934; Metelev U.S. Pat. No. 5,652,355; Metelev & Agrawal U.S. Pat. No. 6,143,881; Metelev& Agrawal U.S. Pat. No. 6,346,614; Metelev & Agrawal U.S. Pat. No. 6,683,167, Metelev & Agrawal U.S. Pat. No. 7,045,609).
  • polypyrimidine oligonucleotides that bind to double-stranded DNA or RNA targets.
  • Polypyrimidine oligonucleotides can bind to duplex DNA in the major groove through Hoogsteen hydrogen bonding and form triplex structures containing one polypurine and two polypyrimidine strands with T:A-T and C:G-C + base triplets (Moser, H. E. and Dervan, P. B. (1987) Science 238, 645-650; Cooney, et al(1988) Science 241, 456-459).
  • Intramolecular triplexes are also formed when the DNA homopurine and homopryrimidine strands melt and refold (Vasqueza, K. M. and Wilson, J. H. (1998) Trends Bioche. Sci. 23, 4-9).
  • the presence of a third strand introduces severe restrictions in the flexibility of the DNA, changing its ability to recognize specific proteins along the major groove (Shields, G. C., et al. (1997) Am. Chem. Soc., 119, 7463 -7469; Jimenez-Garcia, E., et al. (1998) J. Biol. Chem. 273, 24640-24648, resulting in an inhibiton of transcription and ultimately reduced gene expression.
  • Oligonucleotides that can sequence-specifically bind to double-stranded DNA or RNA can act as transcriptional/translational regulators and offered a promising antigene/antisense strategy to control the regulation of gene expression (Giovannangeli, C. and Helene, C. (1997) Antisense Nucleic Acid Drug Dev., 413; Giovannangeli, C., et al. (1996) Biochemistry 35, 10539; Maher, L. J., et al. (1992) Biochemistry 31, 70).
  • the conditions for forming stable triplexes are problematic because of limited base recognition and the non-physiologic acidic pH conditions required for protonation of cytosines in the triplex-forming oligonucleotides.
  • polypyrimidine oligonucleotides with inverted polarity linked Via a linker i.e. one sequence having polarity 5′ ⁇ 3′ followed by another sequence with 3′ ⁇ 5′ polarity, or vice versa
  • linker i.e. one sequence having polarity 5′ ⁇ 3′ followed by another sequence with 3′ ⁇ 5′ polarity, or vice versa
  • the sequence on one side of the inversion binds to polypurine strand of a duplex according to the triple helix code and the sequence on the other side will bind to the adjacently located polypurine site in the opposite strand of the duplex ( FIG. 14 ).
  • triple helix recognition can be extended by switching recognition from one strand of the duplex to the other and then back again, if desired and such target sequence stretch is available.
  • these oligonucleotides may also form D-loops with the duplex as shown in Diagram 1B.
  • the region of the first polarity may form triplex, while the inverted portion displaces a section of one strand of the duplex to result in a substitute duplex in the relevant region.
  • the switchback oligonucleotides are capable of significant duplex binding activity, these oligonucleotides may be useful to inactivate the disease causing and undesirable DNA or RNA that are in duplex form.
  • the composition of the molecules is limited to polypyrimidine sequences targeting polypurine sites of double-stranded RNA or DNA.
  • Such oligonucleotides containing complementary sequences attached through 3′-3′ or 5′-5′ linkages form parallel-stranded duplexes through Hoogsteen or reverse Hoogsteen base pairing.
  • a complementary polypyrimidine strand When a complementary polypyrimidine strand is available, they form triple helical structures ( FIG. 15 ).
  • the present invention is directed to compounds, compositions, and methods useful for modulating gene expression using oligonucleotide-based compounds comprising two or more single stranded antisense oligonucleotides that are linked through their 5′-ends to allow the presence of two or more accessible 3′-ends, which effectively inhibit or decrease gene expression.
  • oligonucleotide-based compounds comprising two or more single stranded antisense oligonucleotides that are linked through their 5′-ends to allow the presence of two or more accessible 3′-ends, which effectively inhibit or decrease gene expression.
  • the present inventors have discovered that such oligonucleotide compounds are more effective than non-linked antisense oligonucleotides.
  • compositions may comprise any synthetic oligonucleotide-based compounds according to the first aspect in a pharmaceutically or physiologically acceptable carrier.
  • the invention provides a method for inhibiting gene expression, the method comprising contacting a cell with a synthetic oligonucleotide-based compound according to the first aspect of the invention.
  • the invention provides a method for inhibiting gene expression in a mammal, the method comprising administering to the mammal a synthetic oligonucleotide-based compound according to the first aspect of the invention.
  • the invention provides a method for inhibiting a TLR-mediated, Bcl-2-mediated, EGFR-mediated, mdm2-mediated, MyD88-mediated, PCSK9-mediated, survivin-mediated or VEGF-mediated response in a mammal through administration of a synthetic oligonucleotide-based compound according to the first aspect of the invention wherein the oligonucleotides are complementary to one or more TLR, Bcl-2, EGFR, mdm2, MyD88, PCSK9, survivin or VEGF mRNA sequence.
  • the invention provides a method for inhibiting a TLR-mediated, Bcl-2-mediated, EGFR-mediated, mdm2-mediated, MyD88-mediated, PCSK9-mediated, survivin-mediated or VEGF-mediated response in a mammal though administration of a synthetic oligonucleotide-based compound according to the first aspect of the invention wherein the oligonucleotides are complementary to one or more TLR, Bcl-2, EGFR, mdm2, MyD88, PCSK9, survivin or VEGF mRNA sequence in combination with an antagonist of TLR, EGFR, mdm2, MyD88, PCSK9, survivin or VEGF protein activity.
  • the invention provides methods for inhibiting gene expression in a mammal, such methods comprising administering to the mammal an oligonucleotide-based compound according to the invention.
  • the mammal is a human.
  • the oligonucleotide-based compound according to the invention is administered to a mammal in need of inhibiting its immune response.
  • the invention provides methods for therapeutically treating a patient having a disease or disorder, such methods comprising administering to the patient an oligonucleotide-based compound according to the invention in a therapeutically effective amount.
  • the disease or disorder to be treated is cancer, an autoimmune disorder, infectious disease, airway inflammation, inflammatory disorders, skin disorder, allergy, asthma or a disease caused by a pathogen.
  • Pathogens include, without limitation, bacteria, parasites, fungi, viruses, viroids, and prions.
  • the invention provides methods for preventing a disease or disorder, such methods comprising administering to a subject at risk for developing the disease or disorder an oligonucleotide-based compound according to the invention in a pharmaceutically effective amount.
  • the disease or disorder to be prevented is cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, allergy, asthma or a disease caused by a pathogen.
  • Pathogens include, without limitation, bacteria, parasites, fungi, viruses, viroids, and prions.
  • the invention provides a method of preventing or treating a disorder, such methods comprises isolating cells capable of producing cytokines or chemokines including, but not limited to, immune cells, T-regulatory cells, B-cells, PBMCs, pDCs, and lymphoid cells; culturing such cells under standard cell culture conditions, treating such cells ex vivo with an oligonucleotide-based compound according to the first aspect of the invention such that the isolated cells produce or secrete decreased levels of cytokines or chemokines, and administering or re-administering the treated cells to a patient in need of therapy to inhibit cytokines and/or chemokines for the prevention and/or treatment of disease.
  • This aspect of the invention would be in accordance with standard adoptive cellular immunotherapy techniques to produce activated immune cells.
  • the invention provides a composition comprising a compound according to the first aspect of the invention and one or more vaccines, antigens, antibodies, cytotoxic agents, chemotherapeutic agents (both traditional chemotherapy and modem targeted therapies), kinase inhibitors, allergens, antibiotics, agonist, antagonist, antisense oligonucleotides, ribozymes, RNAi molecules, siRNA molecules, miRNA molecules, aptamers, proteins, gene therapy vectors, DNA vaccines, adjuvants, co-stimulatory molecules or combinations thereof.
  • FIG. 1A is a synthetic scheme for the linear synthesis of antisense oligonucleotides of the invention.
  • FIG. 1B is synthetic scheme for the parallel synthesis of antisense oligonucleotides of the invention.
  • FIGS. 2A and 2B depict the antisense activity of exemplary antisense oligonucleotides according to the invention in HEK293 cells expressing murine TLR9.
  • the data demonstrate the ability of antisense oligonucleotides according to the invention to inhibit TLR9 agonist activity in cells cultured and treated according to Example 2.
  • FIG. 2C depicts the antisense activity of exemplary antisense oligonucleotides according to the invention in HEK293 cells expressing murine TLR7.
  • the data demonstrate the ability of antisense oligonucleotides according to the invention to inhibit TLR7 agonist activity in cells cultured and treated according to Example 2.
  • FIG. 2D depicts the antisense activity of exemplary antisense oligonucleotides according to the invention in HEK293 cells expressing murine MyD88.
  • the data demonstrate the ability of antisense oligonucleotides according to the invention to inhibit MyD88 agonist activity in cells cultured and treated according to Example 2.
  • FIG. 3 depicts the antisense activity of exemplary antisense oligonucleotides according to the invention in mouse splenocytes.
  • the data demonstrate the ability of antisense oligonucleotides according to the invention to inhibit TLR9 mRNA translation, or protein synthesis, in splenocytes treated according to Example 2.
  • FIGS. 5A and 5B depict the activity of exemplary antisense oligonucleotides according to the invention to inhibit TLR9-induced IL-12 following in vivo administration according to Example 3.
  • the data demonstrate that administration of an exemplary TLR9 antisense oligonucleotide according to the invention can cause down-regulation of TLR9 expression in vivo and prevent the induction of IL-12 by a TLR9 agonist. More generally, the data demonstrate the ability of a TLR9 antisense oligonucleotide according to the invention to inhibit the induction of pro-inflammatory cytokines by a TLR9 agonist.
  • FIG. 5C depicts the duration of in vivo activity of exemplary antisense oligonucleotides according to the invention to inhibit MyD88-induced IL-12 following in vivo administration according to Example 3.
  • the data demonstrate that administration of an exemplary MyD88 antisense oligonucleotide according to the invention can cause down-regulation of MyD88 expression in vivo and prevent the induction of IL-12 by a TLR9 agonist for a longer duration than either linear antisense oligonucleotides or 3′-3′ linked antisense oligonucleotides.
  • the data demonstrate the ability of a MyD88 antisense oligonucleotide according to the invention to inhibit the induction of pro-inflammatory cytokines by a TLR agonist.
  • FIG. 6 depicts the activity of exemplary antisense oligonucleotides according to the invention to inhibit TLR9-induced IL-12 in a dose dependent manner following in vivo administration according to Example 3.
  • the data demonstrate that in vivo administration of a TLR9 antisense oligonucleotide according to the invention can cause down-regulation of TLR9 expression in vivo in a dose dependent manner and prevent the induction of IL-12 by a TLR9 agonist. More generally, the data demonstrate the ability of a TLR9 antisense oligonucleotide according to the invention to selectively inhibit the induction of pro-inflammatory cytokines by a TLR9 agonist.
  • FIG. 7 depicts the activity of exemplary antisense oligonucleotides according to the invention to inhibit TLR9-induced IL-12 in a time dependent manner following in vivo administration according to Example 3.
  • the data demonstrate that in vivo administration of a TLR9 antisense oligonucleotide according to the invention can cause down-regulation of TLR9 expression in vivo in a time dependent manner and prevent the induction of IL-12 by a TLR9 agonist for an extended period of time. More generally, the data demonstrate the ability of a TLR9 antisense oligonucleotide according to the invention to inhibit the induction of pro-inflammatory cytokines by a TLR9 agonist in a time dependent manner.
  • FIGS. 8A , 8 B, 8 C depict the antisense activity of exemplary antisense oligonucleotides according to the invention in murine J774 cells.
  • the data demonstrate the ability of antisense oligonucleotides according to the invention to inhibit TLR9 mRNA, transcription, translation, or protein synthesis, in murine J774 cells treated according to Example 2.
  • FIG. 8D depicts the antisense activity of exemplary antisense oligonucleotides according to the invention in human HeLa cells.
  • the data demonstrate the ability of antisense oligonucleotides according to the invention to inhibit VEGF mRNA transcription in human HeLa cells treated according to Example 2.
  • FIG. 9 depicts the antisense activity of exemplary antisense oligonucleotides according to the invention in human B cells.
  • the data demonstrate the ability of antisense oligonucleotides according to the invention to inhibit TLR9 mRNA translation, or protein synthesis, in human B cells treated according to Example 2.
  • FIG. 10 depicts the antisense activity of exemplary antisense oligonucleotides according to the invention in human pDCs.
  • the data demonstrate the ability of antisense oligonucleotides according to the invention to inhibit TLR9 mRNA translation, or protein synthesis, in human pDCs treated according to Example 2.
  • FIG. 11 depicts the activity of exemplary antisense oligonucleotides according to the invention to inhibit TLR9-induced IL-12 following in vivo administration according to Example 3.
  • the data demonstrate that in vivo administration of an exemplar TLR9 antisense oligonucleotide according to the invention can cause down-regulation of TLR9 expression in vivo and prevent the induction of IL-12 by a TLR9 agonist. More generally, the data demonstrate the ability of a TLR9 antisense oligonucleotide according to the invention to inhibit the induction of pro-inflammatory cytokines by a TLR9 agonist.
  • FIG. 12 depicts the antisense activity of exemplary antisense oligonucleotides according to the invention in HEK293 cells expressing mouse TLR7.
  • the data demonstrate the ability of antisense oligonucleotides according to the invention to inhibit TLR7 agonist activity in cells cultured and treated according to Example 2.
  • FIG. 13 depicts the selective binding and cleavage of exemplary antisense oligonucleotides according to the invention treated according to Example 4.
  • Lane 1 is substrate alone;
  • Lane 2 is T1 nuclease;
  • Lane 3 is 5′-AAUGCUUGUCUGUGCAGUCC-3′ (SEQ ID NO.
  • Lane 4 is 5′-AAUGCUUGUCUGUGCAGUCC-X-CCUGACGUGUCUGUUCGUAA-5′; Lane 5 is 3′-CCUGACGUGUCUGUUCGUAA-X-AAUGCUUGUCUGUGCAGUCC-3′ (SEQ ID 21); Lane 6 is 5′-AAUGCUUGUCUGUGCAGUCC-AAUGCUUGUCUGUGCAGUCC-3′; Lane 7 is 5% CUGU CoAoAoAoUoGoCoUoUoGoUoGoUoGoCoAoGoUoCoCoA CGAU -3′ (SEQ ID NO.
  • Lane 8 is dsRNA; and Lane 9 is 20-mer DNA antisense; wherein all sequences have phosphorothioate backbone except where indicated with an “o” (phosphodiester linkage); underlined nucleotides indicate 2′-O-methylribonucleotides.
  • oligonucleotides according to the invention provide an optimal structure for binding and cleavage by proteins and enzymes associated with RNAi-mediated inhibition of gene expression.
  • FIG. 14 shows switchback triplex-forming (A) and D-loop (B) modes of binding oligonucleotides with inverted polarity.
  • FIG. 15 shows parallel-stranded hairpin modes of oligonucleotides containing purine-pyrimidine strands attached covalently at either 3′-3′ or 5′-5′ ends.
  • FIG. 16 shows antisense mode of binding of the oligonucleotide-based compounds according to the invention.
  • the invention relates to the therapeutic and prophylactic use of novel antisense oligonucleotides to down-regulate gene expression.
  • novel antisense oligonucleotides to down-regulate gene expression.
  • Such molecules are useful, for example, in providing compositions for modulation of gene expression or for treating and/or preventing diseases and/or conditions that are capable of responding to modulation of gene expression in patients, subjects, animals or organisms.
  • 2′-O-substituted means substitution of the 2′ position of the pentose moiety with an —O-lower alkyl group containing 1-6 saturated or unsaturated carbon atoms (for example, but not limited to, 2′-O-methyl), or with an —O-aryl or allyl group having 2-6 carbon atoms, wherein such alkyl, aryl or allyl group may be unsubstituted or may be substituted, (for example, with 2′-O-methoxyethyl, ethoxy, methoxy, halo, hydroxyl, trifluoromethyl, cyano, nitro, acyl, acyloxy, alkoxy, carboxyl, carbalkoxyl, or amino groups); or with a hydroxyl, an amino or a halo group, but not with a 2′-H group.
  • an —O-lower alkyl group containing 1-6 saturated or unsaturated carbon atoms for example, but not limited to
  • the oligonucleotides of the invention include four or five 2′-O-alky nucleotides at their 5′ terminus, and/or four or five 2′-O-alky nucleotides at their 3′ terminus.
  • 3′ when used directionally, generally refers to a region or position in a polynucleotide or oligonucleotide 3′ (toward the 3′ end of the nucleotide) from another region or position in the same polynucleotide or oligonucleotide.
  • 3′ end generally refers to the 3′ terminal nucleotide of the component oligonucleotides.
  • “Two or more oligonucleotides linked at their 3′ ends” generally refers to a linkage between the 3′ terminal nucleotides of the oligonucleotides which may be directly via 5′, 3′ or 2′ hydroxyl groups, or indirectly, via a non-nucleotide linker. Such linkages may also be via a nucleoside, utilizing both 2′ and 3′ hydroxyl positions of the nucleoside. Such linkages may also utilize a functionalized sugar or nucleobase of a 3′terminal nucleotide.
  • 5′ when used directionally, generally refers to a region or position in a polynucleotide or oligonucleotide 5′ (toward the 5′end of the nucleotide) from another region or position in the same polynucleotide or oligonucleotide.
  • 5′ end generally refers to the 5′ terminal nucleotide of the component oligonucleotides.
  • “Two or more single-stranded antisense oligonucleotides linked at their 5′ ends” generally refers to a linkage between the 5′ terminal nucleotides of the oligonucleotides which may be directly via 5′, 3′ or 2′ hydroxyl groups, or indirectly, via a non-nucleotide linker. Such linkages may also be via a nucleoside, utilizing both 2′ and 3′ hydroxyl positions of the nucleoside. Such linkages may also utilize a functionalized sugar or nucleobase of a 5′terminal nucleotide.
  • oligonucleotides having one or two fewer nucleoside residues, or from one to several additional nucleoside residues are contemplated as equivalents of each of the embodiments described above.
  • accessible generally means when related to a compound according to the invention, that the relevant portion of the molecule is able to be recognized by the cellular components necessary to elicit an intended response to the compound.
  • agonist generally refers to a substance that binds to a receptor of a cell and induces a response.
  • An agonist often mimics the action of a naturally occurring substance such as a ligand.
  • antagonist generally refers to a substance that attenuates the effects of an agonist or ligand.
  • airway inflammation generally includes, without limitation, inflammation in the respiratory tract caused by allergens, including asthma.
  • allergen generally refers to an antigen or antigenic portion of a molecule, usually a protein, which elicits an allergic response upon exposure to a subject.
  • a subject is allergic to the allergen as indicated, for instance, by the wheal and flare test or any method known in the art.
  • a molecule is said to be an allergen even if only a small subset of subjects exhibit an allergic (e.g., IgE) immune response upon exposure to the molecule.
  • allergy generally includes, without limitation, food allergies, respiratory allergies and skin allergies.
  • antigen generally refers to a substance that is recognized and selectively bound by an antibody or by a T cell antigen receptor.
  • Antigens may include but are not limited to peptides, proteins, lipids, carbohydrates, nucleosides, nucleotides, nucleic acids, and combinations thereof. Antigens may be natural or synthetic and generally induce an immune response that is specific for that antigen.
  • autoimmune disorder generally refers to disorders in which “self” antigen undergo attack by the immune system. Such term includes, without limitation, lupus erythematosus, multiple sclerosis, type I diabetes mellitus, irritable bowel syndrome, Chron's disease, rheumatoid arthritis, septic shock, alopecia universalis, acute disseminated encephalomyelitis, Addison's disease, ankylosing spondylitis, antiphospholipid antibody syndrome, autoimmune hemolytic anemia, autoimmune hepatitis, Bullous pemphigoid, chagas disease, chronic obstructive pulmonary disease, hydrox disease, dermatomyositis, endometriosis, Goodpasture's syndrome, Graves' disease, Guillain-Barré syndrome, Hashimoto's disease, hidradenitis suppurativa, idiopathic thrombocytopenic purpura, interstitial cystitis, morphe
  • biological instability generally refers to a molecule's ability to be degraded and subsequently inactivated in vivo.
  • degradation results from exonuclease activity and/or endonuclease activity, wherein exonuclease activity refers to cleaving nucleotides from the 3′ or 5′ end of an oligonucleotide, and endonuclease activity refers to cleaving phosphodiester bonds at positions other than at the ends of the oligonucleotide.
  • cancer generally refers to, without limitation, any malignant growth or tumor caused by abnormal or uncontrolled cell proliferation and/or division. Cancers may occur in humans and/or mammals and may arise in any and all tissues. Treating a patient having cancer may include administration of a compound, pharmaceutical formulation or vaccine according to the invention such that the abnormal or uncontrolled cell proliferation and/or division, or metastasis is affected.
  • carrier generally encompasses any excipient, diluent, filler, salt, buffer, stabilizer, solubilizer, oil, lipid, lipid containing vesicle, microspheres, liposomal encapsulation, or other material for use in pharmaceutical formulations. It will be understood that the characteristics Of the carrier, excipient or diluent will depend on the route of administration for a particular application. The preparation of pharmaceutically acceptable formulations containing these materials is described in, for example, Remington's Pharmaceutical Sciences, 18 th Edition, ed. A. Gennaro, Mack Publishing Co., Easton, Pa., 1990.
  • co-administration generally refers to the administration of at least two different substances sufficiently close in time to modulate an immune response.
  • Co-administration refers to simultaneous administration, as well as temporally spaced order of up to several days apart, of at least two different substances in any order, either in a single dose or separate doses.
  • combination with generally means administering an oligonucleotide-based compound according to the invention and another agent useful for treating the disease or condition that does not abolish the activity of the compound in the course of treating a patient.
  • administration may be done in any order, including simultaneous administration, as well as temporally spaced order from a few seconds up to several days apart.
  • Such combination treatment may also include more than a single administration of the compound according to the invention and/or independently the other agent.
  • the administration of the compound according to the invention and the other agent may be by the same or different routes.
  • subject or “subject” or “patient” generally refers to a mammal, such as a human.
  • kinase inhibitor generally refers to molecules that antagonize or inhibit phosphorylation-dependent cell signaling and/or growth pathways in a cell.
  • Kinase inhibitors may be naturally occurring or synthetic and include small molecules that have the potential to be administered as oral therapeutics.
  • Kinase inhibitors have the ability to rapidly and specifically inhibit the activation of the target kinase molecules.
  • Protein kinases are attractive drug targets, in part because they regulate a wide variety of signaling and growth pathways and include many different proteins. As such, they have great potential in the treatment of diseases involving kinase signaling, including cancer, cardiovascular disease, inflammatory disorders, diabetes, macular degeneration and neurological disorders.
  • a non-limiting example of a kinase inhibitor is sorafenib.
  • linear synthesis generally refers to a synthesis that starts at one end of an oligonucleotide and progresses linearly to the other end. Linear synthesis permits incorporation of either identical or non-identical (in terms of length, base composition and/or chemical modifications incorporated) monomeric units into an oligonucleotide.
  • mammal is expressly intended to include warm blooded, vertebrate animals, including, without limitation, humans, non-human primates, rats, mice, cats, dogs, horses, cattle, cows, pigs, sheep and rabbits.
  • nucleoside generally refers to compounds consisting of a sugar, usually ribose, deoxyribose, pentose, arabinose or hexose, and a purine or pyrimidine base.
  • nucleotide generally refers to a nucleoside comprising a phosphorous-containing group attached to the sugar.
  • modified nucleoside or “nucleotide derivative” generally is a nucleoside that includes a modified heterocyclic base, a modified sugar moiety, or any combination thereof.
  • the modified nucleoside or nucleotide derivative is a non-natural pyrimidine or purine nucleoside, as herein described.
  • a modified nucleoside or nucleotide derivative, a pyrimidine or purine analog or non-naturally occurring pyrimidine or purine can be used interchangeably and refers to a nucleoside that includes a non-naturally occurring base and/or non-naturally occurring sugar moiety.
  • a base is considered to be non-natural if it is not guanine, cytosine, adenine, thymine or uracil and a sugar is considered to be non-natural if it is not ⁇ -ribo-furanoside or 2′-deoxyribo-furanoside.
  • modified oligonucleotide as used herein describes an oligonucleotide in which at least two of its nucleotides are covalently linked via a synthetic linkage, i.e., a linkage other than a phosphodiester linkage between the 5′ end of one nucleotide and the 3′ end of another nucleotide in which the 5′ nucleotide phosphate has been replaced with any number of chemical groups.
  • modified oligonucleotide also encompasses 2′-O,4′-C-methylene-b-D-ribofuranosyl nucleic acids, arabinose nucleic acids, substituted arabinose nucleic acids, hexose nucleic acids, peptide nucleic acids, morpholino, and oligonucleotides having at least one nucleotide with a modified base and/or sugar, such as a 2′-O-substituted, a 5-methylcytosine and/or a 3′-O-substituted ribonucleotide.
  • nucleic acid encompasses a genomic region or an RNA molecule transcribed therefrom. In some embodiments, the nucleic acid is mRNA.
  • linker generally refers to any moiety that can be attached to an oligonucleotide by way of covalent or non-covalent bonding through a sugar, a base, or the backbone.
  • the non-covalent linkage may be, without limitation, electrostatic interactions, hydrophobic interactions, n-stacking interactions, hydrogen bonding and combinations thereof.
  • Non-limiting examples of such non-covalent linkage includes Watson-Crick base pairing, Hoogsteen base pairing, and base stacking.
  • the linker can be used to attach two or more nucleosides or can be attached to the 5′ and/or 3′ terminal nucleotide in the oligonucleotide.
  • Such linker can be either a non-nucleotide linker or a nucleoside linker.
  • non-nucleotide linker generally refers to a chemical moiety, other than a linkage directly between two nucleotides that can be attached to an oligonucleotide by way of covalent or non-covalent bonding.
  • non-nucleotide linker is from about 2 angstroms to about 200 angstroms in length, and may be either in a cis or trans orientation.
  • nucleoside linkage generally refer to a chemical linkage to join two nucleosides through their sugars (e.g. 3′-3′, 2′-3′, 2′-5′, 3′-5′, 5′-5′) consisting of a phosphorous atom and a charged, or neutral group (e.g., phosphodiester, phosphorothioate, phosphorodithioate or methylphosphonate) between adjacent nucleosides.
  • sugars e.g. 3′-3′, 2′-3′, 2′-5′, 3′-5′, 5′-5′
  • neutral group e.g., phosphodiester, phosphorothioate, phosphorodithioate or methylphosphonate
  • oligonucleotide refers to a polynucleoside formed from a plurality of linked nucleoside units, which may include, for example, deoxyribonucleotides or ribonucleotides, synthetic or natural nucleotides, phosphodiester or modified linkages, natural bases or modified bases natural sugars or modified sugars, or combinations of these components.
  • the nucleoside units may be part of viruses, bacteria, cell debris or oligonucleotide-based compositions (for example, siRNA and microRNA).
  • Such oligonucleotides can also be obtained from existing nucleic acid sources, including genomic or cDNA, but are preferably produced by synthetic methods.
  • each nucleoside unit includes a heterocyclic base and a pentofuranosyl, trehalose, arabinose, 2′-deoxy-2′-substituted nucleoside, 2′-deoxy-2′-substituted arabinose, 2′-O-substitutedarabinose or hexose sugar group.
  • the nucleoside residues can be coupled to each other by any of the numerous known intemucleoside linkages.
  • Such intemucleoside linkages include, without limitation, phosphodiester, phosphorothioate, phosphorodithioate, methylphosphonate, alkylphosphonate, alkylphosphonothioate, phosphotriester, phosphoramidate, siloxane, carbonate, carboalkoxy, acetamidate, carbamate, morpholino, borano, thioether, bridged phosphoramidate, bridged methylene phosphonate, bridged phosphorothioate, and sulfone intemucleoside linkages.
  • oligonucleotide also encompasses polynucleosides having one or more stereospecific intemucleoside linkage (e.g., (Rp)- or (Sp)-phosphorothioate, alkylphosphonate, or phosphotriester linkages).
  • stereospecific intemucleoside linkage e.g., (Rp)- or (Sp)-phosphorothioate, alkylphosphonate, or phosphotriester linkages.
  • the terms “oligonucleotide” and “dinucleotide” are expressly intended to include polynucleosides and dinucleosides having any such intemucleoside linkage, whether or not the linkage comprises a phosphate group.
  • these intemucleoside linkages may be phosphodiester, phosphorothioate or phosphorodithioate linkages, or combinations thereof.
  • the nucleotides of the synthetic oligonucleotides are linked by at least one phosphorothioate internucleotide linkage.
  • the phosphorothioate linkages may be mixed Rp and Sp enantiomers, or they may be stereoregular or substantially stereoregular in either Rp or Sp form (see Iyer et al. (1995) Tetrahedron Asymmetry 6:1051-1054).
  • one or more of the oligonucleotides within the antisense compositions of the invention contain one or more 2′-O,4′-C-methylene-b-D-ribofuranosyl nucleic acids, wherein the ribose is modified with a bond between the 2′ and 4′ carbons, which fixes the ribose in the 3′-endo structural conformation.
  • an oligonucleotide that is complementary to a single-stranded RNA sequence means that the oligonucleotide forms a sufficient number of hydrogen bonds through Watson-Crick interactions of its nucleobases with nucelobases of the single-stranded RNA sequence to form a double helix with the single-stranded RNA sequence under physiological conditions. This is in contrast to oligonucleotides that form a triple helix with a double-stranded DNA or RNA through Hoogsteen hydrogen bonding.
  • complementary is intended to mean an oligonucleotide that binds to the nucleic acid sequence under physiological conditions, for example, by Watson-Crick base pairing (interaction between oligonucleotide and single-stranded nucleic acid) or by Hoogsteen base pairing (interaction between oligonucleotide and double-stranded nucleic acid) or by any other means, including in the case of an oligonucleotide, binding to RNA and causing pseudoknot formation. Binding by Watson-Crick or Hoogsteen base pairing under physiological conditions is measured as a practical matter by observing interference with the function of the nucleic acid sequence.
  • peptide generally refers to oligomers or polymers of amino acids that are of sufficient length and composition to affect a biological response, for example, antibody production or cytokine activity whether or not the peptide is a hapten.
  • peptide may include modified amino acids (whether or not naturally or non-naturally occurring), where such modifications include, but are not limited to, phosphorylation, glycosylation, pegylation, lipidization, and methylation.
  • pharmaceutically acceptable means a non-toxic material that does not interfere with the effectiveness of a compound according to the invention or the biological activity of a compound according to the invention.
  • physiologically acceptable refers to a non-toxic material that is compatible with a biological system such as a cell, cell culture, tissue, or organism.
  • a biological system such as a cell, cell culture, tissue, or organism.
  • the biological system is a living organism, such as a mammal, particularly a human.
  • prophylactically effective amount generally refers to an amount sufficient to prevent or reduce the development of an undesired biological effect.
  • terapéuticaally effective amount generally refers to an amount sufficient to affect a desired biological effect, such as a beneficial result, including, without limitation, prevention, diminution, amelioration or elimination of signs or symptoms of a disease or disorder.
  • a desired biological effect such as a beneficial result, including, without limitation, prevention, diminution, amelioration or elimination of signs or symptoms of a disease or disorder.
  • the total amount of each active component of the pharmaceutical composition or method is sufficient to show a meaningful patient benefit, for example, but not limited to, healing of chronic conditions characterized by immune stimulation.
  • a “pharmaceutically effective amount” will depend upon the context in which it is being administered.
  • a pharmaceutically effective amount may be administered in one or more prophylactic or therapeutic administrations.
  • the term refers to that ingredient alone.
  • the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.
  • treatment generally refers to an approach intended to obtain a beneficial or desired result, which may include alleviation of symptoms, or delaying or ameliorating a disease progression.
  • gene expression generally refers to process by which information from a gene is used in the synthesis of a functional gene product, which may be a protein.
  • the process may involve transcription, RNA splicing, translation, and post-translational modification of a protein, and may include mRNA, preRNA, ribosomal RNA, and other templates for protein synthesis.
  • the invention provides novel oligonucleotide-based compounds comprising two or more single-stranded antisense oligonucleotides linked at their 5′ ends, wherein the compounds have two or more accessible 3′ ends.
  • the linkage at the 5′ ends of the component oligonucleotides is independent of the other oligonucleotide linkages and may be directly via 5′, 3′ or 2′ hydroxyl groups, or indirectly, via a non-nucleotide linker or a nucleoside, utilizing either the 2′ or 3′ hydroxyl positions of the nucleoside.
  • Linkages may also utilize a functionalized sugar or nucleobase of a 5′ terminal nucleotide.
  • Oligonucleotide-based compounds according to the invention comprise two identical or different sequences conjugated at their 5′-5′ ends via a phosphodiester, phosphorothioate or non-nucleoside linker (Diagram 3). Such compounds comprise 15 to 27 nucleotides that are complementary to specific portions of mRNA targets of interest for antisense down regulation of gene product. Oligonucleotide-based compounds according to the invention that comprise identical sequences are able to bind to a specific mRNA via Watson-Crick hydrogen bonding interactions and inhibit protein expression ( FIG. 16 ). Oligonucleotide-based compounds according to the invention that comprise different sequences are able to bind to two or more different regions of one or more mRNA target and inhibit protein expression.
  • Such compounds are comprised of heteronucleotide sequences complementary to target mRNA and form stable duplex structures through Watson-Crick hydrogen bonding. Surprisingly, such sequences containing two free 3′-ends (5′-5′-attached antisense) are more potent inhibitors of gene expression than those containing a single free 3′-end or no free 3′-end.
  • Oligonucleotide-based compounds according to the invention are useful in treating and/or preventing diseases wherein inhibiting a gene expression would be beneficial.
  • Oligonucleotide-based compounds according to the invention include, but are not limited to, antisense oligonucleotides comprising naturally occurring nucleotides, modified nucleotides, modified oligonucleotides and/or backbone modified oligonucleotides.
  • antisense oligonucleotides that inhibit the translation of mRNA encoded proteins may produce undesired biological effects, including but not limited to insufficient antisense activity, inadequate bioavailability, suboptimal pharmacokinetics or pharmacodynamics, unintended immune stimulation, off target activity, and biologic instability.
  • an antisense oligonucleotide according to the invention requires many considerations beyond simple design of a molecule that is complementary to the target RNA sequence.
  • preparation of antisense oligonucleotides according to the invention is intended to incorporate changes necessary to limit secondary structure interference with antisense activity, enhance the oligonucleotide's target specificity, minimize interaction with binding or competing factors (for example, proteins), optimize cellular uptake, bioavailability, pharmacokinetics, and pharmacodynamics, and/or inhibit, prevent or suppress immune cell activation.
  • oligonucleotide-based compounds of the invention may be described by the following formula
  • L is a nucleotide linker or non-nucleotide linker; N1-N8, at each occurrence, is independently a nucleotide or nucleotide derivative; Nm and Nn, at each occurrence, are independently a nucleotide or nucleotide derivative; and wherein m and n are independently numbers from 0 to about 40.
  • Representative non-nucleotide linkers are set forth in Table 1.
  • Non-Nucleotide Linkers Glycerol (1,2,3-Propanetriol) 1,2,4-Butanetriol 2-(hydroxymethyl)-1,3-propanediol 2-(hydroxymethyl)1,4-butanediol 1,3,5-Pentanetriol 1,1,1-Tris(hydroxymethyl)ethane 1,1,1-Tris(hydroxymethyl)nitromethane 1,1,1-Tris(hydroxymethyl)propane 1,2,6-Hexanetriol 3-Methyl-1,3,5-pentanetriol 1,2,3-Heptanetriol 2-Amino-2-(hydroxymethyl)-1,3-propanediol N-[Tris(hydroxymethyl)methyl]acrylamide cis-1,3,5-Cyclohexanetriol cis-1,3,5-Tri(hydroxymethyl)cyclohexane 1,3,5,-Trihydroxyl-benzene 3,5,-Di(hydroxymethyl)phenol 1,3,5,-Tri(hydroxymethyl)benzene 1,3-D
  • the small molecule linker is glycerol or a glycerol homolog of the formula HO—(CH 2 ) 0 —CH(OH)—(CH 2 ) p —OH, wherein o and p independently are integers from 1 to about 6, from 1 to about 4 or from 1 to about 3.
  • the small molecule linker is a derivative of 1,3-diamino-2-hydroxypropane.
  • Some such derivatives have the formula HO—(CH 2 ) m C(O)NH—CH 2 —CH(OH)—CH 2 —NHC(O)—(CH 2 ) m —OH, wherein m is an integer from 0 to about 10, from 0 to about 6, from 2 to about 6 or from 2 to about 4.
  • Some non-nucleotide linkers according to the invention permit attachment of more than two oligonucleotide-based compounds of the invention.
  • the small molecule linker glycerol has three hydroxyl groups to which such oligonucleotides may be covalently attached.
  • Some oligonucleotide-based compounds of the invention therefore, comprise two or more oligonucleotides linked to a nucleotide or a non-nucleotide linker. Such oligonucleotides according to the invention are referred to as being “branched”.
  • Oligonucleotide-based compounds according to the invention may comprise at least two linked antisense oligonucleotides with two or more free 3′ ends. Some of the ways in which two or more oligonucleotides can be linked are shown in Table 2.
  • L is a linker or a nucleotide linkage and Domain A and/or Domain B are antisense oligonucleotides that are designed to selectively hybridize to the same target RNA sequence or different target RNA sequences.
  • L is a linker and Domain A and/or Domain B and/or Domain C are antisense oligonucleotides that are designed to selectively hybridize to the same target RNA sequence or different target RNA sequences.
  • Domain A and/or Domain B and/or Domain C of Formulas II and/or III are antisense oligonucleotides that are designed to selectively hybridize to the same target RNA sequence.
  • Domain A and/or Domain B and/or Domain C can be designed to hybridize to the same region on the target RNA sequence or to different regions of the same target RNA sequence.
  • Domain A, Domain B, and Domain C are independently RNA or DNA-based oligonucleotides.
  • the oligonucleotides comprise mixed backbone oligonucleotides.
  • one or more of Domain A and/or Domain B and/or Domain C of Formula IV is an antisense oligonucleotide that is designed to selectively hybridize to one target RNA sequence and one or more of the remaining Domain A and/or Domain B and/or Domain C is an antisense oligonucleotide that is designed to selectively hybridized to a different target RNA sequence.
  • one or more of Domain A, Domain B or Domain C of Formula IV is an antagonist of a cell-surface or intracellular receptor.
  • the antagonist is a TLR antagonist.
  • one or more of Domain A and/or Domain B and/or Domain C of Formula II, III, IV and/or V is an RNA-based oligonucleotide hybridized to a complimentary RNA-based oligonucleotide such that the domain comprises an siRNA molecule.
  • the component oligonucleotides of oligonucleotide-based compounds of the invention are at least 14 nucleotides in length, but are preferably 15 to 40 nucleotides long, preferably 20 to 30 nucleotides in length.
  • the component oligonucleotides of the oligonucleotide-based compounds of the invention can independently be 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40 nucleotides in length.
  • These oligonucleotides can be prepared by the art recognized methods such as phosphoramidate or H-phosphonate chemistry which can be carried out manually or by an automated synthesizer.
  • the synthetic antisense oligonucleotides of the invention may also be modified in a number of ways without compromising their ability to hybridize to mRNA. Such modifications may include at least one internucleotide linkage of the oligonucleotide being an alkylphosphonate, phosphorothioate, phosphorodithioate, methylphosphonate, phosphate ester, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate hydroxyl, acetamidate or carboxymethyl ester or a combination of these and other internucleotide linkages between the 5′ end of one nucleotide and the 3′ end of another nucleotide in which the 5′ nucleotide phosphodiester linkage has been replaced with any number of chemical groups.
  • the synthetic antisense oligonucleotides of the invention may comprise combinations of intemucleotide linkages.
  • U.S. Pat. No. 5,149,797 describes traditional chimeric oligonucleotides having a phosphorothioate core region interposed between methylphosphonate or phosphoramidate flanking regions.
  • U.S. Pat. No. 5,652,356 discloses “inverted” chimeric oligonucleotides comprising one or more nonionic oligonucleotide region (e.g.
  • alkylphosphonate and/or phosphoramidate and/or phosphotriester intemucleoside linkage flanked by one or more region of oligonucleotide phosphorothioate.
  • Various synthetic antisense oligonucleotides with modified intemucleotide linkages can be prepared according to standard methods.
  • the phosphorothioate linkages may be mixed Rp and Sp enantiomers, or they may be made stereoregular or substantially stereoregular in either Rp or Sp form.
  • oligonucleotide-based compounds of the invention include those that are intemal or at the end(s) of the oligonucleotide molecule and include additions to the molecule of the intemucleoside phosphate linkages, such as cholesterol, cholesteryl, or diamine compounds with varying numbers of carbon residues between the amino groups and terminal ribose, deoxyribose and phosphate modifications which cleave, or crosslink to the opposite chains or to associated enzymes or other proteins which bind to the genome.
  • intemucleoside phosphate linkages such as cholesterol, cholesteryl, or diamine compounds with varying numbers of carbon residues between the amino groups and terminal ribose, deoxyribose and phosphate modifications which cleave, or crosslink to the opposite chains or to associated enzymes or other proteins which bind to the genome.
  • modified oligonucleotides include oligonucleotides with a modified base and/or sugar such as 2′-O,4′-C-methylene-b-D-ribofuranosyl, or arabinose instead of ribose, or a 3′,5′-substituted oligonucleotide having a sugar which, at both its 3′ and 5′ positions, is attached to a chemical group other than a hydroxyl group (at its 3′ position) and other than a phosphate group (at its 5′ position).
  • a modified base and/or sugar such as 2′-O,4′-C-methylene-b-D-ribofuranosyl, or arabinose instead of ribose
  • modifications to sugars of the oligonucleotide-based compounds of the invention include modifications to the 2′ position of the ribose moiety which include but are not limited to 2′-O-substituted with an —O-alkyl group containing 1-6 saturated or unsaturated carbon atoms, or with an —O-aryl, or —O-allyl group having 2-6 carbon atoms wherein such —O-alkyl, —O-aryl or —O-allyl group may be unsubstituted or may be substituted, for example with halo, hydroxyl, trifluoromethyl, cyano, nitro, acyl, acyloxy, alkoxy, carboxy, carbalkoxyl or amino groups. None of these substitutions are intended to exclude the presence of other residues having native 2′-hydroxyl group in the case of ribose or 2′ H— in the case of deoxyribose.
  • the oligonucleotides-based compounds according to the invention can comprise one or more ribonucleotides.
  • U.S. Pat. No. 5,652,355 discloses traditional hybrid oligonucleotides having regions of 2′-O-substituted ribonucleotides flanking a DNA core region.
  • 5,652,356 discloses an “inverted” hybrid oligonucleotide that includes an oligonucleotide comprising a 2′-O-substituted (or 2′ OH, unsubstituted) RNA region which is in between two oligodeoxyribonucleotide regions, a structure that “inverted relative to the “traditional” hybrid oligonucleotides.
  • Non-limiting examples of particularly useful oligonucleotides of the invention have 2′-O-alkylated ribonucleotides at their 3′, 5′, or 3′ and 5° termini, with at least four, and in some exemplary embodiments five, contiguous nucleotides being so modified.
  • Non-limiting examples of 2′-O-alkylated groups include 2′-O-methyl, 2′-O-ethyl, 2′-O-propyl, 2′-O-butyls and 2′-O-methoxy-ethyl.
  • the oligonucleotide-based compounds of the invention may conveniently be synthesized using an automated synthesizer and phosphoramidite approach as schematically depicted in FIG. 1B , and further described in Example 1.
  • the oligonucleotide-based compounds of the invention are synthesized by a linear synthesis approach (see FIG. 1A ).
  • An alternative mode of synthesis is “parallel synthesis”, in which synthesis proceeds outward from a central linker moiety (see FIG. 1 ).
  • a solid support attached linker can be used for parallel synthesis, as is described in U.S. Pat. No. 5,912,332.
  • a universal solid support such as phosphate attached controlled pore glass support can be used.
  • Parallel synthesis of the oligonucleotide-based compounds of the invention has several advantages over linear synthesis: (1) parallel synthesis permits the incorporation of identical monomeric units; (2) unlike in linear synthesis, both (or all) the monomeric units are synthesized at the same time, thereby the number of synthetic steps and the time required for the synthesis is the same as that of a monomeric unit; and (3) the reduction in synthetic steps improves purity and yield of the final immune modulatory oligoribonucleotide product.
  • the oligonucleotide-based compounds of the invention may conveniently be deprotected with concentrated ammonia solution or as recommended by the phosphoramidite supplier, if a modified nucleoside is incorporated.
  • the product oligonucleotide-based compounds is preferably purified by reversed phase HPLC, detritylated, desalted and dialyzed.
  • oligonucleotide-based compounds of the invention are shown in SEQ ID NO. 1 through SEQ ID NO. 175 in Table 3 below.
  • the oligonucleotide-based compounds have phosphorothioate (PS) linkages, but may also include phosphodiester (o) linkages.
  • PS phosphorothioate
  • o phosphodiester
  • TLR9 RNA (m/h) 3′-ACCGACAAGGACUUCAGACA-Y-ACAGAC-3′ 3′-(SEQ ID NO. 131)-5′ - AS131 X-5′-(SEQ ID NO. 131)-3′ 132/ TLR9 RNA (m/h) 3′-ACCGACAAGGACUUCAGACA-X3- 3′-(SEQ ID NO. 132)-5′- AS132 ACAGACUUCAGGAACAGCCA-3′ X-5′-(SEQ ID NO. 132)-3′ 133/ TLR9 RNA (m/h) 3′-ACCGACAAGGACUUCAGACA-X1- 3′-(SEQ ID NO.
  • TLR9 RNA 3′-AACCGACAAGGACUUCAGA CA -X- 3′-(SEQ ID NO. 141)-5′- AS141 AC AGACUUCAGGAACAGCCAA-3′ X-5′-(SEQ ID NO. 141)-3′ 142/ TLR9 RNA (m) 3′- AAC CGACAAGGACUUCAGACA-X- 3′-(SEQ ID NO. 142)-5′- AS142 ACAGACUUCAGGAACAGC CAA -3′ X-5′-(SEQ ID NO. 142)-3′ 143/ TLR9/ RNA/ 3′-ACCGACAAGGACUUCAGACA-Y- 3′-(SEQ ID NO.
  • the composition lacks immune stimulatory activity of certain oligonucleotide compositions. It is known that certain oligonucleotide-based compositions can possess immune stimulatory motifs. This immune stimulatory activity requires the oligonucleotides to be non-linked or linked at their 3′ ends.
  • oligonucleotide-based compositions according to the invention utilizing a linkage at the 5′ ends, as set forth in Formulas I, II, III or IV, that any inherent immune stimulatory activity is suppressed, as compared to the immune stimulatory activity that would be present in non-linked or oligonucleotide-based compositions linked at their 3′ ends or in a 2′-5′ fashion.
  • the structure of the oligonucleotide-based compound according to the invention provides an optimal compound for binding by enzymes and,other proteins that are involved in RNaseH-mediated and/or RNAi-mediated inhibition of gene expression.
  • the oligonucleotide-based compounds according to the invention can be selectively bound by RNaseH, Dicer, Argonaut, RISC or other proteins that are involved in RNAi-mediated inhibition of gene expression. This selective binding provides optimal oligonucleotide-based compounds for utilizing RNaseH-mediated and/or RNAi-mediated inhibition of gene expression in vitro and in vivo.
  • the invention provides pharmaceutical formulations comprising an oligonucleotide-based compound according to the invention and a physiologically acceptable carrier.
  • the invention provides a method for inhibiting gene expression, the method comprising contacting a cell with a synthetic oligonucleotide-based compound according to the first aspect of the invention.
  • the invention provides a method for inhibiting gene expression in a mammal, the method comprising administering to the mammal a synthetic oligonucleotide-based compound according to the first aspect of the invention.
  • the synthetic oligonucleotide-based compounds according to the first aspect of the invention can inhibit the expression and activity of certain genes related to cellular proliferation, including but not limited to oncogenes.
  • the invention provides a method of inhibiting a TLR-mediated, Bcl-2-mediated, EGFR-mediated, mdm2-mediated, MyD88-mediated, PCSK9-mediated, survivin-mediated or VEGF-mediated response in a mammal though administration of a synthetic oligonucleotide-based compound according to the first aspect of the invention wherein the oligonucleotides are complementary to one or more mRNA sequence encoding a molecule involved in TLR signaling or Bcl-2, EGFR, mdm2, MyD88, PCSK9, survivin or VEGF activity.
  • the invention provides a method of inhibiting a TLR-mediated, Bcl-2-mediated, EGFR-mediated, mdm2-mediated, MyD88-mediated, PCSK9-mediated, survivin-mediated or VEGF-mediated response in a mammal through administration of a synthetic oligonucleotide-based compound according to the first aspect of the invention wherein the oligonucleotides are complementary to one or more TLR, Bcl-2, EGFR, mdm2, MyD88, PCSK9, survivin or VEGF mRNA sequence in combination with an antagonist of TLR, Bcl-2, EGFR, mdm2, MyD88, PCSK9, survivin or VEGF protein activity.
  • the invention provides methods for inhibitinggene expression in a mammal, such methods comprising administering to the mammal an oligonucleotide-based compound according to the invention.
  • the mammal is a human.
  • the oligonucleotide-based compound according to the invention is administered to a mammal in need of inhibiting its immune response.
  • the invention provides methods for therapeutically treating a patient having a disease or disorder, such methods comprising administering to the patient an oligonucleotide-based compound according to the invention in a therapeutically effective amount.
  • the disease or disorder to be treated is cancer, an autoimmune disorder, infectious disease, airway inflammation, inflammatory disorders, allergy, asthma, or a disease caused by a pathogen.
  • Pathogens include bacteria, parasites, fungi, viruses, viroids, and prions.
  • the invention provides methods for preventing a disease or disorder, such methods comprising administering to a subject at risk for developing the disease or disorder an oligonucleotide-based compound according to the invention in a pharmaceutically effective amount.
  • a subject is considered at risk for developing a disease or disorder if the subject has been or may be or will be exposed to an etiologic agent of the disease or disorder or is genetically predispositioned to contract the disease or disorder.
  • the disease or disorder to be prevented is cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, allergy, asthma, or a disease caused by a pathogen.
  • Pathogens include bacteria, parasites, fungi, viruses, viroids, and prions.
  • the invention provides a method of preventing or treating a disorder, such methods comprises isolating cells capable of producing cytokines or chemokines including, but not limited to, immune cells, T-regulatory cells, B-cells, PBMCs, pDCs, and lymphoid cells; culturing such cells under standard cell culture conditions, treating such cells ex vivo with an oligonucleotide-based compound according to the first aspect of the invention such that the isolated cells produce or secrete decreased levels of cytokines or chemokines, and administering or re-administering the treated cells to a patient in need of therapy to inhibit cytokines and/or chemokine for the prevention and/or treatment of disease.
  • This aspect of the invention would be in accordance with standard adoptive cellular immunotherapy techniques to produce activated immune cells.
  • the cells capable of producing cytokines or chemokines may be isolated from subjects with or without a disease or disorder. Such isolation may include identification and selection and could be performed using standard cell isolation procedures, including those set forth in the specific examples below. Such isolated cells would be cultured according to standard cell culturing procedures and using standard cell culture conditions, which may include the culturing procedures and conditions set forth in the specific examples below.
  • the isolated cells would be cultured in the presence of at least one oligonucleotide-based compound according to the invention, in an amount and for a time period sufficient to suppress or inhibit the production and/or secretion of cytokines and/or chemokines as compared to the isolated cells cultured in the absence of such one or more oligonucleotide-based compound according to the invention.
  • Such time may be from minutes, to hours, to days.
  • Such isolated and treated cells may find use following re-administration to the donor or administration to a second patient, wherein such donor or second patient are in need of suppressed or inhibited production and/or secretion of cytokines and/or chemokines.
  • re-administration to a donor or administration to a second patient having cancer an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, allergy, asthma, or a disease caused by a pathogen.
  • Such re-administration or administration may be accomplished using various modes, including catheter or injection administration or any other effective route.
  • This aspect of the invention may also find use in patients who may have a limited or incomplete ability to mount an immune response or are immune compromised (e.g. patient infected with HIV and bone marrow transplant patients).
  • the invention provides a composition comprising a compound according to the first aspect of the invention and one or more vaccines, antigens, antibodies, cytotoxic agents, chemotherapeutic agents (both traditional chemotherapy and modem targeted therapies), kinase inhibitors, allergens, antibiotics, agonist, antagonist, antisense oligonucleotides, ribozymes, RNAi molecules, siRNA molecules, miRNA molecules, aptamers, proteins, gene therapy vectors, DNA vaccines, adjuvants, co-stimulatory molecules or combinations thereof.
  • the oligonucleotide-based compound according to the invention can variously act by producing direct gene expression modulation effects alone and/or in combination with any other agent useful for treating or preventing the disease or condition that does not diminish the gene expression modulation effect of the oligonucleotide-based compound according to the invention.
  • the agent(s) useful for treating or preventing the disease or condition includes, but is not limited to, vaccines, antigens, antibodies, preferably monoclonal antibodies, cytotoxic agents, kinase inhibitors, allergens, antibiotics, siRNA molecules, antisense oligonucleotides, TLR antagonist (e.g.
  • TLR3 and/or TLR7 and/or antagonists of TLR8 and/or antagonists of TLR9 include chemotherapeutic agents (both traditional chemotherapy and modem targeted therapies), targeted therapeutic agents, activated cells, peptides, proteins, gene therapy vectors, peptide vaccines, protein vaccines, DNA vaccines, adjuvants, and co-stimulatory molecules (e.g. cytokines, chemokines, protein ligands, trans-activating factors, peptides or peptides comprising modified amino acids), or combinations thereof.
  • the oligonucleotide-based compound according to the invention may be administered in combination with one or more chemotherapeutic compound, targeted therapeutic agent and/or monoclonal antibody.
  • the agent can include DNA vectors encoding for antigen or allergen.
  • the oligonucleotide-based compound according to the invention can be administered in combination with other compounds (for example lipids or liposomes) to enhance the specificity or magnitude of the gene expression modulation of the oligonucleotide-based compound according to the invention.
  • administration of oligonucleotide-based compounds according to the invention can be by any suitable route, including, without limitation, parenteral, mucosal delivery, oral, sublingual, transdermal, topical, inhalation, intranasal, aerosol, intraocular, intratracheal, intrarectal, vaginal, by gene gun, dermal patch or in eye drop or mouthwash form.
  • Administration of the therapeutic compositions of oligonucleotide-based compounds according to the invention can be carried out using known procedures using an effective amount and for periods of time effective to reduce symptoms or surrogate markers of the disease.
  • an effective amount of an oligonucleotide-based compound according to the invention for treating a disease and/or disorder could be that amount necessary to alleviate or reduce the symptoms, or delay or ameliorate a tumor, cancer, or bacterial, viral or fungal infection.
  • an effective amount of an oligonucleotide-based compound according to the invention is an amount sufficient to achieve the desired modulation as compared to the gene expression in the absence of the oligonucleotide-based compound according to the invention.
  • the effective amount for any particular application can vary depending on such factors as the disease or condition being treated, the particular oligonucleotide being administered, the size of the subject, or the severity of the disease or condition.
  • One of ordinary skill in the art can empirically determine the effective amount of a particular oligonucleotide without necessitating undue experimentation.
  • the therapeutic composition When administered systemically, the therapeutic composition is preferably administered at a sufficient dosage to attain a blood level of oligonucleotide-based compound according to the invention from about 0.0001 micromolar to about 10 micromolar. For localized administration, much lower concentrations than this may be effective, and much higher concentrations may be tolerated.
  • a total dosage of oligonucleotide-based compound according to the invention ranges from about 0.001 mg per patient per day to about 200 mg per kg body weight per day. In certain embodiments, the total dosage may be 0.08, 0.16, 0.32, 0.48, 0.32, 0.64, 1, 10 or 30 mg/kg body weight administered daily, twice weekly or weekly. It may be desirable to administer simultaneously, or sequentially a therapeutically effective amount of one or more of the therapeutic compositions of the invention to an individual as a single treatment episode.
  • the methods according to this aspect of the invention are useful for model studies of gene expression.
  • the methods are also useful for the prophylactic or therapeutic treatment of human or animal disease.
  • the methods are useful for pediatric and veterinary inhibition of gene expression applications.
  • oligonucleotide-based compounds of the invention were chemically synthesized using phosphoramidite chemistry on automated DNA/RNA synthesizer.
  • TAC protected (Except U) 2′-O-TBDMS RNA monomers, A, G, C and U, were purchased from Sigma-Aldrich. 7-deaza-G, inosine and loxoribine monomers were purchased from ChemGenes Corporation. 0.25M 5-ethylthio-1H-tetrazole, PAC-anhydride Cap A and Cap B were purchased from Glen Research.
  • Oligonucleotide-based compounds of the invention were synthesized at 1-2 ⁇ M scale using a standard RNA synthesis protocol.
  • Oligonucleotide-based compounds of the invention were cleaved from solid support and the solution was further heated at 65° C. to removing protecting groups of exo cyclic-amines. The resulting solution was dried completely in a SpeedVac.
  • Oligonucleotide-based compounds of the invention were purified by ion exchange HPLC.
  • Buffer A 20 mM Tris-HCl, pH 7.0, 20% acetinitrile
  • Buffer B 3.0 M NaCl, 20 mM Tris-HCl, pH 7.0, 20% acetonitrile
  • CC-18 Sep-Pak cartridge purchased from Waters was first conditioned with 10m1 of acetonitrile followed by 10 ml of 0.5 M sodium acetate. 10 ml of the solution of oligonucleotide-based compounds of the invention was loaded. 15 ml of water was then used to wash out the salt. The oligonucleotide-based compounds of the invention was eluted out by 1 ml of 50% acetonitrile in water.
  • the solution is placed in SpeedVac for 30 minutes. The remaining solution was filter through a 0.2 micro filter and then was lyophilized to dryness. The solid was then re-dissolved in water to make the desired concentration.
  • the final solution was stored below 0° C.
  • Oligonucleotide-based compounds of the invention were analyzed by capillary electrophoresis according to the following conditions.
  • Oligonucleotide-based compounds of the invention were analyzed by ion exchange HPLC according to the following conditions
  • Buffer A 100 mM Tris-HCl, pH 8.0, 20% acetinitrile
  • Buffer B 2.0 M LiCl, 100 mM Tris-HCl, pH 8.0, 20% acetonitrile
  • oligonucleotide-based compounds of the invention was loaded on 20% polyacrylamide gel and was running at constant power of 4 watts for approximately 5 hours. The gel was viewed under short wavelength UV light.
  • PBMCs Peripheral blood mononuclear cells
  • pDCs Human plasmacytoid dendritic cells
  • Human PBMCs were plated in 48-well plates using 5 ⁇ 10 6 cells/ml.
  • Human pDCs were plated in 96-well dishes using 1 ⁇ 10 6 cells/ml.
  • the exemplary oligonucleotide-based compounds of the invention dissolved in DPBS (pH 7.4; Mediatech), were added to the cell cultures at doses of 0, 0.01, 1.0 or 10.0 ⁇ g/ml.
  • the cells were then incubated at 37° C. for 24 hours and subsequently stimulated with 10 ⁇ g/ml TLR9 agonist for 24 h. After treatment and stimulation, the supernatants were collected for luminex multiplex or ELISA assays.
  • the levels of IFN- ⁇ , IL-6, and/or IL-12 were measured by sandwich ELISA.
  • the required reagents including cytokine antibodies and standards, were purchased from PharMingen.
  • Human B cells were isolated from PBMCs by positive selection using the CD19 Cell Isolation Kit (Miltenyi Biotec, Auburn, Calif.) according to the manufacturer's instructions.
  • the culture medium used for the assay consisted of RPMI 1640 medium supplemented with 1.5 mM glutamine, 1 mM sodium pyruvate, 0.1 mM non-essential amino acids, 50 ⁇ M 2-mercaptoethanol, 100 IU/ml penicillin-streptomycin mix and 10% heat-inactivated fetal bovine serum.
  • a total of 0.5 ⁇ 10 6 B cells per ml (i.e.1 ⁇ 10 5 /200 ⁇ l/well) were incubated in 96 well flat bottom plates with 50 ⁇ g/ml of exemplary oligonucleotide-based compounds of the invention for 24 hours. After 24 hours, cells were stimulated with 10 ⁇ g/ml TLR9 agonist for 24 h. Following treatment and stimulation, cell extracts were prepared and analyzed for the amount of TLR9 mRNA.
  • HEK293 cells stably expressing mouse TLR9 or TLR7 were plated in 48-well plates in 250 ⁇ L/well DMEM supplemented with 10% heat-inactivated FBS in a 5% CO2 incubator. At 80% confluence, cultures were transiently transfected with 400 ng/mL of the secreted form of human embryonic alkaline phosphatase (SEAP) reporter plasmid (pNifty2-Seap) (Invivogen) in the presence of 4 ⁇ L/mL of lipofectamine (Invitrogen, Carlsbad, Calif.) in culture medium.
  • SEAP human embryonic alkaline phosphatase
  • Plasmid DNA and lipofectamine were diluted separately in serum-free medium and incubated at room emperature for 5 min. After incubation, the diluted DNA and lipofectamine were mixed and the mixtures were incubated further at room temperature for 20 min. Aliquots of 25 ⁇ L of the DNA/lipofectamine mixture containing 100 ng of plasmid DNA and 1 ⁇ L of lipofectamine were added to each well of the cell culture plate, and the cells were transfected for 6 h.
  • TLR9 or TLR7 specific oligonucleotide-based compounds of the invention were added to the wells, and incubation continued for 24 h.
  • cells were then stimulated with the 10 ⁇ g/ml TLR9 or TLR7 agonist for 24 h.
  • HEK293 cells stably expressing mouse TLR7 or TLR8 or another specific RNA target would be plated in 48-well plates in 250 ⁇ L/well DMEM supplemented with 10% heat-inactivated FBS in a 5% CO2 incubator.
  • cultures would be transiently transfected with 400 ng/mL of the secreted form of human embryonic alkaline phosphatase (SEAP) reporter plasmid (pNifty2-Seap) (Invivogen) in the presence of 4 ⁇ L/mL of lipofectamine (Invitrogen, Carlsbad, Calif.) in culture medium. Plasmid DNA and lipofectamine would be diluted separately in serum-free medium and incubated at room temperature for 5 min. After incubation, the diluted DNA and lipofectamine would be mixed and the mixtures would be incubated further at room temperature for 20 min.
  • SEAP human embryonic alkaline phosphatase
  • Murine J774 macrophage cells (American Type Culture Collection, Rockville, Md.) were cultured in Dulbecco's modified Eagle's medium supplemented with 10% (v/v) fetal bovine serum (FBS) and antibiotics (100 IU/ml penicillin G/100 ⁇ g/ml streptomycin). J774 cells were plated at a density of 5 ⁇ 10 6 cells/well in six-well plates. For dose dependent experiments, the J774 cells were then treated with 0,1, 10, 50 or 100 ⁇ g/ml of TLR9 specific oligonucleotide-based compounds of the invention and incubation continued for 24 h.
  • FBS fetal bovine serum
  • antibiotics 100 IU/ml penicillin G/100 ⁇ g/ml streptomycin
  • the J774 cells were then treated with 0, 1 or 3 ⁇ g/ml of TLR9 specific oligonucleotide-based compounds of the invention or control oligonucleotides and incubation continued for 48 h.
  • the J774 cells were then treated with 0, or 50 ⁇ g/ml of TLR9 specific oligonucleotide-based compounds of the invention or control oligonucleotides and incubation continued for 48 h.
  • cellular extracts were prepared and analyzed for the amount of TLR9 mRNA or TLR9 protein.
  • HeLa cells 5 ⁇ 10 6 HeLa cells (ATCC, Manassas, Va.) were plated in a 12-well culture plate in Dulbecco's Modified Eagle Medium (DMEM, Mediatech, Manassas, Va.) supplemented with 10% fetal bovine serum (FBS, Mediatch, Manassas, Va.).
  • DMEM Dulbecco's Modified Eagle Medium
  • FBS fetal bovine serum
  • 5 ⁇ l Lipofectamine® 2000 Invitrogen, Carlsbad, Calif.
  • 5 ⁇ g antisense oligonucleotides were mixed in 100 ⁇ l DMEM without serum and incubated at room temperature for 15 minutes.
  • RNA was used to reverse transcribe to cDNA using a High Capacity cDNA Reverse Transcription kit (Appliedbiosystems, Carlsbad, Calif.) according to manufacturer's recommendation.
  • a High Capacity cDNA Reverse Transcription kit (Appliedbiosystems, Carlsbad, Calif.) according to manufacturer's recommendation.
  • primers and probes for VEGF catalog no. Hs00900057_ml
  • GAPDH Hs99999905_ml
  • 50 ng cDNA was used in the qPCR with Taqman® Fast Universal PCR Master Mix (Applied Biosystems) and reactions were run on an Applied Biosystems StepOnePlusTM Real-Time PCR System according to manufacturer's instructions. Data is depicted in FIG.
  • Spleen cells from 4- to 8-week old C57BL/6 mice were cultured in RPMI complete medium.
  • Mouse spleen cells were plated in 24-well dishes using 5 ⁇ 10 6 cells/ml, treated with TLR9 specific oligonucleotide-based compounds of the invention dissolved in TE buffer (10 mM Tris-HCl, pH 7.5, 1 mM EDTA), and incubated at 37° C. for 24 hrs. Following antisense treatment, cells were then stimulated with 10 ⁇ g/ml TLR9 agonist for 24 hrs. After treatment and stimulation, the supernatants were collected and the secretion of IL-12 and IL-6 in cell culture supernatants was measured by sandwich ELISA.
  • oligonucleotide-based compounds according to the invention or control oligonucleotides were treated as follows:
  • the 5′-end [ ⁇ -32P] labeled target mRNA e.g. SED ID NO. 21; 10 nM human/mouse TLR7
  • complementary RNA or DNA 10 nM; human/mouse TLR7
  • Buffer (10 ⁇ buffer, Invitrogen) were heated at 85° C. for 5 min, and then cooled down to room temperature for 20 min to allow annealing of the two strands.
  • the human dicer enzyme (0.025 U, Invitrogen) was added to reaction solution, and then incubated at 37° C. for 1 hr. 1 ml of stop solution (Invitrogen) and 10 ml of gel loading dye were added to sample solution and mixed well. The sample was frozen immediately at ⁇ 80° C. RNA digestion products were analyzed on 16% denaturing PAGE and the gel was exposed to x-ray film and the autoradiogram was developed. Results are shown in FIG. 13 .

Abstract

The inventors have examined the means for providing more efficacious gene expression blocking compounds. The inventors have discovered new structural features that surprisingly improve the efficacy of gene expression blocking molecules. These features include the presence of multiple 3′ ends and a linker at the 5′ ends. Surprisingly, these features improve the efficacy of the gene expression blocking compounds in a manner that decreases the compound's biologic instability. Even more surprisingly, this effect has been found to be applicable to both DNA and RNA oligonucleotide-based compounds and to have application in traditional antisense and RNAi technologies.

Description

    RELATED APPLICATIONS
  • This application is a continuation of U.S. application Ser. No. 12/869,185, filed Aug. 26, 2010, and claims the benefit of U.S. Provisional Application Ser. No. 61/275,252, filed on Aug. 27, 2009; and U.S. Provisional Application Ser. No. 61/240,553, filed on Sep. 8, 2009, the contents of which are incorporated herein by reference in their entirety.
    • BACKGROUND OF THE INVENTION
  • 1. Field of the Invention
  • The present invention relates to compounds, compositions, and methods of use for the inhibition of gene expression and/or activity or for diagnosing, treating and/or preventing diseases and/or conditions that respond to the inhibition of gene expression and/or activity.
  • 2. Summary of the Related Art
  • An approach to inhibit gene expression is antisense technology or RNA inhibition (RNAi). These approaches make use of sequence-specific binding of DNA and/or RNA based oligonucleotides to selected mRNA, microRNA, preRNA or mitochondrial RNA targets and the inhibition of translation that results therefrom. This oligonucleotide-based inhibition of translation and ultimately gene expression is the result of one or more cellular mechanisms, which may include but is not limited to (i) direct (steric) blockage of translation, (ii) RNase H-mediated inhibition, and (iii) RNAi-mediated inhibition (e.g. short interfering-RNA (siRNA), microRNA (miRNA), DNA-directed-RNAi (ddRNAi), and single-stranded RNAi (ssRNAi)).
  • The history of antisense technology has revealed that while determination of antisense oligonucleotides that bind to mRNA is relatively straight forward, the optimization of antisense oligonucleotides that have true potential to inhibit gene expression and therefore be good clinical candidates is not. Accordingly, if an oligonucleotide-based approach to down-regulating gene expression is to be successful, there is a need for optimized antisense oligonucleotides that most efficiently achieve this result. Such optimized antisense oligonucleotides could be used alone or in conjunction with other prophylactic and/or therapeutic compositions.
  • Since Zamecnik & Stephenson published the first demonstration of using antisense oligonucleotides as a means to inhibit translation of viral proteins (Zemecnik and Stephenson (1978) Proc. Natl. Acad. Sci. 75: 285-288), there has been great interest in utilizing oligonucleotide-based compounds to inhibit expression of genes. These initial efforts utilized single-stranded, unmodified oligodeoxyribonucleotides or oligoribonucleotides (Agrawal et al. (1992) Ann. NY Acad. Sci. 660:2-10), which are inherently unstable in vivo, to bind to mRNA in vivo and create a double-stranded RNA template for enzymatic, or RNAse, degradation. Subsequent efforts were made to determine the utility of oligodoexyribonucleotides that incorporated nuclease-resistant phosphorothioate and/or methylphosphonate linkages (Agrawal et. al (1988) Proc. Natl. Acad. Sci. 85:7079-7083; Metelev & Agrawal U.S. Pat. No. 5,652,355; Metelev & Agrawal U.S. Pat. No. 6,143,881; Matsukura et al. (1987) Proc. Natl. Acad. Sci. 84:7706).
  • Another class of RNA-based molecules that inhibit gene expression are referred to as ribozymes. Ribozymes form stem loop structures and bind to an RNA target to mediate its cleavage directly (Cech, T. (1990) Ann. Rev. Biochem. 59:543). Ribozymes selectively bind to target-RNA and catalyze a transesterification or a hydrolysis reaction to cleave specific phosphodiester linkages in single-stranded RNA. If introduced into cells, ribozymes have the potential to bind to target-mRNA and inhibit translation of such mRNA. As with single-stranded antisense technologies, the stability and activity of ribozymes have been improved through incorporation of certain chemical modifications into the ribozyme structure (Goodchild U.S. Pat. No. 6,204,027; Goodchild U.S. Pat. No. 6,573,072). While antisense oligonucleotide and ribozyme technologies continue to advance, discoveries with other oligonucleotide-based technologies are being made.
  • Based on the pioneering discoveries of Fire and Mello (Fire et al. (1998) Nature, 391:806-811), efforts have turned toward RNA-interfering (RNAi) technologies (e.g. short interfering-RNA (siRNA), microRNA (miRNA), DNA-directed-RNAi (ddRNAi), and single-stranded RNAi (ssRNAi)) in mammalian systems. RNAi refers to the process of post-transcriptional inhibition of gene expression using short oligonucleotides that are designed to hybridize to specific mRNA targets (Fire et al. (1998) Nature 391:806-811; Zamore et al. (2000) Cell, 101:25-33). In the case of siRNA, short, double-stranded RNA molecules utilize cellular enzymatic machinery to cleave homologous target RNA molecules. (Rana (2007) Nature Rev. Mol. Cell. Biol. 8:23-36). Double-stranded RNAi technologies rely upon administration or expression of double stranded RNA (dsRNA), which once inside the cell, is bound by an enzyme called dicer and cleaved into 21-23 nucleotides. The resulting dicer-dsRNA complex is delivered to and interacts with an Argonaut-containing complex of proteins referred to as an RNA-induced silencing complex (RISC). RISC is thought to be present in cells to catalytically break down specific mRNA molecules. Once bound by RISC, the dsRNA is unwound resulting in a ssRNA-RISC complex, which is able to hybridize to targeted mRNA. Once hybridized, the RISC complex breaks down the mRNA. In some cases, the dsRNA specific processes of dicer have been circumvented using single-stranded RNAi (ssRNAi) compositions that interact directly with RISC to achieve inhibition of gene expression (Holen et al. (2003) Nuc. Acids Res. 31:2401-2407). Although RNAi technologies are able to selectively bind to target mRNA, such molecules have also been recognized to induce non-specific immune stimulation through interaction with TLR3 (Kleinman et al., (2008) Nature 452:591-597; De Veer et. al. (2005) Immun. Cell Bio. 83:224-228; Kariko et al. (2004) J. Immunol. 172:6545-6549). This non-specific immune activation has raised questions as to the utility of RNAi technologies as pharmaceutical agents.
  • Although each of the antisense-based technologies has been used with some success, as a result of being based on oligonucleotides, each of these technologies has the inherent problem of being unstable in vivo and having the potential to produce off-target effects, for example unintended immune stimulation (Agrawal & Kandimalla (2004) Nature Biotech. 22:1533-1537). In the case of dsRNA, these oligonucleotides appear to have the additional issue of inefficient, in vivo delivery to cells (Medarova et. al (2007) Nature Med. 13:372-377). Despite many clinical trials of antisense oligonucleotide drug candidates, only one such compound has been approved as a drug by the FDA. This antisense compound was approved for treating CMV, but has never been marketed as a product. Additionally, no ribozyme or siRNA drug candidate has yet been approved by the FDA.
  • Approaches to optimizing each of these technologies have focused on addressing biostability, target recognition (e.g., cell permeability, thermostability), and in vivo activity. Often, these have represented competing considerations. For example, traditional antisense oligonucleotides utilized phosphate ester intemucleotide linkages, which proved to be too biologically unstable to be effective. Thus, there was a focus on modifying antisense oligonucleotides to render them more biologically stable. Early approaches focused on modifying the intemucleotide linkages to make them more resistant to degradation by cellular nucleases. These approaches led to the development of antisense oligonucleotides having a variety of non-naturally occurring intemucleotide linkages, such as phosphorothioate, methylphosphonate (Sarin et al. (1988) Proc. Natl. Acad. Sci. 85:7448-7451), and peptide based linkages. (Matsukura et. al (1987) Proc. Natl. Acad. Sci. 84:7706; Agrawal et al. (1988) Proc. Natl. Acad. Sci. 85:7079-7083; Miller (1991) Bio-Technology 9:358). However, these modifications caused the molecules to decrease their target specificity and produced unwanted biological activities.
  • Later approaches to improve stability and retain specificity and biologic activity utilized mixed backbone oligonucleotides, which contain phosphodiester and phosphorothioate intemucleotide linkeages. This mixed backbone resulted in oligonucleotides that retained or improved their biological stability as compared to oligonucleotides with only phosphodiester linkages (Agrawal et al. (1990) Proc. Natl. Acad. Sci. 87:1401-1405; US Patent Publication No. 20010049436). Throughout oligonucleotide research, it has been recognized that these molecules are succeptable in vivo to degradation by exonucleases, with the primary degradation occurring from the 3′-end of the molecule (Shaw et. al (1991) Nucleic Acids Res. 19:747-750; Temsamani et al. (1993) Analytical Bioc. 215:54-58). As such, approaches to avoid this exonuclease activity have utilized (i) capping structures at the 5′ and/or 3′ termini (Tesamani et. al (1992) Ann. NY Acad. Sci. 660:318-320; Temsamani et al. (1993) Antisense Res. Dev. 3:277-284; Tang et al. (1993) Nucl. Acids Res. 20:2729-2735), (ii) linking two or more oligonucleotides through 5′-3′, 5′-2, 2′-3′, 3′-2′ or 3′-3′ linkages between the molecules (Agrawal et al. U.S. Pat. No. 6,489,464), (iii) self-hybridizing oligonucleotides that fold back on themselves at the 3′-end, which creates a hair-pin and removes'the point of access for 3′-exonuclease activity to begin (Tang et al. (1993) Nucl. Acids Res. 20:2729-2735), or (iv) incorporating RNA into the oligonucleotide molecule, thus creating an RNA/DNA hybrid molecule (Metelev at al. (1994) Bioorg. Med. Chem. Lett. 4:2929-2934; Metelev U.S. Pat. No. 5,652,355; Metelev & Agrawal U.S. Pat. No. 6,143,881; Metelev& Agrawal U.S. Pat. No. 6,346,614; Metelev & Agrawal U.S. Pat. No. 6,683,167, Metelev & Agrawal U.S. Pat. No. 7,045,609).
  • Other approaches to improve stability and retain specificity and biologic activity of antisense oligonucleotides utilized triplex forming, polypyrimidine oligonucleotides that bind to double-stranded DNA or RNA targets. Polypyrimidine oligonucleotides can bind to duplex DNA in the major groove through Hoogsteen hydrogen bonding and form triplex structures containing one polypurine and two polypyrimidine strands with T:A-T and C:G-C+ base triplets (Moser, H. E. and Dervan, P. B. (1987) Science 238, 645-650; Cooney, et al(1988) Science 241, 456-459). Intramolecular triplexes are also formed when the DNA homopurine and homopryrimidine strands melt and refold (Vasqueza, K. M. and Wilson, J. H. (1998) Trends Bioche. Sci. 23, 4-9). The presence of a third strand introduces severe restrictions in the flexibility of the DNA, changing its ability to recognize specific proteins along the major groove (Shields, G. C., et al. (1997) Am. Chem. Soc., 119, 7463 -7469; Jimenez-Garcia, E., et al. (1998) J. Biol. Chem. 273, 24640-24648, resulting in an inhibiton of transcription and ultimately reduced gene expression. Oligonucleotides that can sequence-specifically bind to double-stranded DNA or RNA can act as transcriptional/translational regulators and offered a promising antigene/antisense strategy to control the regulation of gene expression (Giovannangeli, C. and Helene, C. (1997) Antisense Nucleic Acid Drug Dev., 413; Giovannangeli, C., et al. (1996) Biochemistry 35, 10539; Maher, L. J., et al. (1992) Biochemistry 31, 70). However, the conditions for forming stable triplexes are problematic because of limited base recognition and the non-physiologic acidic pH conditions required for protonation of cytosines in the triplex-forming oligonucleotides.
  • In an attempt to form such stable triplexes, polypyrimidine oligonucleotides with inverted polarity linked Via a linker (i.e. one sequence having polarity 5′→3′ followed by another sequence with 3′→5′ polarity, or vice versa) have been described (Froehler, U.S. Pat. No. 5,399,676; Froehler U.S. Pat. No. 5,527,899; Froehler U.S. Pat. No. 5,721,218). In such inverted polarity oligonucleotides, the sequence on one side of the inversion binds to polypurine strand of a duplex according to the triple helix code and the sequence on the other side will bind to the adjacently located polypurine site in the opposite strand of the duplex (FIG. 14). In this manner triple helix recognition can be extended by switching recognition from one strand of the duplex to the other and then back again, if desired and such target sequence stretch is available. In addition, these oligonucleotides may also form D-loops with the duplex as shown in Diagram 1B. In this situation, the region of the first polarity may form triplex, while the inverted portion displaces a section of one strand of the duplex to result in a substitute duplex in the relevant region. As the switchback oligonucleotides are capable of significant duplex binding activity, these oligonucleotides may be useful to inactivate the disease causing and undesirable DNA or RNA that are in duplex form. However, the composition of the molecules is limited to polypyrimidine sequences targeting polypurine sites of double-stranded RNA or DNA.
  • Alternatively, strategies have been developed to target single stranded DNA and RNA by triple helix formation. One of the approaches is to target polypyrimidine DNA or RNA single strands with foldback triplex-forming oligonucleotides with inverted polarity (Kandimalla, E. R., et al. (1995) J. Am. Chem. Soc. 117, 6416-6417; Kandimalla, E. R., and Agrawal, S. (1996) Biochemistry 35, 15332). In such foldback triplex-forming oligonucleotides, a polypyrimidine oligonucleotide and its complementary polypurine strand are attached through 3′-3′ attachment or 5′-5′-attachment. Such oligonucleotides containing complementary sequences attached through 3′-3′ or 5′-5′ linkages form parallel-stranded duplexes through Hoogsteen or reverse Hoogsteen base pairing. When a complementary polypyrimidine strand is available, they form triple helical structures (FIG. 15).
  • Despite considerable efforts, the efforts to improve the stability and maintain target recognition, without off-target effects has not generally produced oligonucleotides that would be perceived as having clinical utility. Thus, the existing antisense-based technologies leave open the challenge of creating compounds that are biologically stable, target specific, and efficient inhibitors of gene expression. New approaches are therefore needed.
    • BRIEF SUMMARY OF THE INVENTION
  • The present invention is directed to compounds, compositions, and methods useful for modulating gene expression using oligonucleotide-based compounds comprising two or more single stranded antisense oligonucleotides that are linked through their 5′-ends to allow the presence of two or more accessible 3′-ends, which effectively inhibit or decrease gene expression. Surprisingly, the present inventors have discovered that such oligonucleotide compounds are more effective than non-linked antisense oligonucleotides.
  • In a first aspect, the invention provides novel synthetic oligonucleotide-based compounds comprising two or more oligonucleotides that are complementary to one or more mRNA sequence, wherein the oligonucleotides are linked through their 5′ ends to allow the presence of two or more accessible 3′-ends, and specifically hybridize to and inhibit the expression of the one or more mRNA sequence.
  • In as second aspect, the invention provides for pharmaceutical compositions. These compositions may comprise any synthetic oligonucleotide-based compounds according to the first aspect in a pharmaceutically or physiologically acceptable carrier.
  • In a third aspect, the invention provides a method for inhibiting gene expression, the method comprising contacting a cell with a synthetic oligonucleotide-based compound according to the first aspect of the invention.
  • In a fourth aspect, the invention provides a method for inhibiting gene expression in a mammal, the method comprising administering to the mammal a synthetic oligonucleotide-based compound according to the first aspect of the invention.
  • In a fifth aspect, the invention provides a method for inhibiting a TLR-mediated, Bcl-2-mediated, EGFR-mediated, mdm2-mediated, MyD88-mediated, PCSK9-mediated, survivin-mediated or VEGF-mediated response in a mammal through administration of a synthetic oligonucleotide-based compound according to the first aspect of the invention wherein the oligonucleotides are complementary to one or more TLR, Bcl-2, EGFR, mdm2, MyD88, PCSK9, survivin or VEGF mRNA sequence.
  • In a sixth aspect, the invention provides a method for inhibiting a TLR-mediated, Bcl-2-mediated, EGFR-mediated, mdm2-mediated, MyD88-mediated, PCSK9-mediated, survivin-mediated or VEGF-mediated response in a mammal though administration of a synthetic oligonucleotide-based compound according to the first aspect of the invention wherein the oligonucleotides are complementary to one or more TLR, Bcl-2, EGFR, mdm2, MyD88, PCSK9, survivin or VEGF mRNA sequence in combination with an antagonist of TLR, EGFR, mdm2, MyD88, PCSK9, survivin or VEGF protein activity.
  • In a seventh aspect, the invention provides methods for inhibiting gene expression in a mammal, such methods comprising administering to the mammal an oligonucleotide-based compound according to the invention. In some embodiments, the mammal is a human. In some preferred embodiments, the oligonucleotide-based compound according to the invention is administered to a mammal in need of inhibiting its immune response.
  • In an eighth aspect, the invention provides methods for therapeutically treating a patient having a disease or disorder, such methods comprising administering to the patient an oligonucleotide-based compound according to the invention in a therapeutically effective amount. In various embodiments, the disease or disorder to be treated is cancer, an autoimmune disorder, infectious disease, airway inflammation, inflammatory disorders, skin disorder, allergy, asthma or a disease caused by a pathogen. Pathogens include, without limitation, bacteria, parasites, fungi, viruses, viroids, and prions.
  • In a ninth aspect, the invention provides methods for preventing a disease or disorder, such methods comprising administering to a subject at risk for developing the disease or disorder an oligonucleotide-based compound according to the invention in a pharmaceutically effective amount. In various embodiments, the disease or disorder to be prevented is cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, allergy, asthma or a disease caused by a pathogen. Pathogens include, without limitation, bacteria, parasites, fungi, viruses, viroids, and prions.
  • In a tenth aspect the invention provides a method of preventing or treating a disorder, such methods comprises isolating cells capable of producing cytokines or chemokines including, but not limited to, immune cells, T-regulatory cells, B-cells, PBMCs, pDCs, and lymphoid cells; culturing such cells under standard cell culture conditions, treating such cells ex vivo with an oligonucleotide-based compound according to the first aspect of the invention such that the isolated cells produce or secrete decreased levels of cytokines or chemokines, and administering or re-administering the treated cells to a patient in need of therapy to inhibit cytokines and/or chemokines for the prevention and/or treatment of disease. This aspect of the invention would be in accordance with standard adoptive cellular immunotherapy techniques to produce activated immune cells.
  • In an eleventh aspect, the invention provides a composition comprising a compound according to the first aspect of the invention and one or more vaccines, antigens, antibodies, cytotoxic agents, chemotherapeutic agents (both traditional chemotherapy and modem targeted therapies), kinase inhibitors, allergens, antibiotics, agonist, antagonist, antisense oligonucleotides, ribozymes, RNAi molecules, siRNA molecules, miRNA molecules, aptamers, proteins, gene therapy vectors, DNA vaccines, adjuvants, co-stimulatory molecules or combinations thereof.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1A is a synthetic scheme for the linear synthesis of antisense oligonucleotides of the invention. DMTr=4,4′-dimethoxytrityl; CE=cyanoethyl.
  • FIG. 1B is synthetic scheme for the parallel synthesis of antisense oligonucleotides of the invention. DMTr=4,4′-dimethoxytrityl; CE=cyanoethyl.
  • FIGS. 2A and 2B depict the antisense activity of exemplary antisense oligonucleotides according to the invention in HEK293 cells expressing murine TLR9. The data demonstrate the ability of antisense oligonucleotides according to the invention to inhibit TLR9 agonist activity in cells cultured and treated according to Example 2.
  • FIG. 2C depicts the antisense activity of exemplary antisense oligonucleotides according to the invention in HEK293 cells expressing murine TLR7. The data demonstrate the ability of antisense oligonucleotides according to the invention to inhibit TLR7 agonist activity in cells cultured and treated according to Example 2.
  • FIG. 2D depicts the antisense activity of exemplary antisense oligonucleotides according to the invention in HEK293 cells expressing murine MyD88. The data demonstrate the ability of antisense oligonucleotides according to the invention to inhibit MyD88 agonist activity in cells cultured and treated according to Example 2.
  • FIG. 3 depicts the antisense activity of exemplary antisense oligonucleotides according to the invention in mouse splenocytes. The data demonstrate the ability of antisense oligonucleotides according to the invention to inhibit TLR9 mRNA translation, or protein synthesis, in splenocytes treated according to Example 2.
  • FIG. 4 depicts the antisense activity of exemplary antisense oligonucleotides according to the invention in human PBMCs. The data demonstrate the ability of antisense oligonucleotides according to the invention to inhibit TLR9 mRNA translation, or protein synthesis, in human PBMCs treated according to Example 2.
  • FIGS. 5A and 5B depict the activity of exemplary antisense oligonucleotides according to the invention to inhibit TLR9-induced IL-12 following in vivo administration according to Example 3. The data demonstrate that administration of an exemplary TLR9 antisense oligonucleotide according to the invention can cause down-regulation of TLR9 expression in vivo and prevent the induction of IL-12 by a TLR9 agonist. More generally, the data demonstrate the ability of a TLR9 antisense oligonucleotide according to the invention to inhibit the induction of pro-inflammatory cytokines by a TLR9 agonist.
  • FIG. 5C depicts the duration of in vivo activity of exemplary antisense oligonucleotides according to the invention to inhibit MyD88-induced IL-12 following in vivo administration according to Example 3. The data demonstrate that administration of an exemplary MyD88 antisense oligonucleotide according to the invention can cause down-regulation of MyD88 expression in vivo and prevent the induction of IL-12 by a TLR9 agonist for a longer duration than either linear antisense oligonucleotides or 3′-3′ linked antisense oligonucleotides. More generally, the data demonstrate the ability of a MyD88 antisense oligonucleotide according to the invention to inhibit the induction of pro-inflammatory cytokines by a TLR agonist.
  • FIG. 6 depicts the activity of exemplary antisense oligonucleotides according to the invention to inhibit TLR9-induced IL-12 in a dose dependent manner following in vivo administration according to Example 3. The data demonstrate that in vivo administration of a TLR9 antisense oligonucleotide according to the invention can cause down-regulation of TLR9 expression in vivo in a dose dependent manner and prevent the induction of IL-12 by a TLR9 agonist. More generally, the data demonstrate the ability of a TLR9 antisense oligonucleotide according to the invention to selectively inhibit the induction of pro-inflammatory cytokines by a TLR9 agonist.
  • FIG. 7 depicts the activity of exemplary antisense oligonucleotides according to the invention to inhibit TLR9-induced IL-12 in a time dependent manner following in vivo administration according to Example 3. The data demonstrate that in vivo administration of a TLR9 antisense oligonucleotide according to the invention can cause down-regulation of TLR9 expression in vivo in a time dependent manner and prevent the induction of IL-12 by a TLR9 agonist for an extended period of time. More generally, the data demonstrate the ability of a TLR9 antisense oligonucleotide according to the invention to inhibit the induction of pro-inflammatory cytokines by a TLR9 agonist in a time dependent manner.
  • FIGS. 8A, 8B, 8C depict the antisense activity of exemplary antisense oligonucleotides according to the invention in murine J774 cells. The data demonstrate the ability of antisense oligonucleotides according to the invention to inhibit TLR9 mRNA, transcription, translation, or protein synthesis, in murine J774 cells treated according to Example 2.
  • FIG. 8D depicts the antisense activity of exemplary antisense oligonucleotides according to the invention in human HeLa cells. The data demonstrate the ability of antisense oligonucleotides according to the invention to inhibit VEGF mRNA transcription in human HeLa cells treated according to Example 2.
  • FIG. 9 depicts the antisense activity of exemplary antisense oligonucleotides according to the invention in human B cells. The data demonstrate the ability of antisense oligonucleotides according to the invention to inhibit TLR9 mRNA translation, or protein synthesis, in human B cells treated according to Example 2.
  • FIG. 10 depicts the antisense activity of exemplary antisense oligonucleotides according to the invention in human pDCs. The data demonstrate the ability of antisense oligonucleotides according to the invention to inhibit TLR9 mRNA translation, or protein synthesis, in human pDCs treated according to Example 2.
  • FIG. 11 depicts the activity of exemplary antisense oligonucleotides according to the invention to inhibit TLR9-induced IL-12 following in vivo administration according to Example 3. The data demonstrate that in vivo administration of an exemplar TLR9 antisense oligonucleotide according to the invention can cause down-regulation of TLR9 expression in vivo and prevent the induction of IL-12 by a TLR9 agonist. More generally, the data demonstrate the ability of a TLR9 antisense oligonucleotide according to the invention to inhibit the induction of pro-inflammatory cytokines by a TLR9 agonist.
  • FIG. 12 depicts the antisense activity of exemplary antisense oligonucleotides according to the invention in HEK293 cells expressing mouse TLR7. The data demonstrate the ability of antisense oligonucleotides according to the invention to inhibit TLR7 agonist activity in cells cultured and treated according to Example 2.
  • FIG. 13 depicts the selective binding and cleavage of exemplary antisense oligonucleotides according to the invention treated according to Example 4. In FIG. 13, Lane 1 is substrate alone; Lane 2 is T1 nuclease; Lane 3 is 5′-AAUGCUUGUCUGUGCAGUCC-3′ (SEQ ID NO. 28); Lane 4 is 5′-AAUGCUUGUCUGUGCAGUCC-X-CCUGACGUGUCUGUUCGUAA-5′; Lane 5 is 3′-CCUGACGUGUCUGUUCGUAA-X-AAUGCUUGUCUGUGCAGUCC-3′ (SEQ ID 21); Lane 6 is 5′-AAUGCUUGUCUGUGCAGUCC-AAUGCUUGUCUGUGCAGUCC-3′; Lane 7 is 5% CUGUCoAoAoAoUoGoCoUoUoGoUoCoUoGoUoGoCoAoGoUoCoCoACGAU-3′ (SEQ ID NO. 29); Lane 8 is dsRNA; and Lane 9 is 20-mer DNA antisense; wherein all sequences have phosphorothioate backbone except where indicated with an “o” (phosphodiester linkage); underlined nucleotides indicate 2′-O-methylribonucleotides. The data demonstrate that oligonucleotides according to the invention provide an optimal structure for binding and cleavage by proteins and enzymes associated with RNAi-mediated inhibition of gene expression.
  • FIG. 14 shows switchback triplex-forming (A) and D-loop (B) modes of binding oligonucleotides with inverted polarity.
  • FIG. 15 shows parallel-stranded hairpin modes of oligonucleotides containing purine-pyrimidine strands attached covalently at either 3′-3′ or 5′-5′ ends.
  • FIG. 16 shows antisense mode of binding of the oligonucleotide-based compounds according to the invention.
    •  DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • The invention relates to the therapeutic and prophylactic use of novel antisense oligonucleotides to down-regulate gene expression. Such molecules are useful, for example, in providing compositions for modulation of gene expression or for treating and/or preventing diseases and/or conditions that are capable of responding to modulation of gene expression in patients, subjects, animals or organisms.
  • The patents and publications cited herein reflect the level of knowledge in the art and are hereby incorporated by reference in their entirety. Any conflict between the teachings of these patents and publications and this specification shall be resolved in favor of the latter.
  • The objects of the present invention, the various features thereof, as well as the invention itself may be more fully understood from the following description, when read together with the accompanying drawings in which the following terms have the ascribed meaning.
  • The term “2′-O-substituted” means substitution of the 2′ position of the pentose moiety with an —O-lower alkyl group containing 1-6 saturated or unsaturated carbon atoms (for example, but not limited to, 2′-O-methyl), or with an —O-aryl or allyl group having 2-6 carbon atoms, wherein such alkyl, aryl or allyl group may be unsubstituted or may be substituted, (for example, with 2′-O-methoxyethyl, ethoxy, methoxy, halo, hydroxyl, trifluoromethyl, cyano, nitro, acyl, acyloxy, alkoxy, carboxyl, carbalkoxyl, or amino groups); or with a hydroxyl, an amino or a halo group, but not with a 2′-H group. In some embodiments the oligonucleotides of the invention include four or five 2′-O-alky nucleotides at their 5′ terminus, and/or four or five 2′-O-alky nucleotides at their 3′ terminus.
  • The term “3′”, when used directionally, generally refers to a region or position in a polynucleotide or oligonucleotide 3′ (toward the 3′ end of the nucleotide) from another region or position in the same polynucleotide or oligonucleotide.
  • The term “3′ end” generally refers to the 3′ terminal nucleotide of the component oligonucleotides. “Two or more oligonucleotides linked at their 3′ ends” generally refers to a linkage between the 3′ terminal nucleotides of the oligonucleotides which may be directly via 5′, 3′ or 2′ hydroxyl groups, or indirectly, via a non-nucleotide linker. Such linkages may also be via a nucleoside, utilizing both 2′ and 3′ hydroxyl positions of the nucleoside. Such linkages may also utilize a functionalized sugar or nucleobase of a 3′terminal nucleotide.
  • The term “5′”, when used directionally, generally refers to a region or position in a polynucleotide or oligonucleotide 5′ (toward the 5′end of the nucleotide) from another region or position in the same polynucleotide or oligonucleotide.
  • The term “5′ end” generally refers to the 5′ terminal nucleotide of the component oligonucleotides. “Two or more single-stranded antisense oligonucleotides linked at their 5′ ends” generally refers to a linkage between the 5′ terminal nucleotides of the oligonucleotides which may be directly via 5′, 3′ or 2′ hydroxyl groups, or indirectly, via a non-nucleotide linker. Such linkages may also be via a nucleoside, utilizing both 2′ and 3′ hydroxyl positions of the nucleoside. Such linkages may also utilize a functionalized sugar or nucleobase of a 5′terminal nucleotide.
  • The term “about” generally means that the exact number is not critical. Thus, oligonucleotides having one or two fewer nucleoside residues, or from one to several additional nucleoside residues are contemplated as equivalents of each of the embodiments described above.
  • The term “accessible” generally means when related to a compound according to the invention, that the relevant portion of the molecule is able to be recognized by the cellular components necessary to elicit an intended response to the compound.
  • The term “agonist” generally refers to a substance that binds to a receptor of a cell and induces a response. An agonist often mimics the action of a naturally occurring substance such as a ligand.
  • The term “antagonist” generally refers to a substance that attenuates the effects of an agonist or ligand.
  • The term “airway inflammation” generally includes, without limitation, inflammation in the respiratory tract caused by allergens, including asthma.
  • The term “allergen” generally refers to an antigen or antigenic portion of a molecule, usually a protein, which elicits an allergic response upon exposure to a subject. Typically the subject is allergic to the allergen as indicated, for instance, by the wheal and flare test or any method known in the art. A molecule is said to be an allergen even if only a small subset of subjects exhibit an allergic (e.g., IgE) immune response upon exposure to the molecule.
  • The term “allergy” generally includes, without limitation, food allergies, respiratory allergies and skin allergies.
  • The term “antigen” generally refers to a substance that is recognized and selectively bound by an antibody or by a T cell antigen receptor. Antigens may include but are not limited to peptides, proteins, lipids, carbohydrates, nucleosides, nucleotides, nucleic acids, and combinations thereof. Antigens may be natural or synthetic and generally induce an immune response that is specific for that antigen.
  • The term “autoimmune disorder” generally refers to disorders in which “self” antigen undergo attack by the immune system. Such term includes, without limitation, lupus erythematosus, multiple sclerosis, type I diabetes mellitus, irritable bowel syndrome, Chron's disease, rheumatoid arthritis, septic shock, alopecia universalis, acute disseminated encephalomyelitis, Addison's disease, ankylosing spondylitis, antiphospholipid antibody syndrome, autoimmune hemolytic anemia, autoimmune hepatitis, Bullous pemphigoid, chagas disease, chronic obstructive pulmonary disease, hydrox disease, dermatomyositis, endometriosis, Goodpasture's syndrome, Graves' disease, Guillain-Barré syndrome, Hashimoto's disease, hidradenitis suppurativa, idiopathic thrombocytopenic purpura, interstitial cystitis, morphea, myasthenia gravis, narcolepsy, neuromyotonia, pemphigus, pernicious anaemia, polymyositis, primary biliary cirrhosis, schizophrenia, Sjögren's syndrome, temporal arteritis (“giant cell arteritis”), vasculitis, vitiligo, vulvodynia and Wegener's granulomatosis autoimmune asthma, septic shock and psoriasis.
  • The term “biologic instability” generally refers to a molecule's ability to be degraded and subsequently inactivated in vivo. For oligonucleotides, such degradation results from exonuclease activity and/or endonuclease activity, wherein exonuclease activity refers to cleaving nucleotides from the 3′ or 5′ end of an oligonucleotide, and endonuclease activity refers to cleaving phosphodiester bonds at positions other than at the ends of the oligonucleotide.
  • The term “cancer” generally refers to, without limitation, any malignant growth or tumor caused by abnormal or uncontrolled cell proliferation and/or division. Cancers may occur in humans and/or mammals and may arise in any and all tissues. Treating a patient having cancer may include administration of a compound, pharmaceutical formulation or vaccine according to the invention such that the abnormal or uncontrolled cell proliferation and/or division, or metastasis is affected.
  • The term “carrier” generally encompasses any excipient, diluent, filler, salt, buffer, stabilizer, solubilizer, oil, lipid, lipid containing vesicle, microspheres, liposomal encapsulation, or other material for use in pharmaceutical formulations. It will be understood that the characteristics Of the carrier, excipient or diluent will depend on the route of administration for a particular application. The preparation of pharmaceutically acceptable formulations containing these materials is described in, for example, Remington's Pharmaceutical Sciences, 18th Edition, ed. A. Gennaro, Mack Publishing Co., Easton, Pa., 1990.
  • The term “co-administration” or “co-administered” generally refers to the administration of at least two different substances sufficiently close in time to modulate an immune response. Co-administration refers to simultaneous administration, as well as temporally spaced order of up to several days apart, of at least two different substances in any order, either in a single dose or separate doses.
  • The term “in combination with” generally means administering an oligonucleotide-based compound according to the invention and another agent useful for treating the disease or condition that does not abolish the activity of the compound in the course of treating a patient. Such administration may be done in any order, including simultaneous administration, as well as temporally spaced order from a few seconds up to several days apart. Such combination treatment may also include more than a single administration of the compound according to the invention and/or independently the other agent. The administration of the compound according to the invention and the other agent may be by the same or different routes.
  • The term “individual” or “subject” or “patient” generally refers to a mammal, such as a human.
  • The term “kinase inhibitor” generally refers to molecules that antagonize or inhibit phosphorylation-dependent cell signaling and/or growth pathways in a cell. Kinase inhibitors may be naturally occurring or synthetic and include small molecules that have the potential to be administered as oral therapeutics. Kinase inhibitors have the ability to rapidly and specifically inhibit the activation of the target kinase molecules. Protein kinases are attractive drug targets, in part because they regulate a wide variety of signaling and growth pathways and include many different proteins. As such, they have great potential in the treatment of diseases involving kinase signaling, including cancer, cardiovascular disease, inflammatory disorders, diabetes, macular degeneration and neurological disorders. A non-limiting example of a kinase inhibitor is sorafenib.
  • The term “linear synthesis” generally refers to a synthesis that starts at one end of an oligonucleotide and progresses linearly to the other end. Linear synthesis permits incorporation of either identical or non-identical (in terms of length, base composition and/or chemical modifications incorporated) monomeric units into an oligonucleotide.
  • The term “mammal” is expressly intended to include warm blooded, vertebrate animals, including, without limitation, humans, non-human primates, rats, mice, cats, dogs, horses, cattle, cows, pigs, sheep and rabbits.
  • The term “nucleoside” generally refers to compounds consisting of a sugar, usually ribose, deoxyribose, pentose, arabinose or hexose, and a purine or pyrimidine base.
  • The term “nucleotide” generally refers to a nucleoside comprising a phosphorous-containing group attached to the sugar.
  • The term “modified nucleoside” or “nucleotide derivative” generally is a nucleoside that includes a modified heterocyclic base, a modified sugar moiety, or any combination thereof. In some embodiments, the modified nucleoside or nucleotide derivative is a non-natural pyrimidine or purine nucleoside, as herein described. For purposes of the invention, a modified nucleoside or nucleotide derivative, a pyrimidine or purine analog or non-naturally occurring pyrimidine or purine can be used interchangeably and refers to a nucleoside that includes a non-naturally occurring base and/or non-naturally occurring sugar moiety. For purposes of the invention, a base is considered to be non-natural if it is not guanine, cytosine, adenine, thymine or uracil and a sugar is considered to be non-natural if it is not β-ribo-furanoside or 2′-deoxyribo-furanoside.
  • The term “modified oligonucleotide” as used herein describes an oligonucleotide in which at least two of its nucleotides are covalently linked via a synthetic linkage, i.e., a linkage other than a phosphodiester linkage between the 5′ end of one nucleotide and the 3′ end of another nucleotide in which the 5′ nucleotide phosphate has been replaced with any number of chemical groups. The term “modified oligonucleotide” also encompasses 2′-O,4′-C-methylene-b-D-ribofuranosyl nucleic acids, arabinose nucleic acids, substituted arabinose nucleic acids, hexose nucleic acids, peptide nucleic acids, morpholino, and oligonucleotides having at least one nucleotide with a modified base and/or sugar, such as a 2′-O-substituted, a 5-methylcytosine and/or a 3′-O-substituted ribonucleotide.
  • The term “nucleic acid” encompasses a genomic region or an RNA molecule transcribed therefrom. In some embodiments, the nucleic acid is mRNA.
  • The term “linker” generally refers to any moiety that can be attached to an oligonucleotide by way of covalent or non-covalent bonding through a sugar, a base, or the backbone. The non-covalent linkage may be, without limitation, electrostatic interactions, hydrophobic interactions, n-stacking interactions, hydrogen bonding and combinations thereof. Non-limiting examples of such non-covalent linkage includes Watson-Crick base pairing, Hoogsteen base pairing, and base stacking. The linker can be used to attach two or more nucleosides or can be attached to the 5′ and/or 3′ terminal nucleotide in the oligonucleotide. Such linker can be either a non-nucleotide linker or a nucleoside linker.
  • The term “non-nucleotide linker” generally refers to a chemical moiety, other than a linkage directly between two nucleotides that can be attached to an oligonucleotide by way of covalent or non-covalent bonding. Preferably such non-nucleotide linker is from about 2 angstroms to about 200 angstroms in length, and may be either in a cis or trans orientation.
  • The term “intemucleotide linkage” generally refer to a chemical linkage to join two nucleosides through their sugars (e.g. 3′-3′, 2′-3′, 2′-5′, 3′-5′, 5′-5′) consisting of a phosphorous atom and a charged, or neutral group (e.g., phosphodiester, phosphorothioate, phosphorodithioate or methylphosphonate) between adjacent nucleosides.
  • The term “oligonucleotide” refers to a polynucleoside formed from a plurality of linked nucleoside units, which may include, for example, deoxyribonucleotides or ribonucleotides, synthetic or natural nucleotides, phosphodiester or modified linkages, natural bases or modified bases natural sugars or modified sugars, or combinations of these components. The nucleoside units may be part of viruses, bacteria, cell debris or oligonucleotide-based compositions (for example, siRNA and microRNA). Such oligonucleotides can also be obtained from existing nucleic acid sources, including genomic or cDNA, but are preferably produced by synthetic methods. In certain embodiments each nucleoside unit includes a heterocyclic base and a pentofuranosyl, trehalose, arabinose, 2′-deoxy-2′-substituted nucleoside, 2′-deoxy-2′-substituted arabinose, 2′-O-substitutedarabinose or hexose sugar group. The nucleoside residues can be coupled to each other by any of the numerous known intemucleoside linkages. Such intemucleoside linkages include, without limitation, phosphodiester, phosphorothioate, phosphorodithioate, methylphosphonate, alkylphosphonate, alkylphosphonothioate, phosphotriester, phosphoramidate, siloxane, carbonate, carboalkoxy, acetamidate, carbamate, morpholino, borano, thioether, bridged phosphoramidate, bridged methylene phosphonate, bridged phosphorothioate, and sulfone intemucleoside linkages. The term “oligonucleotide” also encompasses polynucleosides having one or more stereospecific intemucleoside linkage (e.g., (Rp)- or (Sp)-phosphorothioate, alkylphosphonate, or phosphotriester linkages). As used herein, the terms “oligonucleotide” and “dinucleotide” are expressly intended to include polynucleosides and dinucleosides having any such intemucleoside linkage, whether or not the linkage comprises a phosphate group. In certain exemplary embodiments, these intemucleoside linkages may be phosphodiester, phosphorothioate or phosphorodithioate linkages, or combinations thereof. In exemplary embodiments, the nucleotides of the synthetic oligonucleotides are linked by at least one phosphorothioate internucleotide linkage. The phosphorothioate linkages may be mixed Rp and Sp enantiomers, or they may be stereoregular or substantially stereoregular in either Rp or Sp form (see Iyer et al. (1995) Tetrahedron Asymmetry 6:1051-1054). In certain embodiments, one or more of the oligonucleotides within the antisense compositions of the invention contain one or more 2′-O,4′-C-methylene-b-D-ribofuranosyl nucleic acids, wherein the ribose is modified with a bond between the 2′ and 4′ carbons, which fixes the ribose in the 3′-endo structural conformation.
  • The phrase “an oligonucleotide that is complementary to a single-stranded RNA sequence” and the like, means that the oligonucleotide forms a sufficient number of hydrogen bonds through Watson-Crick interactions of its nucleobases with nucelobases of the single-stranded RNA sequence to form a double helix with the single-stranded RNA sequence under physiological conditions. This is in contrast to oligonucleotides that form a triple helix with a double-stranded DNA or RNA through Hoogsteen hydrogen bonding.
  • The term “complementary” is intended to mean an oligonucleotide that binds to the nucleic acid sequence under physiological conditions, for example, by Watson-Crick base pairing (interaction between oligonucleotide and single-stranded nucleic acid) or by Hoogsteen base pairing (interaction between oligonucleotide and double-stranded nucleic acid) or by any other means, including in the case of an oligonucleotide, binding to RNA and causing pseudoknot formation. Binding by Watson-Crick or Hoogsteen base pairing under physiological conditions is measured as a practical matter by observing interference with the function of the nucleic acid sequence.
  • The term “peptide” generally refers to oligomers or polymers of amino acids that are of sufficient length and composition to affect a biological response, for example, antibody production or cytokine activity whether or not the peptide is a hapten. The term “peptide” may include modified amino acids (whether or not naturally or non-naturally occurring), where such modifications include, but are not limited to, phosphorylation, glycosylation, pegylation, lipidization, and methylation.
  • The term “pharmaceutically acceptable” means a non-toxic material that does not interfere with the effectiveness of a compound according to the invention or the biological activity of a compound according to the invention.
  • The term “physiologically acceptable” refers to a non-toxic material that is compatible with a biological system such as a cell, cell culture, tissue, or organism. Preferably, the biological system is a living organism, such as a mammal, particularly a human.
  • The term “prophylactically effective amount” generally refers to an amount sufficient to prevent or reduce the development of an undesired biological effect.
  • The term “therapeutically effective amount” or “pharmaceutically effective amount” generally refers to an amount sufficient to affect a desired biological effect, such as a beneficial result, including, without limitation, prevention, diminution, amelioration or elimination of signs or symptoms of a disease or disorder. Thus, the total amount of each active component of the pharmaceutical composition or method is sufficient to show a meaningful patient benefit, for example, but not limited to, healing of chronic conditions characterized by immune stimulation. Thus, a “pharmaceutically effective amount” will depend upon the context in which it is being administered. A pharmaceutically effective amount may be administered in one or more prophylactic or therapeutic administrations. When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.
  • The term “treatment” generally refers to an approach intended to obtain a beneficial or desired result, which may include alleviation of symptoms, or delaying or ameliorating a disease progression.
  • The term “gene expression” generally refers to process by which information from a gene is used in the synthesis of a functional gene product, which may be a protein. The process may involve transcription, RNA splicing, translation, and post-translational modification of a protein, and may include mRNA, preRNA, ribosomal RNA, and other templates for protein synthesis.
  • In a first aspect, the invention provides novel oligonucleotide-based compounds comprising two or more single-stranded antisense oligonucleotides linked at their 5′ ends, wherein the compounds have two or more accessible 3′ ends. The linkage at the 5′ ends of the component oligonucleotides is independent of the other oligonucleotide linkages and may be directly via 5′, 3′ or 2′ hydroxyl groups, or indirectly, via a non-nucleotide linker or a nucleoside, utilizing either the 2′ or 3′ hydroxyl positions of the nucleoside. Linkages may also utilize a functionalized sugar or nucleobase of a 5′ terminal nucleotide.
  • Oligonucleotide-based compounds according to the invention comprise two identical or different sequences conjugated at their 5′-5′ ends via a phosphodiester, phosphorothioate or non-nucleoside linker (Diagram 3). Such compounds comprise 15 to 27 nucleotides that are complementary to specific portions of mRNA targets of interest for antisense down regulation of gene product. Oligonucleotide-based compounds according to the invention that comprise identical sequences are able to bind to a specific mRNA via Watson-Crick hydrogen bonding interactions and inhibit protein expression (FIG. 16). Oligonucleotide-based compounds according to the invention that comprise different sequences are able to bind to two or more different regions of one or more mRNA target and inhibit protein expression. Such compounds are comprised of heteronucleotide sequences complementary to target mRNA and form stable duplex structures through Watson-Crick hydrogen bonding. Surprisingly, such sequences containing two free 3′-ends (5′-5′-attached antisense) are more potent inhibitors of gene expression than those containing a single free 3′-end or no free 3′-end.
  • Oligonucleotide-based compounds according to the invention are useful in treating and/or preventing diseases wherein inhibiting a gene expression would be beneficial. Oligonucleotide-based compounds according to the invention include, but are not limited to, antisense oligonucleotides comprising naturally occurring nucleotides, modified nucleotides, modified oligonucleotides and/or backbone modified oligonucleotides. However, antisense oligonucleotides that inhibit the translation of mRNA encoded proteins may produce undesired biological effects, including but not limited to insufficient antisense activity, inadequate bioavailability, suboptimal pharmacokinetics or pharmacodynamics, unintended immune stimulation, off target activity, and biologic instability. The optimal design of an antisense oligonucleotide according to the invention requires many considerations beyond simple design of a molecule that is complementary to the target RNA sequence. Thus, preparation of antisense oligonucleotides according to the invention is intended to incorporate changes necessary to limit secondary structure interference with antisense activity, enhance the oligonucleotide's target specificity, minimize interaction with binding or competing factors (for example, proteins), optimize cellular uptake, bioavailability, pharmacokinetics, and pharmacodynamics, and/or inhibit, prevent or suppress immune cell activation.
  • The general structure of the oligonucleotide-based compounds of the invention may be described by the following formula

  • 3′-Nn . . . N1N2N3N4-5′-L-5′-N8N7N6N5 . . . Nm-3′  (Formula I)
  • Wherein L is a nucleotide linker or non-nucleotide linker; N1-N8, at each occurrence, is independently a nucleotide or nucleotide derivative; Nm and Nn, at each occurrence, are independently a nucleotide or nucleotide derivative; and wherein m and n are independently numbers from 0 to about 40. Representative non-nucleotide linkers are set forth in Table 1.
  • TABLE 1
    Representative Non-Nucleotide Linkers
    Figure US20120016004A1-20120119-C00001
    Glycerol (1,2,3-Propanetriol)
    Figure US20120016004A1-20120119-C00002
    1,2,4-Butanetriol
    Figure US20120016004A1-20120119-C00003
    2-(hydroxymethyl)-1,3-propanediol
    Figure US20120016004A1-20120119-C00004
    2-(hydroxymethyl)1,4-butanediol
    Figure US20120016004A1-20120119-C00005
    1,3,5-Pentanetriol
    Figure US20120016004A1-20120119-C00006
    1,1,1-Tris(hydroxymethyl)ethane
    Figure US20120016004A1-20120119-C00007
    1,1,1-Tris(hydroxymethyl)nitromethane
    Figure US20120016004A1-20120119-C00008
    1,1,1-Tris(hydroxymethyl)propane
    Figure US20120016004A1-20120119-C00009
    1,2,6-Hexanetriol
    Figure US20120016004A1-20120119-C00010
    3-Methyl-1,3,5-pentanetriol
    Figure US20120016004A1-20120119-C00011
    1,2,3-Heptanetriol
    Figure US20120016004A1-20120119-C00012
    2-Amino-2-(hydroxymethyl)-1,3-propanediol
    Figure US20120016004A1-20120119-C00013
    N-[Tris(hydroxymethyl)methyl]acrylamide
    Figure US20120016004A1-20120119-C00014
    cis-1,3,5-Cyclohexanetriol
    Figure US20120016004A1-20120119-C00015
    cis-1,3,5-Tri(hydroxymethyl)cyclohexane
    Figure US20120016004A1-20120119-C00016
    1,3,5,-Trihydroxyl-benzene
    Figure US20120016004A1-20120119-C00017
    3,5,-Di(hydroxymethyl)phenol
    Figure US20120016004A1-20120119-C00018
    1,3,5,-Tri(hydroxymethyl)benzene
    Figure US20120016004A1-20120119-C00019
    1,3-Di(hydroxyethoxy)-2-hydroxyl-propane
    Figure US20120016004A1-20120119-C00020
    1,3-Di(hydroxypropoxy)-2-hydroxyl-propane
    Figure US20120016004A1-20120119-C00021
    2-Deoxy-D-ribose
    Figure US20120016004A1-20120119-C00022
    1,2,4,-Trihydroxyl-benzene
    Figure US20120016004A1-20120119-C00023
    D-Galactoal
    Figure US20120016004A1-20120119-C00024
    1,6-anhydro-β-D-Glucose
    Figure US20120016004A1-20120119-C00025
    1,3,5-Tris(2-hydroxyethyl)-Cyanuric acid
    Figure US20120016004A1-20120119-C00026
    Gallic acid
    Figure US20120016004A1-20120119-C00027
    3,5,7-Trihydroxyflavone
    Figure US20120016004A1-20120119-C00028
    4,6-Nitropyrogallol
    Figure US20120016004A1-20120119-C00029
    Ethylene glycol
    Figure US20120016004A1-20120119-C00030
    1,3-Propanediol
    Figure US20120016004A1-20120119-C00031
    1,2-Propanediol
    Figure US20120016004A1-20120119-C00032
    1,4-Butanediol
    Figure US20120016004A1-20120119-C00033
    1,3-Butanediol
    Figure US20120016004A1-20120119-C00034
    2,3-Butanediol
    Figure US20120016004A1-20120119-C00035
    1,4-Butanediol
    Figure US20120016004A1-20120119-C00036
    1,5-Pentanediol
    Figure US20120016004A1-20120119-C00037
    2,4-Pentanediol
    Figure US20120016004A1-20120119-C00038
    1,6-Hexanediol
    Figure US20120016004A1-20120119-C00039
    1,2-Hexanediol
    Figure US20120016004A1-20120119-C00040
    1,5-Hexanediol
    Figure US20120016004A1-20120119-C00041
    2,5-Hexanediol
    Figure US20120016004A1-20120119-C00042
    1,7-Heptanediol
    Figure US20120016004A1-20120119-C00043
    1,8-Octanediol
    Figure US20120016004A1-20120119-C00044
    1,2-Octanediol
    Figure US20120016004A1-20120119-C00045
    1,9-Nonanediol
    Figure US20120016004A1-20120119-C00046
    1,12-Dodecanediol
    Figure US20120016004A1-20120119-C00047
    Triethylene glycol
    Figure US20120016004A1-20120119-C00048
    Tetraethylene glycol
    Figure US20120016004A1-20120119-C00049
    Hexaethylene glycol
    Figure US20120016004A1-20120119-C00050
    2-(1-Aminopropyl)-1,3-propanediol
    Figure US20120016004A1-20120119-C00051
    1,2-Dideoxyribose
  • In some embodiments, the small molecule linker is glycerol or a glycerol homolog of the formula HO—(CH2)0—CH(OH)—(CH2)p—OH, wherein o and p independently are integers from 1 to about 6, from 1 to about 4 or from 1 to about 3. In some other embodiments, the small molecule linker is a derivative of 1,3-diamino-2-hydroxypropane. Some such derivatives have the formula HO—(CH2)mC(O)NH—CH2—CH(OH)—CH2—NHC(O)—(CH2)m—OH, wherein m is an integer from 0 to about 10, from 0 to about 6, from 2 to about 6 or from 2 to about 4.
  • Some non-nucleotide linkers according to the invention permit attachment of more than two oligonucleotide-based compounds of the invention. For example, the small molecule linker glycerol has three hydroxyl groups to which such oligonucleotides may be covalently attached. Some oligonucleotide-based compounds of the invention, therefore, comprise two or more oligonucleotides linked to a nucleotide or a non-nucleotide linker. Such oligonucleotides according to the invention are referred to as being “branched”.
  • Oligonucleotide-based compounds according to the invention may comprise at least two linked antisense oligonucleotides with two or more free 3′ ends. Some of the ways in which two or more oligonucleotides can be linked are shown in Table 2.
  • TABLE 2
    Oligoribonucleotide Formulas II-V
    Formula II
    Figure US20120016004A1-20120119-C00052
    Formula III
    Figure US20120016004A1-20120119-C00053
    Formula IV
    Figure US20120016004A1-20120119-C00054
    Formula V
    Figure US20120016004A1-20120119-C00055
  • In certain embodiments of Formulas II and/or V, L is a linker or a nucleotide linkage and Domain A and/or Domain B are antisense oligonucleotides that are designed to selectively hybridize to the same target RNA sequence or different target RNA sequences.
  • In certain embodiments of Formulas II, III, IV or V, L is a linker and Domain A and/or Domain B and/or Domain C are antisense oligonucleotides that are designed to selectively hybridize to the same target RNA sequence or different target RNA sequences. For example, in one embodiment, Domain A and/or Domain B and/or Domain C of Formulas II and/or III are antisense oligonucleotides that are designed to selectively hybridize to the same target RNA sequence. In this embodiment, Domain A and/or Domain B and/or Domain C can be designed to hybridize to the same region on the target RNA sequence or to different regions of the same target RNA sequence.
  • In a further embodiment of this aspect of the invention, Domain A, Domain B, and Domain C are independently RNA or DNA-based oligonucleotides. In certain aspects of this embodiment, the oligonucleotides comprise mixed backbone oligonucleotides.
  • In another embodiment, one or more of Domain A and/or Domain B and/or Domain C of Formula IV is an antisense oligonucleotide that is designed to selectively hybridize to one target RNA sequence and one or more of the remaining Domain A and/or Domain B and/or Domain C is an antisense oligonucleotide that is designed to selectively hybridized to a different target RNA sequence.
  • In another embodiments, one or more of Domain A, Domain B or Domain C of Formula IV is an antagonist of a cell-surface or intracellular receptor. In certain embodiments, the antagonist is a TLR antagonist.
  • In another embodiment, one or more of Domain A and/or Domain B and/or Domain C of Formula II, III, IV and/or V is an RNA-based oligonucleotide hybridized to a complimentary RNA-based oligonucleotide such that the domain comprises an siRNA molecule.
  • The component oligonucleotides of oligonucleotide-based compounds of the invention are at least 14 nucleotides in length, but are preferably 15 to 40 nucleotides long, preferably 20 to 30 nucleotides in length. Thus, the component oligonucleotides of the oligonucleotide-based compounds of the invention can independently be 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40 nucleotides in length. These oligonucleotides can be prepared by the art recognized methods such as phosphoramidate or H-phosphonate chemistry which can be carried out manually or by an automated synthesizer. Representative synthetic approaches are shown in FIGS. 1A and 1B. The synthetic antisense oligonucleotides of the invention may also be modified in a number of ways without compromising their ability to hybridize to mRNA. Such modifications may include at least one internucleotide linkage of the oligonucleotide being an alkylphosphonate, phosphorothioate, phosphorodithioate, methylphosphonate, phosphate ester, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate hydroxyl, acetamidate or carboxymethyl ester or a combination of these and other internucleotide linkages between the 5′ end of one nucleotide and the 3′ end of another nucleotide in which the 5′ nucleotide phosphodiester linkage has been replaced with any number of chemical groups.
  • The synthetic antisense oligonucleotides of the invention may comprise combinations of intemucleotide linkages. For example, U.S. Pat. No. 5,149,797 describes traditional chimeric oligonucleotides having a phosphorothioate core region interposed between methylphosphonate or phosphoramidate flanking regions. Additionally, U.S. Pat. No. 5,652,356 discloses “inverted” chimeric oligonucleotides comprising one or more nonionic oligonucleotide region (e.g. alkylphosphonate and/or phosphoramidate and/or phosphotriester intemucleoside linkage) flanked by one or more region of oligonucleotide phosphorothioate. Various synthetic antisense oligonucleotides with modified intemucleotide linkages can be prepared according to standard methods. In certain embodiments, the phosphorothioate linkages may be mixed Rp and Sp enantiomers, or they may be made stereoregular or substantially stereoregular in either Rp or Sp form.
  • Other modifications of oligonucleotide-based compounds of the invention include those that are intemal or at the end(s) of the oligonucleotide molecule and include additions to the molecule of the intemucleoside phosphate linkages, such as cholesterol, cholesteryl, or diamine compounds with varying numbers of carbon residues between the amino groups and terminal ribose, deoxyribose and phosphate modifications which cleave, or crosslink to the opposite chains or to associated enzymes or other proteins which bind to the genome. Examples of such modified oligonucleotides include oligonucleotides with a modified base and/or sugar such as 2′-O,4′-C-methylene-b-D-ribofuranosyl, or arabinose instead of ribose, or a 3′,5′-substituted oligonucleotide having a sugar which, at both its 3′ and 5′ positions, is attached to a chemical group other than a hydroxyl group (at its 3′ position) and other than a phosphate group (at its 5′ position).
  • Other examples of modifications to sugars of the oligonucleotide-based compounds of the invention include modifications to the 2′ position of the ribose moiety which include but are not limited to 2′-O-substituted with an —O-alkyl group containing 1-6 saturated or unsaturated carbon atoms, or with an —O-aryl, or —O-allyl group having 2-6 carbon atoms wherein such —O-alkyl, —O-aryl or —O-allyl group may be unsubstituted or may be substituted, for example with halo, hydroxyl, trifluoromethyl, cyano, nitro, acyl, acyloxy, alkoxy, carboxy, carbalkoxyl or amino groups. None of these substitutions are intended to exclude the presence of other residues having native 2′-hydroxyl group in the case of ribose or 2′ H— in the case of deoxyribose.
  • The oligonucleotides-based compounds according to the invention can comprise one or more ribonucleotides. For example, U.S. Pat. No. 5,652,355 discloses traditional hybrid oligonucleotides having regions of 2′-O-substituted ribonucleotides flanking a DNA core region. U.S. Pat. No. 5,652,356 discloses an “inverted” hybrid oligonucleotide that includes an oligonucleotide comprising a 2′-O-substituted (or 2′ OH, unsubstituted) RNA region which is in between two oligodeoxyribonucleotide regions, a structure that “inverted relative to the “traditional” hybrid oligonucleotides. Non-limiting examples of particularly useful oligonucleotides of the invention have 2′-O-alkylated ribonucleotides at their 3′, 5′, or 3′ and 5° termini, with at least four, and in some exemplary embodiments five, contiguous nucleotides being so modified. Non-limiting examples of 2′-O-alkylated groups include 2′-O-methyl, 2′-O-ethyl, 2′-O-propyl, 2′-O-butyls and 2′-O-methoxy-ethyl.
  • The oligonucleotide-based compounds of the invention may conveniently be synthesized using an automated synthesizer and phosphoramidite approach as schematically depicted in FIG. 1B, and further described in Example 1. In some embodiments, the oligonucleotide-based compounds of the invention are synthesized by a linear synthesis approach (see FIG. 1A).
  • An alternative mode of synthesis is “parallel synthesis”, in which synthesis proceeds outward from a central linker moiety (see FIG. 1). A solid support attached linker can be used for parallel synthesis, as is described in U.S. Pat. No. 5,912,332. Alternatively, a universal solid support (such as phosphate attached controlled pore glass) support can be used.
  • Parallel synthesis of the oligonucleotide-based compounds of the invention has several advantages over linear synthesis: (1) parallel synthesis permits the incorporation of identical monomeric units; (2) unlike in linear synthesis, both (or all) the monomeric units are synthesized at the same time, thereby the number of synthetic steps and the time required for the synthesis is the same as that of a monomeric unit; and (3) the reduction in synthetic steps improves purity and yield of the final immune modulatory oligoribonucleotide product.
  • At the end of the synthesis by either linear synthesis or parallel synthesis protocols, the oligonucleotide-based compounds of the invention may conveniently be deprotected with concentrated ammonia solution or as recommended by the phosphoramidite supplier, if a modified nucleoside is incorporated. The product oligonucleotide-based compounds is preferably purified by reversed phase HPLC, detritylated, desalted and dialyzed.
  • A non-limiting list of the oligonucleotide-based compounds of the invention are shown in SEQ ID NO. 1 through SEQ ID NO. 175 in Table 3 below. As shown in Table 3, the oligonucleotide-based compounds have phosphorothioate (PS) linkages, but may also include phosphodiester (o) linkages. Those skilled in the art will recognize, however, that other linkages, based on phosphodiester or non-phosphodiester moieties may be included.
  • TABLE 3
    SEQ ID DNA/
    NO./ mRNA RNA Exemplarty Sequences of the
    AS# Target (species) Invention and Control Oligonucleotides Structure
    1/AS1 TLR9 DNA (h) 5′-ACAGACTTCAGGAACAGCCA-3′ (Control) 5′-(SEQ ID NO. 1)-3′
    2/AS2 TLR9 DNA (h) 3′-ACCGACAAGGACTTCAGACA-X- 3′-(SEQ ID NO. 2)-5′-X-
    ACAGACTTCAGGAACAGCCA-3′ 5′-(SEQ ID NO. 2)-3′
    3/AS3 TLR9 DNA (h) 5′-ACAGACTTCAGGAACAGCCA-X- 5′-(SEQ ID NO. 3)-3′-X-
    ACAGACTTCAGGAACAGCCA-3′ (Control) 3′-(SEQ ID NO. 3)-5′
    4/AS4 TLR9 RNA (h) 5′-ACAGACUUCAGGAACAGCCA-3′ (Control) 5′-(SEQ ID NO. 4)-3′
    5/AS5 TLR9 RNA (m/h) 5′-ACCGACAAGGACUUCAGACA-X- 3′-(SEQ ID NO. 5)-5′-X-
    ACAGACUUCAGGAACAGCCA-3′ 5′-(SEQ ID NO. 5)-3′
    6/AS6 TLR9 DNA (m/h) 3′-ACCGACAAGGACTTCAGACA-X- 3′-(SEQ ID NO. 6)-5′-X-
    ACAGACTTCAGGAACAGCCA-3′ 5′-(SEQ ID NO. 6)-3′
    7/AS7 TLR9 DNA (m/h) 3′-ACCGACAAGGACTTCAGACA-X- 3′-(SEQ ID NO. 7)-5′-X-
    ACAGACTTCAGGAACAGCCA-3′ 5′-(SEQ ID NO. 7)-3′
    8/AS8 TLR9 DNA (m/h) 3′-AoCCoGACAAGGACTTCAoGAoCAo-X- 3′-(SEQ ID NO. 8)-5′-X-
    oACoAGoACTTCAGGAACAGoCCoA-3′ 5′-(SEQ ID NO. 8)-3′
    9/AS9 TLR9 DNA (m/h) 3′-ACCGACAAGGACTTCAGACA-X3- 3′-(SEQ ID NO. 9)-5′-X3-
    ACAGACTTCAGGAACAGCCA-3′ 5′-(SEQ ID NO. 9)-3′
    10/AS10 TLR9 DNA (m/h) 3′-ACCGACAAGGACTTCAGACA-X1- 3′-(SEQ ID NO. 10)-5′-
    ACAGACTTCAGGAACAGCCA-3′ X1-5′-(SEQ ID NO. 10)-3′
    11/AS11 TLR9 DNA (m/h) 3′-ACCGACAAGGACTTCAGACA-Z- 3′-(SEQ ID NO. 11)-5′-Z-
    ACAGACTTCAGGAACAGCCA-3′ 5′-(SEQ ID NO. 11)-3′
    12/AS12 TLR9 DNA (m/h) 3′-ACCGACAAGGACTTCAGACA-M- 3′-(SEQ ID NO. 12)-5′-M-
    ACAGACTTCAGGAACAGCCA-3′ 5′-(SEQ ID NO. 12)-3′
    13/AS13 TLR9 DNA (m/h) 3′-ACCGACAAGGACTTCAGACA-L- 3′-(SEQ ID NO. 13)-5′-L-
    ACAGACTTCAGGAACAGCCA-3′ 5′-(SEQ ID NO. 13)-3′
    14/AS14 TLR9 DNA (m/h) 3′-ACCGACAAGGACTUCAGACA-X- 3′-(SEQ ID NO. 14)-5′-X-
    ACAGACUTCAGGAACAGCCA-3′ 5′-(SEQ ID NO. 14)-3′
    15/AS15 TLR9 DNA (m/h) 3′-ACCGACAAGGACTTCAGACA-X- 3′-(SEQ ID NO. 15)-5′-X-
    ACAGACTTCAGGAACAGCCA-3′ 5′-(SEQ ID NO. 15)-3′
    16/AS16 TLR9 DNA (m/h) 3′-ACCGACAAGGACUTCAGACA-X- 3′-(SEQ ID NO. 16)-5′-X-
    ACAGACTUCAGGAACAGCCA-3′ 5′-(SEQ ID NO. 16)-3′
    17/AS17 TLR9 RNA (m/h) 3′-AGGACUUCAGACA-X- 3′-(SEQ ID NO. 17)-5′-X-
    ACAGACUUCAGGA-3′ 5′-(SEQ ID NO. 17)-3′
    17/AS18 TLR9 RNA (m/h) 3′-CAAGGACUUCAGACA-X- 3′-(SEQ ID NO. 18)-5′-X-
    ACAGACUUCAGGAAC-3′ 5′-(SEQ ID NO. 18)-3′
    19/AS19 TLR9 RNA (h) 3′-ACGCCGUACAGUUGGAGUUC-X- 3′-(SEQ ID NO. 19)-5′-X-
    CUUGAGGUUGAGAUGCCGCA-3′ 5′-(SEQ ID NO. 19)-3′
    20/AS20 TLR7 DNA (m) 3′-CCTGACGTGTCTGTTCGTAA-X- 3′-(SEQ ID NO. 20)-5′-X-
    AATGCTTGTCTGTGCAGTCC-3′ 5′-(SEQ ID NO. 20)-3′
    21/AS21 TLR7 RNA (m) 3′-CCUGACGUGUCUGUUCGUAA-X- 3′-(SEQ ID NO. 21)-5′-X-
    AAUGCUUGUCUGUGCAGUCC-3′ 5′-(SEQ ID NO. 21)-3′
    22/AS22 TLR7 RNA (m) 3′-UCGUGUGUUUCCAGUUUCA-X- 3′-(SEQ ID NO. 22)-5′-X-
    ACUUUGACCUUUGUGUGCU-3′ 5′-(SEQ ID NO. 22)-3′
    23/AS23 TLR7 RNA (h) 3′-UUGUAGUUGUUUGAGGUCC-X- 3′-(SEQ ID NO. 23)-5′-X-
    CCUGGAGUUUGUUGAUGUU-3′ 5′-(SEQ ID NO. 23)-3′
    24/AS24 MyD88 DNA (m) 3′-GTCCGACGATCTCGACGACC-X- 3′-(SEQ ID NO. 24)-5′-X-
    CCAGCAGCTCTAGCAGCCTG-3′ 5′-(SEQ ID NO. 24)-3′
    25/AS25 MyD88 RNA (m) 3′-GUCCGACGAUCUCGACGACC-X- 3′-(SEQ ID NO. 25)-5′-X-
    CCAGCAGCUCUAGCAGCCUG-3′ 5′-(SEQ ID NO. 25)-3′
    26/AS26 TLR7 DNA (m) 5′-AATGCTTGTCTGTGCAGTCC-3′ (Control) 5′-(SEQ ID NO. 26)-3′
    27/AS27 TLR7 DNA (m) 3′-CCTGACGTGTCTGTTCGTAA-X- 3′-(SEQ ID NO. 27)-5′-X-
    AATGCTTGTCTGTGCAGTCC-3′ 5′-(SEQ ID NO. 27)-3′
    28/AS28 TLR7 RNA (m/h) 3′-CCUGACGUGUCUGUUCGUAA-5′ (Control) 3′-(SEQ ID NO. 28)-5′
    29/AS29 TLR7 RNA (m/h) 5′- 5′-(SEQ ID NO. 29)-3′
    CUGUCoAoAoAoUoGoCoUoUoGoUoCoUoGoUoGoCoAoGoUoCo
    CoACGAU-3′ (Control)
    30/AS30 TLR9 DNA (m/h) 3′-CCGACAAGGACTTCAGACA-X- 3′-(SEQ ID NO. 30)-5′-X-
    ACAGACTTCAGGAACAGCC-3′ 5′-(SEQ ID NO. 30)-3′
    31/AS31 TLR9 DNA (m/h) 5′-ACAGACTTCAGGAACAGCC-X- 5′-(SEQ ID NO. 31)-3′-X-
    CCGACAAGGACTTCAGACA-5′ (Control) 3′-(SEQ ID NO. 31)-5′
    32/AS32 TLR9 DNA (m/h) 5′-ACAGACTTCAGGAACAGCC-3′ (Control) 5′-(SEQ ID NO. 32)-3′
    33/AS33 TLR7 DNA (m/h) 3′-CTGACGTGTCTGTTCGTAA-X- 3′-(SEQ ID NO. 33)-5′-X-
    AATGCTTGTCTGTGCAGTC-3′ 5′-(SEQ ID NO. 33)-3′
    34/AS34 TLR7 DNA (m/h) 5′-AATGCTTGTCTGTGCAGTC-X- 5′-(SEQ ID NO. 34)-3′-X-
    CTGACGTGTCTGTTCGTAA-5′ (Control) 3′-(SEQ ID NO. 34)-5′
    35/AS35 TLR7 DNA (m/h) 5′-AATGCTTGTCTGTGCAGTCC-3′ (Control) 5′-(SEQ ID NO. 35)-3′
    36/AS36 MyD88 DNA (h) 3′-CGTTGACCTCTGTGTTCGC-X- 3′-(SEQ ID NO. 36)-5′-X-
    CGCTTGTGTCTCCAGTTGC-3′ 5′-(SEQ ID NO. 36)-3′
    37/AS37 MyD88 DNA (h) 5′-CGCTTGTGTCTCCAGTTGC-X- 5′-(SEQ ID NO. 37)-3′-X-
    CGTTGACCTCTGTGTTCGC-5′ (Control) 3′-(SEQ ID NO. 37)-5′
    38/AS38 MyD88 DNA (h) 5′-CGCTTGTGTCTCCAGTTGC-3′ (Control) 5′-(SEQ ID NO. 38)-3′
    39/AS39 VEGF DNA (h) 3′-GAAAGACGACAGAACCCAC-X- 3′-(SEQ ID NO. 39)-5′-X-
    CACCCAAGACAGCAGAAAG-3′ 5′-(SEQ ID NO. 39)-3′
    40/AS40 VEGF DNA (h) 5′-CACCCAAGACAGCAGAAAG-X- 5′-(SEQ ID NO. 40)-3′-X-
    GAAAGACGACAGAACCCAC-5′ (Control) 3′-(SEQ ID NO. 40)-5′
    41/AS41 VEGF DNA (h) 5′-CACCCAAGACAGCAGAAAG-3′ (Control) 5′-(SEQ ID NO. 41)-3′
    42/AS42 TLR9 DNA (m/h) 3′-CAAGGACTTCAGACA-X- 3′-(SEQ ID NO. 42)-5′-X-
    ACAGACTTCAGGAAC-3′ 5′-(SEQ ID NO. 42)-3′
    43/AS43 TLR9 DNA (m/h) 3′-GACAAGGACTTCAGACA-X- 3′-(SEQ ID NO. 43)-5′-X-
    ACAGACTTCAGGAACAG-3′ 5′-(SEQ ID NO. 43)-3′
    44/AS44 TLR9 DNA (m/h) 3′-CCGACAAGGACTTCAGACA-X- 3′-(SEQ ID NO. 44)-5′-X-
    ACAGACTTCAGGAACAGCC-3′ 5′-(SEQ ID NO. 44)-3′
    45/AS45 TLR9 DNA (m/h) 3′-AACCGACAAGGACTTCAGACA-X- 3′-(SEQ ID NO. 45)-5′-X-
    ACAGACTTCAGGAACAGCCAA-3′ 5′-(SEQ ID NO. 45)-3′
    46/AS46 TLR9 DNA (m/h) 3′-TTAACCGACAAGGACTTCAGACA-X- 3′-(SEQ ID NO. 46)-5′-X-
    ACAGACTTCAGGAACAGCCAATT-3′ 5′-(SEQ ID NO. 46)-3′
    47/AS47 TLR9 DNA (m/h) 3′-CGTTAACCGACAAGGACTTCAGACA-X- 3′-(SEQ ID NO. 47)-5′-X-
    ACAGACTTCAGGAACAGCCAATTGC-3′ 5′-(SEQ ID NO. 47)-3′
    48/AS48 TLR9 DNA (m/h) 3′-GACGTTAACCGACAAGGACTTCAGACA-X- 3′-(SEQ ID NO. 48)-5′-X-
    ACAGACTTCAGGAACAGCCAATTGCAG-3′ 5′-(SEQ ID NO. 48)-3′
    49/AS49 TLR9 DNA (h) 3′-GACCGACAAGGACUUCAGACA-X- 3′-(SEQ ID NO. 49)-5′-X-
    ACAGACUUCAGGAACAGCCAG-3′ 5′-(SEQ ID NO. 49)-3′
    50/AS50 TLR9 DNA (h) 3′-TTGACCGACAAGGACUUCAGACA-X- 3′-(SEQ ID NO. 50)-5′-X-
    ACAGACUUCAGGAACAGCCAGTT-3′ 5′-(SEQ ID NO. 50)-3′
    51/AS51 TLR9 DNA (m/h) 3′-CoCoGoAoCoAoAoGoGoAoCoToToCoAoGoAoCoAo-X- 3′-(SEQ ID NO. 51)-5′-X-
    oAoCoAoGoAoCoToToCoAoGoGoAoAoCoAoGoCoC-3′ 5′-(SEQ ID NO. 51)-3′
    52/AS52 TLR9 DNA (m/h) 5′-C-3′-3′-CCGACAAGGACTTCAGACA-X- 3′-(SEQ ID NO. 52)-5′-X-
    ACAGACTTCAGGAACAGCC-3′-3′-C-5′ 5′-(SEQ ID NO. 52)-3′
    53/AS53 TLR9 DNA (m/h) 5′-GCC-3′-3′-CCGACAAGGACTTCAGACA-X- 3′-(SEQ ID NO. 53)-5′-X-
    ACAGACTTCAGGAACAGCC-3′-3′-CCG-5′ 5′-(SEQ ID NO. 53)-3′
    54/AS54 TLR9 DNA (m/h) 5′-CAGCC-3′-3′-CCGACAAGGACTTCAGACA-X- 3′-(SEQ ID NO. 54)-5′-X-
    ACAGACTTCAGGAACAGCC3′-3′-CCGAC-5′ 5′-(SEQ ID NO. 54)-3′
    55/AS55 TLR9 DNA (m/h) 3′-CCGACAAGGACTTCAGACA-X- 3′-(SEQ ID NO. 55)-5′-X-
    ACAGACTTCAGGAACAGCC-3′ 5′-(SEQ ID NO. 55)-3′
    56/AS56 TLR9 DNA (m/h) 3′-CCGACAAGGACTTCAGACA-X- 3′-(SEQ ID NO. 56)-5′-X-
    ACAGACTTCAGGAACAGCC-3′ 5′-(SEQ ID NO. 56)-3′
    57/AS57 TLR9 DNA (m/h) 3′-CCGACAAGGACTTCAGACA- 3′-(SEQ ID NO. 57)-5′-X-
    ACAGACTTCAGGAACAGCC-3′ 5′-(SEQ ID NO. 57)-3′
    58/AS58 TLR9 DNA (m/h) 3′-CCGACAAGGACTTCAGACA-Y-ACAGACTTC-3′ 3′-(SEQ ID NO. 58)-5′-X-
    5′-(SEQ ID NO. 58)-3′
    59/AS59 TLR9 DNA (m/h) 3′-CTTCAGACA-X-ACAGACTTC-3′ 3′-(SEQ ID NO. 59)-5′-X-
    5′-(SEQ ID NO. 59)-3′
    60/AS60 TLR9 DNA (m/h) 3′-CCGACAAGGACTTCAGACA-X- 3′-(SEQ ID NO. 60)-5′-X-
    ACAGACTTCAGGAACAGCC-3′ 5′-(SEQ ID NO. 60)-3′
    61/AS61 TLR9 DNA (m/h) 3′TTGACCGACAAGGACTTCAGACA-X- 3′-(SEQ ID NO. 61)-5′-X-
    ACAGACTTCAGGAACAGCCAGTT-3′ 5′-(SEQ ID NO. 61)-3′
    62/AS62 TLR9 DNA (m/h) 3′-CCGACAAGGACTTCAGACA-X5- 3′-(SEQ ID NO. 62)-5′-X-
    ACAGACTTCAGGAACAGCC-3′ 5′-(SEQ ID NO. 62)-3′
    63/AS63 TLR7 DNA (m/h) 3′-GACGTGTCTGTTCGTAA-X- 3′-(SEQ ID NO. 63)-5′-X-
    AATGCTTGTCTGTGCAG-3′ 5′-(SEQ ID NO. 63)-3′
    64/AS64 TLR7 DNA (m/h) 3′-CTGACGTGTCTGTTCGTAA-X- 3′-(SEQ ID NO. 64)-5′-X-
    AATGCTTGTCTGTGCAGTC-3′ 5′-(SEQ ID NO. 64)-3′
    65/AS65 TLR9 DNA (m/h) 3′-ACCTGACGTGTCTGTTCGTAA-X- 3′-(SEQ ID NO. 65)-5′-X-
    AATGCTTGTCTGTGCAGTCCA-3′ 5′-(SEQ ID NO. 65)-3′
    66/AS66 MyD88 DNA (m) 3′-ACGATCTCGACGACC-X- 3′-(SEQ ID NO. 66)-5′-X-
    CCAGCAGCTCTAGC-3′ 5′-(SEQ ID NO. 66)-3′
    67/AS67 MyD88 DNA (m) 3′-CGACGATCTCGACGACC-X- 3′-(SEQ ID NO. 67)-5′-X-
    CCAGCAGCTCTAGCAGC-3′ 5′-(SEQ ID NO. 67)-3′
    68/AS68 MyD88 DNA (m) 3′-TCCGACGATCTCGACGACC-X- 3′-(SEQ ID NO. 68)-5′-X-
    CCAGCAGCTCTAGCAGCCT-3′ 5′-(SEQ ID NO. 68)-3′
    69/AS69 MyD88 DNA (m) 3′-CGTCCGACGATCTCGACGACC-X- 3′-(SEQ ID NO. 69)-5′-X-
    CCAGCAGCTCTAGCAGCCTGC-3′ 5′-(SEQ ID NO. 69)-3′
    70/AS70 MyD88 DNA (m) 3′-GCCGTCCGACGATCTCGACGACC-X- 3′-(SEQ ID NO. 70)-5′-X-
    CCAGCAGCTCTAGCAGCCTGCCG-3′ 5′-(SEQ ID NO. 70)-3′
    71/AS71 MyD88 DNA (m) 3′-CAGCCGTCCGACGATCTCGACGACC-X- 3′-(SEQ ID NO. 71)-5′-X-
    CCAGCAGCTCTAGCAGCCTGCCGAC-3′ 5′-(SEQ ID NO. 71)-3′
    72/AS72 MyD88 DNA (h) 3′-GACCTCTGTGTTCGC-X- 3′-(SEQ ID NO. 72)-5′-X-
    CGCTTGTGTCTCCAG-3′ 5′-(SEQ ID NO. 72)-3′
    73/AS73 MyD88 DNA (h) 3′-TTGACCTCTGTGTTCGC-X- 3′-(SEQ ID NO. 73)-5′-X-
    CGCTTGTGTCTCCAGTT-3′ 5′-(SEQ ID NO. 73)-3′
    74/AS74 MyD88 DNA (h) 3′-CGTTGACCTCTGTGTTCGC-X- 3′-(SEQ ID NO. 74)-5′-X-
    CGCTTGTGTCTCCAGTTGC-3′ 5′-(SEQ ID NO. 74)-3′
    75/AS75 MyD88 DNA (h) 3′-GCCGTTGACCTCTGTGTTCGC-X- 3′-(SEQ ID NO. 75)-5′-X-
    CGCTTGTGTCTCCAGTTGCCG-3′ 5′-(SEQ ID NO. 75)-3′
    76/AS76 MyD88 DNA (h) 3′-AGGCCGTTGACCTCTGTGTTCGC-X- 3′-(SEQ ID NO. 76)-5′-X-
    CGCTTGTGTCTCCAGTTGCCGGA-3′ 5′-(SEQ ID NO. 76)-3′
    77/AS77 MyD88 DNA (h) 3′-CTAGGCCGTTGACCTCTGTGTTCGC-X- 3′-(SEQ ID NO. 77)-5′-X-
    CGCTTGTGTCTCCAGTTGCCGGATC-3′ 5′-(SEQ ID NO. 77)-3′
    78/AS78 MyD88 DNA (m) 3′-UCCGACGATCTCGACGACC-X- 3′-(SEQ ID NO. 78)-5′-X-
    CCAGCAGCTCTAGCAGCCU-3′ 5′-(SEQ ID NO. 78)-3′
    79/AS79 MyD88 DNA (h) 3′-CGUUGACCTCTGTGTUCGC-X- 3′-(SEQ ID NO. 79)-5′-X-
    CGCUTGTGTCTCCAGUUGC-3′ 5′-(SEQ ID NO. 79)-3′
    80/AS80 MyD88 DNA (h) 3′-CGTTGACCTCTGTGTTCGC-Z- 3′-(SEQ ID NO. 80)-5′-X-
    CGCTTGTGTCTCCAGTTGC-3′ 5′-(SEQ ID NO. 80)-3′
    81/AS81 MyD88 DNA (h) (3′-CGTTGACCTCTGTGTTCGC)2-Z-Z-Z- 3′-(SEQ ID NO. 81)-5′-X-
    (CGCTTGTGTCTCCAGTTGC-3′)2 5′-(SEQ ID NO. 81)-3′
    82/AS82 TLR3 DNA (m) 3′-CTTGGAGGTTCTTGACG-X- 3′-(SEQ ID NO. 82)-5′-X-
    GCAGTTCTTGGAGGTTC-3′ 5′-(SEQ ID NO. 82)-3′
    83/AS83 TLR3 DNA (m) 3′-CTCTTGGAGGTTCTTGACG-X- 3′-(SEQ ID NO. 83)-5′-X-
    GCAGTTCTTGGAGGTTCTC-3′ 5′-(SEQ ID NO. 83)-3′
    84/AS84 TLR3 DNA (m) 3′-ACCTCTTGGAGGTTCTTGACG-X- 3′-(SEQ ID NO. 84)-5′-X-
    GCAGTTCTTGGAGGTTCTCCA-3′ 5′-(SEQ ID NO. 84)-3′
    85/AS85 TLR3 DNA (h) 3′-CGTGGAATTGTACCTTC-X- 3′-(SEQ ID NO. 85)-5′-X-
    CTTCCATGTTAAGGTGC-3′ 5′-(SEQ ID NO. 85)-3′
    86/AS86 TLR3 DNA (h) 3′-CTCGTGGAATTGTACCTTC-X- 3′-(SEQ ID NO. 86)-5′-X-
    CTTCCATGTTAAGGTGCTC-3′ 5′-(SEQ ID NO. 86)-3′
    87/AS87 TLR3 DNA (h) 3′-ACCTCGTGGAATTGTACCTTC-X- 3′-(SEQ ID NO. 87)-5′-X-
    CTTCCATGTTAAGGTGCTCCA-3′ 5′-(SEQ ID NO. 87)-3′
    88/AS88 VEGF DNA (h) 3′-GAAAGACGACAGAACCCAC-X- 3′-(SEQ ID NO. 88)-5′-X-
    CACCCAAGACAGCAGAAAG-3′ 5′-(SEQ ID NO. 88)-3′
    89/AS89 Mdm2 DNA (h) 3′-CACTCTTGTCCACAG-X- 3′-(SEQ ID NO. 89)-5′-X-
    GACACCTGTTCTCAC-3′ 5′-(SEQ ID NO. 89)-3′
    90/AS90 Mdm2 DNA (h) 3′-CTCACTCTTGTCCACAG-X- 3′-(SEQ ID NO. 90)-5′-X-
    GACACCTGTTCTCACTC-3′ 5′-(SEQ ID NO. 90)-3′
    91/AS91 Mdm2 DNA (h) 3′-CACTCACTCTTGTCCACAG-X- 3′-(SEQ ID NO. 91)-5′-X-
    GACACCTGTTCTCACTCAC-3′ 5′-(SEQ ID NO. 91)-3′
    92/AS92 Mdm2 DNA (h) 3′-GACACTCACTCTTGTCCACAG-X- 3′-(SEQ ID NO. 92)-5′-X-
    GACACCTGTTCTCACTCACAG-3′ 5′-(SEQ ID NO. 92)-3′
    93/AS93 Mdm2 DNA (h) 3′-TAGACACTCACTCTTGTCCACAG-X- 3′-(SEQ ID NO. 93)-5′-X-
    GACACCTGTTCTCACTCACAGAT-3′ 5′-(SEQ ID NO. 93)-3′
    94/AS94 Mdm2 DNA (h) 3′-CACTCACTCTTGTCCACAG-Y- 3′-(SEQ ID NO. 94)-5′-X-
    GACACCTGT-3′ 5′-(SEQ ID NO. 94)-3′
    95/AS95 Mdm2 DNA (h) 3′-TGTCCACAG-X-GACACCTGT-3′ 3′-(SEQ ID NO. 95)-5′-X-
    5′-(SEQ ID NO. 95)-3′
    96/AS96 BCL2 DNA (h) 3′-CCTCTATCACTACTTCATG-X- 3′-(SEQ ID NO. 96)-5′-X-
    GTACTTCATCACTATCTCC-3′ 5′-(SEQ ID NO. 96)-3′
    97/AS97 Survivin DNA (h) 3′CCTGTCTCTTTCTCGGTTC-X- 3′-(SEQ ID NO. 97)-5′-X-
    CTTGGCTCTTTCTCTGTCC-3′ 5′-(SEQ ID NO. 97)-3′
    98/AS98 EGFR DNA (h) 3′-GTTCGACACTGTCTAGTAT-X- 3′-(SEQ ID NO. 98)-5′-X-
    TATGATCTGTCACAGCTTG-3′ 5′-(SEQ ID NO. 98)-3′
    99/AS99 EGFR DNA (h) 3′-CTTTCCCTCCTTTGGATCG-X- 3′-(SEQ ID NO. 99)-5′-X-
    GCTAGGTTTCCTCCCTTTC-3′ 5′-(SEQ ID NO. 99)-3′
    100/ PCSK9 DNA (h) 3′-CTCCGTCTCTGACTAGGTG-X- 3′-(SEQ ID NO. 100)-5′-
    AS100 GTGGATCAGTCTCTGCCTC-3′ X-5′-(SEQ ID NO. 100)-3′
    101/ PCSK9 DNA (h) 3′-CGTCGGACCACCTCCACAT-Y- 3′-(SEQ ID NO. 101)-5′-
    AS101 TACACCTCC-3′ X-5′-(SEQ ID NO. 101)-3′
    102/ PCSK9 DNA (h) 3′-CTCCGTCTCTGACTAGGTG-Y- 3′-(SEQ ID NO. 102)-5′-
    AS102 GTGGATCAG-3′ X-5′-(SEQ ID NO. 102)-3′
    103/ PCSK9 DNA (h) 3′-AGACCTTACGTTTCAGTTC-Y- 3′-(SEQ ID NO. 103)-5′-
    AS103 CTTGACTTT-3′ X-5′-(SEQ ID NO. 103)-3′
    104/ PCSK9 DNA (h) 3′-CCTCCACAT-X-TACACCTCC-3′ 3′-(SEQ ID NO. 104)-5′-
    AS104 X-5′-(SEQ ID NO. 104)-3′
    105/ PCSK9 DNA (h) 3′-GACTAGGTG-X-GTGGATCAG-3′ 3′-(SEQ ID NO. 105)-5′-
    AS105 X-5′-(SEQ ID NO. 105)-3′
    106/ PCSK9 DNA (h) 3′-TTTCAGTTC-X-CTTGACTTT-3′ 3′-(SEQ ID NO. 106)-5′-
    AS106 X-5′-(SEQ ID NO. 106)-3′
    107/ PCSK9 DNA (h) 3′-AGACCTTACGTTTCA-X- 3′-(SEQ ID NO. 107)-5′-
    AS107 ACTTTGCATTCCAGA-3′ X-5′-(SEQ ID NO. 107)-3′
    108/ PCSK9 DNA (h) 3′-AGACCTTACGTTTCAGT-X- 3′-(SEQ ID NO. 108)-5′-
    AS108 TGACTTTGCATTCCAGA-3′ X-5′-(SEQ ID NO. 108)-3′
    109/ PCSK9 DNA (h) 3′-AGACCTTACGTTTCAGTTC-X- 3′-(SEQ ID NO. 109)-5′-
    AS109 CTTGACTTTGCATTCCAGA-3′ X-5′-(SEQ ID NO. 109)-3′
    110/ PCSK9 DNA (h) 3′-AGACCTTACGTTTCAGTTCCT-X- 3′-(SEQ ID NO. 110)-5′-
    AS110 TCCTTGACTTTGCATTCCAGA-3′ X-5′-(SEQ ID NO. 110)-3′
    111/ PCSK9 DNA (h) 3′-AGACCTTACGTTTCAGTTCCTCG-X- 3′-(SEQ ID NO. 111)-5′-
    AS111 GCTCCTTGACTTTGCATTCCAGA-3′ X-5′-(SEQ ID NO. 111-3′
    112/ PCSK9 DNA (h) 3′-AGACCTTACGTTTCAGTTCCTCGTA-X- 3′-(SEQ ID NO. 112)-5′-
    AS112 ATGCTCCTTGACTTTGCATTCCAGA-3′ X-5′-(SEQ ID NO. 112)-3′
    113/ PCSK9 DNA (h) 3′-CGTCGGACCACCTCC-X- 3′-(SEQ ID NO. 113)-5′-
    AS113 CCTCCACCAGGCTGC-3′ X-5′-(SEQ ID NO. 113)-3′
    114/ PCSK9 DNA (h) 3′-CGTCGGACCACCTCCAC-X- 3′-(SEQ ID NO. 114)-5′-
    AS114 CACCTCCACCAGGCTGC-3′ X-5′-(SEQ ID NO. 114)-3′
    115/ PCSK9 DNA (h) 3′-CGTCGGACCACCTCCACAT-X- 3′-(SEQ ID NO. 115)-5′-
    AS115 TACACCTCCACCAGGCTGC-3′ X-5′-(SEQ ID NO. 115)-3′
    116/ PCSK9 DNA (h) 3′-CGTCGGACCACCTCCACATAG-X- 3′-(SEQ ID NO. 116)-5′-
    AS116 GATACACCTCCACCAGGCTGC-3′ X-5′-(SEQ ID NO. 116)-3′
    117/ PCSK9 DNA (h) 3′-CGTCGGACCACCTCCACATAGAG-X- 3′-(SEQ ID NO. 117)-5′-
    AS117 GAGATACACCTCCACCAGGCTGC-3′ X-5′-(SEQ ID NO. 117)-3′
    118/ PCSK9 DNA (h) 3′-CGTCGGACCACCTCCACATAGAGGA-X- 3′-(SEQ ID NO. 118)-5′-
    AS118 AGGAGATACACCTCCACCAGGCTGC-3′ X-5′-(SEQ ID NO. 118)-3′
    119/ PCSK9 DNA (m) 3′-CCAGGAAGTCTCGTCCAGT-X- 3′-(SEQ ID NO. 119)-5′-
    AS119 TGACCTGCTCTGAAGGACC-3′ X-5′-(SEQ ID NO. 119)-3′
    120/ TLR9 RNA (m/h) 3′-GACAAGGACUUCAGACA-X- 3′-(SEQ ID NO. 120)-5′-
    AS120 ACAGACUUCAGGAACAG-3′ X-5′-(SEQ ID NO. 120)-3′
    121/ TLR9 RNA (m/h) 3′-CCGACAAGGACUUCAGACA-X- 3′-(SEQ ID NO. 121)-5′-
    AS121 ACAGACUUCAGGAACAGCC-3′ X-5′-(SEQ ID NO. 121)-3′
    122/ TLR9 RNA (m) 3′-AACCGACAAGGACUUCAGACA-X- 3′-(SEQ ID NO. 122)-5′-
    AS122 ACAGACUUCAGGAACAGCCAA-3′ X-5′-(SEQ ID NO. 122)-3′
    123/ TLR9 RNA (m) 3′-UUAACCGACAAGGACUUCAGACA-X- 3′-(SEQ ID NO. 123)-5′-
    AS123 ACAGACUUCAGGAACAGCCAAUU-3′ X-5′-(SEQ ID NO. 123)-3′
    124/ TLR9 RNA (m) 3′-CGUUAACCGACAAGGACUUCAGACA-X- 3′-(SEQ ID NO. 124)-5′-
    AS124 ACAGACUUCAGGAACAGCCAAUUGC-3′ X-5′-(SEQ ID NO. 124)-3′
    125/ TLR9 RNA (m) 3′-GACGUUAACCGACAAGGACUUCAGACA-X- 3′-(SEQ ID NO. 125)-5′-
    AS125 ACAGACUUCAGGAACAGCCAAUUGCAG-3′ X-5′-(SEQ ID NO. 125)-3′
    126/ TLR9 RNA (h) 3′-GACCGACAAGGACUUCAGACA-X- 3′-(SEQ ID NO. 126)-5′-
    AS126 ACAGACUUCAGGAACAGCCAG-3′ X-5′-(SEQ ID NO. 126)-3′
    127/ TLR9 RNA (h) 3′-UUGACCGACAAGGACUUCAGACA-X- 3′-(SEQ ID NO. 127)-5′-
    AS127 ACAGACUUCAGGAACAGCCAGUU-3′ X-5′-(SEQ ID NO. 127)-3′
    128/ TLR9 RNA (h) 3′-CGUUGACCGACAAGGACUUCAGACA-X- 3′-(SEQ ID NO. 128)-5′-
    AS128 ACAGACUUCAGGAACAGCCAGUUGC-3′ X-5′-(SEQ ID NO. 128)-3′
    129/ TLR9 RNA (m/h) 3′-ACCGACAAGGACUUCAGACA-Y-AC-3′ 3′-(SEQ ID NO. 129)-5′-
    AS129 X-5′-(SEQ ID NO. 129)-3′
    130/ TLR9 RNA (m/h) 3′-ACCGACAAGGACUUCAGACA-Y-ACAG-3′ 3′-(SEQ ID NO. 130)-5′-
    AS130 X-5′-(SEQ ID NO. 130)-3′
    131/ TLR9 RNA (m/h) 3′-ACCGACAAGGACUUCAGACA-Y-ACAGAC-3′ 3′-(SEQ ID NO. 131)-5′ -
    AS131 X-5′-(SEQ ID NO. 131)-3′
    132/ TLR9 RNA (m/h) 3′-ACCGACAAGGACUUCAGACA-X3- 3′-(SEQ ID NO. 132)-5′-
    AS132 ACAGACUUCAGGAACAGCCA-3′ X-5′-(SEQ ID NO. 132)-3′
    133/ TLR9 RNA (m/h) 3′-ACCGACAAGGACUUCAGACA-X1- 3′-(SEQ ID NO. 133)-5′-
    AS133 ACAGACUUCAGGAACAGCCA-3′ X-5′-(SEQ ID NO. 133)-3′
    134/ TLR9 RNA (m/h) 3′-ACCGACAAGGACUUCAGACA-Z- 3′-(SEQ ID NO. 134)-5′-
    AS134 ACAGACUUCAGGAACAGCCA-3′ X-5′-(SEQ ID NO. 134)-3′
    135/ TLR9 RNA (m/h) 3′-ACCGACAAGGACUUCAGACA-M- 3′-(SEQ ID NO. 135)-5′-
    AS135 ACAGACUUCAGGAACAGCCA-3′ X-5′-(SEQ ID NO. 135)-3′
    136/ TLR9 RNA (m/h) 3′-ACCGACAAGGACUUCAGACA-L- 3′-(SEQ ID NO. 136)-5′-
    AS136 ACAGACUUCAGGAACAGCCA-3′ X-5′-(SEQ ID NO. 136)-3′
    137/ TLR9 RNA (m/h) 3′-ACCGACAAGGACUUCAGACA-X- 3′-(SEQ ID NO. 137)-5′-
    AS137 ACAGACUUCAGGAACAGCCA-3′ X-5′-(SEQ ID NO. 137)-3′
    138/ TLR9 RNA (m/h) 3′-ACCGACAAGGACUUCAGACA-X- 3′-(SEQ ID NO. 138)-5′-
    AS138 ACAGACUUCAGGAACAGCCA-3′ X-5′-(SEQ ID NO. 138)-3′
    139/ TLR9 RNA (m) 3′-AACCGACAAGGACUUCAGACA-X- 3′-(SEQ ID NO. 139)-5′-
    AS139 ACAGACUUCAGGAACAGCCAA-3′ X-5′-(SEQ ID NO. 139)-3′
    140/ TLR9 RNA (m) 3′-AACCGACAAGGACUUCAGACA-X- 3′-(SEQ ID NO. 140)-5′-
    AS140 ACAGACUUCAGGAACAGCCAA-3′ X-5′-(SEQ ID NO. 140)-3′
    141/ TLR9 RNA (m) 3′-AACCGACAAGGACUUCAGACA-X- 3′-(SEQ ID NO. 141)-5′-
    AS141 ACAGACUUCAGGAACAGCCAA-3′ X-5′-(SEQ ID NO. 141)-3′
    142/ TLR9 RNA (m) 3′-AACCGACAAGGACUUCAGACA-X- 3′-(SEQ ID NO. 142)-5′-
    AS142 ACAGACUUCAGGAACAGCCAA-3′ X-5′-(SEQ ID NO. 142)-3′
    143/ TLR9/ RNA/ 3′-ACCGACAAGGACUUCAGACA-Y- 3′-(SEQ ID NO. 132)-5′-
    AS143 TLR7 DNA (m/h) d(AATGCTTGTCTGTGCAGTCC)-3′ X-5′-(SEQ ID NO. 35)-3′
    144/ MyD88 RNA (m) 3′-ACGAUCUCGACGACC-X- 3′-(SEQ ID NO. 144)-5′-
    AS144 CCAGCAGCUCUAGCA-3′ X-5′-(SEQ ID NO. 144)-3′
    145/ MyD88 RNA (m) 3′-CGACGAUCUCGACGACC-X- 3′-(SEQ ID NO. 145)-5′-
    AS145 CCAGCAGCUCUAGCAGC-3′ X-5′-(SEQ ID NO. 145)-3′
    146/ MyD88 RNA (m) 3′-UCCGACGAUCUCGACGACC-X- 3′-(SEQ ID NO. 146)-5′-
    AS146 CCAGCAGCUCUAGCAGCCU-3′ X-5′-(SEQ ID NO. 146)-3′
    147/ MyD88 RNA (m) 3′-CGUCCGACGAUCUCGACGACC-X- 3′-(SEQ ID NO. 147)-5′-
    AS147 CCAGCAGCUCUAGCAGCCUGC-3′ X-5′-(SEQ ID NO. 147)-3′
    148/ MyD88 RNA (m) 3′-GCCGUCCGACGAUCUCGACGACC-X- 3′-(SEQ ID NO. 148)-5′-
    AS148 CCAGCAGCUCUAGCAGCCUGCCG-3′ X-5′-(SEQ ID NO. 148)-3′
    149/ MyD88 RNA (m) 3′-CAGCCGUCCGACGAUCUCGACGACC-X- 3′-(SEQ ID NO. 149)-5′
    AS149 CCAGCAGCUCUAGCAGCCUGCCGAC-3′ X-5′-(SEQ ID NO. 149)-3′
    150/ MyD88 RNA (h) 3′-GACCUCUGUCUUCGC-X- 3′-(SEQ ID NO. 150)-5′-
    AS150 CGCUUGUGUCUCCAG-3′ X-5′-(SEQ ID NO. 150)-3′
    151/ MyD88 RNA (h) 3′-UUGACCUCUGUGUUCGC-X- 3′-(SEQ ID NO. 151)-5′-
    AS151 CGCUUGUGUCUCCAGUU-3′ X-5′-(SEQ ID NO. 151)-3′
    152/ MyD88 RNA (h) 3′-CGUUGACCUCUGUGUUCGC-X- 3′-(SEQ ID NO. 152)-5′-
    AS152 CGCUUGUGUCUCCAGUUGC-3′ X-5′-(SEQ ID NO. 152)-3′
    153/ MyD88 RNA (h) 3′-GCCGUUGACCUCUGUGUUCGC-X- 3′-(SEQ ID NO. 153)-5′
    AS153 CGCUUGUGUCUCCAGUUGCCG-3′ X-5′-(SEQ ID NO. 153)-3′
    154/ MyD88 RNA (h) 3′-AGGCCGUUGACCUCUGUGUUCGC-X- 3′-(SEQ ID NO. 154)-5′-
    AS154 CGCUUGUGUCUCCAGUUGCCGGA-3′ X-5′-(SEQ ID NO. 154)-3′
    155/ MyD88 RNA (h) 3′-CUAGGCCGUUGACCUCUGUGUUCGC-X- 3′-(SEQ ID NO. 155)-5′-
    AS155 CGCUUGUGUCUCCAGUUGCCGGAUC-3′ X-5′-(SEQ ID NO. 155)-3′
    156/ TLR7 RNA (m/h) 3′-CGUGUCUGUUCGUAA-X- 3′-(SEQ ID NO. 156)-5′-
    AS156 AAUGCUUGUCUGUGC-3′ X-5′-(SEQ ID NO. 156)-3′
    157/ TLR7 RNA (m/h) 3′-GACGUGUCUGUUCGUAA-X- 3′-(SEQ ID NO. 157)-5′-
    AS157 AAUGCUUGUCUGUGCAG-3′ X-5′-(SEQ ID NO. 157)-3′
    158/ TLR7 RNA (m/h) 3′-CUGACGUGUCUGUUCGUAA-X- 3′-(SEQ ID NO. 158)-5′-
    AS158 AAUGCUUGUCUGUGCAGUC-3′ X-5′-(SEQ ID NO. 158)-3′
    159/ TLR7 RNA (m/h) 3′-ACCUGACGUGUCUGUUCGUAA-X- 3′-(SEQ ID NO. 159)-5′-
    AS159 AAUGCUUGUCUGUGCAGUCCA-3′ X-5′-(SEQ ID NO. 159)-3′
    160/ TLR7 RNA (m/h) 3′-GCACCUGACGUGUCUGUUCGUAA-X- 3′-(SEQ ID NO. 160)-5′-
    AS160 AAUGCUUGUCUGUGCAGUCCACG-3′ X-5′-(SEQ ID NO. 160)-3′
    161/ TLR7 RNA (m/h) 3′-UAGCACCUGACGUGUCUGUUCGUAA-X- 3′-(SEQ ID NO. 161)-5′-
    AS161 AAUGCUUGUCUGUGCAGUCCACGAU-3′ X-5′-(SEQ ID NO. 161)-3′
    162/ TLR7/ RNA/ 3′-CCUGACGUGUCUGUUCGUAA-Y- 3′-(SEQ ID NO. 21)-5′-X-
    AS162 TLR9 DNA (m/h) d(ACAGACTTCAGGAACAGCCA)-3′ 5′-(SEQ ID NO. 1)-3′
    163/ TLR3 RNA (m) 3′-CUUGGAGGUUCUUGACG-X- 3′-(SEQ ID NO. 163)-5′-
    AS163 GCAGUUCUUGGAGGUUC-3′ X-5′-(SEQ ID NO. 163)-3′
    164/ TLR3 RNA (m) 3′-CUCUUGGAGGUUCUUGACG-X- 3′-(SEQ ID NO. 164)-5′-
    AS164 GCAGUUCUUGGAGGUUCUC-3′ X-5′-(SEQ ID NO. 164)-3′
    165/ TLR3 RNA (m) 3′-ACCUCUUGGAGGUUCUUGACG-X- 3′-(SEQ ID NO. 165)-5′-
    AS165 GCAGUUCUUGGAGGUUCUCCA-3′ X-5′-(SEQ ID NO. 165)-3′
    166/ TLR3 RNA (m) 3′-CAAGUCGUUCGAUAACUCG-X- 3′-(SEQ ID NO. 166)-5′-
    AS166 GCUCAAUAGCUUGCUGAAC-3′ X-5′-(SEQ ID NO. 166)-3′
    167/ TLR3 RNA (h) 3′-CGUGGAAUUGUACCUUC-X- 3′-(SEQ ID NO. 167)-5′-
    AS167 CUUCCAUGUUAAGGUGC-3′ X-5′-(SEQ ID NO. 167)-3′
    168/ TLR3 RNA (h) 3′-CUCGUGGAAUUGUACCUUC-X- 3′-(SEQ ID NO. 168)-5′-
    AS168 CUUCCAUGUUAAGGUGCUC-3′ X-5′-(SEQ ID NO. 168)-3′
    169/ TLR3 RNA (h) 3′-ACCUCGUGGAAUUGUACCUUC-X- 3′-(SEQ ID NO. 169)-5′-
    AS169 CUUCCAUGUUAAGGUGCUCCA-3′ X-5′-(SEQ ID NO. 169)-3′
    170/ TLR3 RNA (h) 3′-GUUGUUGUUGUAUCGGUUG-X- 3′-(SEQ ID NO. 170)-5′-
    AS170 GUUGGCUAUGUUGUUGUUG-3′ X-5′-(SEQ ID NO. 170)-3′
    171/ MDM2 RNA (h) 3′-UCACUCUUGUCCACAGU-X- 3′-(SEQ ID NO. 171)-5′-
    AS171 UGACACCUGUUCUCACU-3′ X-5′-(SEQ ID NO. 171)-3′
    172/ MDM2 RNA (h) 3′-ACUCACUCUUGUCCACAGU-X- 3′-(SEQ ID NO. 172)-5′-
    AS172 UGACACCUGUUCUCACUCA-3′ X-5′-(SEQ ID NO. 172)-3′
    173/ MDM2 RNA (h) 3′-ACACUCACUCUUGUCCACAGU-X- 3′-(SEQ ID NO. 173)-5′-
    AS173 UGACACCUGUUCUCACUCACA-3′ X-5′-(SEQ ID NO. 173)-3′
    174/ MDM2 RNA (m) 3′-GGACUUCCACCCUCACUAG-X- 3′-(SEQ ID NO. 174)-5′-
    AS174 GAUCACUCCCACCUUCAGG-3′ X-5′-(SEQ ID NO. 174)-3′
    175/ VEGF RNA (h) 3′-CACCCAAGACAGCAGAAAG-X- 3′-(SEQ ID NO. 175)-5′-
    AS175 GAAAGACGACAGAACCCAC-3′ X-5′-(SEQ ID NO. 175)-3′
    X = glycerol linker; X1 = 1,2,4-Butanetriol linker; X3 = 2-Hydroxymethyl-1,3-propanediol linker; X5 = Bis-1,5-O-(3′thymidyl)-1,3,5-Pentanetriol Linker; Y = 1,3-Propanediol linker; Z = 1,3,5-Pentanetriol linker; M = cis, cis-1,3,5-Cyclohexanetriol linker; L = cis, trans-1,3,5-Cyclohexanetriol linker; A, U, C, G = 2′-OMe; o = phosphodiester internucleotide linkage; h = human; m = mouse; Except where indicated, all molecules in Table 3 contain phosphorothioate intemucleotide linkages.
  • In this aspect of the invention, the composition lacks immune stimulatory activity of certain oligonucleotide compositions. It is known that certain oligonucleotide-based compositions can possess immune stimulatory motifs. This immune stimulatory activity requires the oligonucleotides to be non-linked or linked at their 3′ ends. Thus, it is contemplated that as a result of the oligonucleotide-based compositions according to the invention utilizing a linkage at the 5′ ends, as set forth in Formulas I, II, III or IV, that any inherent immune stimulatory activity is suppressed, as compared to the immune stimulatory activity that would be present in non-linked or oligonucleotide-based compositions linked at their 3′ ends or in a 2′-5′ fashion.
  • The inventors have surprisingly discovered that the structure of the oligonucleotide-based compound according to the invention provides an optimal compound for binding by enzymes and,other proteins that are involved in RNaseH-mediated and/or RNAi-mediated inhibition of gene expression. Thus, in a further embodiment of this aspect of the invention, the oligonucleotide-based compounds according to the invention can be selectively bound by RNaseH, Dicer, Argonaut, RISC or other proteins that are involved in RNAi-mediated inhibition of gene expression. This selective binding provides optimal oligonucleotide-based compounds for utilizing RNaseH-mediated and/or RNAi-mediated inhibition of gene expression in vitro and in vivo.
  • In a second aspect, the invention provides pharmaceutical formulations comprising an oligonucleotide-based compound according to the invention and a physiologically acceptable carrier.
  • In a third aspect, the invention provides a method for inhibiting gene expression, the method comprising contacting a cell with a synthetic oligonucleotide-based compound according to the first aspect of the invention.
  • In a fourth aspect, the invention provides a method for inhibiting gene expression in a mammal, the method comprising administering to the mammal a synthetic oligonucleotide-based compound according to the first aspect of the invention. In a further embodiment of this aspect of the invention, it is contemplated that the synthetic oligonucleotide-based compounds according to the first aspect of the invention can inhibit the expression and activity of certain genes related to cellular proliferation, including but not limited to oncogenes.
  • In a fifth aspect, the invention provides a method of inhibiting a TLR-mediated, Bcl-2-mediated, EGFR-mediated, mdm2-mediated, MyD88-mediated, PCSK9-mediated, survivin-mediated or VEGF-mediated response in a mammal though administration of a synthetic oligonucleotide-based compound according to the first aspect of the invention wherein the oligonucleotides are complementary to one or more mRNA sequence encoding a molecule involved in TLR signaling or Bcl-2, EGFR, mdm2, MyD88, PCSK9, survivin or VEGF activity.
  • In a sixth aspect, the invention provides a method of inhibiting a TLR-mediated, Bcl-2-mediated, EGFR-mediated, mdm2-mediated, MyD88-mediated, PCSK9-mediated, survivin-mediated or VEGF-mediated response in a mammal through administration of a synthetic oligonucleotide-based compound according to the first aspect of the invention wherein the oligonucleotides are complementary to one or more TLR, Bcl-2, EGFR, mdm2, MyD88, PCSK9, survivin or VEGF mRNA sequence in combination with an antagonist of TLR, Bcl-2, EGFR, mdm2, MyD88, PCSK9, survivin or VEGF protein activity.
  • In a seventh aspect, the invention provides methods for inhibitinggene expression in a mammal, such methods comprising administering to the mammal an oligonucleotide-based compound according to the invention. In some embodiments, the mammal is a human. In preferred embodiments, the oligonucleotide-based compound according to the invention is administered to a mammal in need of inhibiting its immune response.
  • In a eighth aspect, the invention provides methods for therapeutically treating a patient having a disease or disorder, such methods comprising administering to the patient an oligonucleotide-based compound according to the invention in a therapeutically effective amount. In various embodiments, the disease or disorder to be treated is cancer, an autoimmune disorder, infectious disease, airway inflammation, inflammatory disorders, allergy, asthma, or a disease caused by a pathogen. Pathogens include bacteria, parasites, fungi, viruses, viroids, and prions.
  • In a ninth aspect, the invention provides methods for preventing a disease or disorder, such methods comprising administering to a subject at risk for developing the disease or disorder an oligonucleotide-based compound according to the invention in a pharmaceutically effective amount. A subject is considered at risk for developing a disease or disorder if the subject has been or may be or will be exposed to an etiologic agent of the disease or disorder or is genetically predispositioned to contract the disease or disorder. In various embodiments, the disease or disorder to be prevented is cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, allergy, asthma, or a disease caused by a pathogen. Pathogens include bacteria, parasites, fungi, viruses, viroids, and prions.
  • In a tenth aspect the invention provides a method of preventing or treating a disorder, such methods comprises isolating cells capable of producing cytokines or chemokines including, but not limited to, immune cells, T-regulatory cells, B-cells, PBMCs, pDCs, and lymphoid cells; culturing such cells under standard cell culture conditions, treating such cells ex vivo with an oligonucleotide-based compound according to the first aspect of the invention such that the isolated cells produce or secrete decreased levels of cytokines or chemokines, and administering or re-administering the treated cells to a patient in need of therapy to inhibit cytokines and/or chemokine for the prevention and/or treatment of disease. This aspect of the invention would be in accordance with standard adoptive cellular immunotherapy techniques to produce activated immune cells.
  • In some embodiments of this aspect of the invention, the cells capable of producing cytokines or chemokines may be isolated from subjects with or without a disease or disorder. Such isolation may include identification and selection and could be performed using standard cell isolation procedures, including those set forth in the specific examples below. Such isolated cells would be cultured according to standard cell culturing procedures and using standard cell culture conditions, which may include the culturing procedures and conditions set forth in the specific examples below. In a further aspect of this embodiment of the invention, the isolated cells would be cultured in the presence of at least one oligonucleotide-based compound according to the invention, in an amount and for a time period sufficient to suppress or inhibit the production and/or secretion of cytokines and/or chemokines as compared to the isolated cells cultured in the absence of such one or more oligonucleotide-based compound according to the invention. Such time may be from minutes, to hours, to days. Such isolated and treated cells may find use following re-administration to the donor or administration to a second patient, wherein such donor or second patient are in need of suppressed or inhibited production and/or secretion of cytokines and/or chemokines. For example, re-administration to a donor or administration to a second patient having cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, allergy, asthma, or a disease caused by a pathogen. Such re-administration or administration may be accomplished using various modes, including catheter or injection administration or any other effective route. This aspect of the invention may also find use in patients who may have a limited or incomplete ability to mount an immune response or are immune compromised (e.g. patient infected with HIV and bone marrow transplant patients).
  • In an eleventh aspect, the invention provides a composition comprising a compound according to the first aspect of the invention and one or more vaccines, antigens, antibodies, cytotoxic agents, chemotherapeutic agents (both traditional chemotherapy and modem targeted therapies), kinase inhibitors, allergens, antibiotics, agonist, antagonist, antisense oligonucleotides, ribozymes, RNAi molecules, siRNA molecules, miRNA molecules, aptamers, proteins, gene therapy vectors, DNA vaccines, adjuvants, co-stimulatory molecules or combinations thereof.
  • In any of the methods according to the invention, the oligonucleotide-based compound according to the invention can variously act by producing direct gene expression modulation effects alone and/or in combination with any other agent useful for treating or preventing the disease or condition that does not diminish the gene expression modulation effect of the oligonucleotide-based compound according to the invention. In any of the methods according to the invention, the agent(s) useful for treating or preventing the disease or condition includes, but is not limited to, vaccines, antigens, antibodies, preferably monoclonal antibodies, cytotoxic agents, kinase inhibitors, allergens, antibiotics, siRNA molecules, antisense oligonucleotides, TLR antagonist (e.g. antagonists of TLR3 and/or TLR7 and/or antagonists of TLR8 and/or antagonists of TLR9), chemotherapeutic agents (both traditional chemotherapy and modem targeted therapies), targeted therapeutic agents, activated cells, peptides, proteins, gene therapy vectors, peptide vaccines, protein vaccines, DNA vaccines, adjuvants, and co-stimulatory molecules (e.g. cytokines, chemokines, protein ligands, trans-activating factors, peptides or peptides comprising modified amino acids), or combinations thereof. For example, in the treatment of cancer, it is contemplated that the oligonucleotide-based compound according to the invention may be administered in combination with one or more chemotherapeutic compound, targeted therapeutic agent and/or monoclonal antibody. Alternatively, the agent can include DNA vectors encoding for antigen or allergen. Alternatively, the oligonucleotide-based compound according to the invention can be administered in combination with other compounds (for example lipids or liposomes) to enhance the specificity or magnitude of the gene expression modulation of the oligonucleotide-based compound according to the invention.
  • In any of the methods according to the invention, administration of oligonucleotide-based compounds according to the invention, alone or in combination with any other agent, can be by any suitable route, including, without limitation, parenteral, mucosal delivery, oral, sublingual, transdermal, topical, inhalation, intranasal, aerosol, intraocular, intratracheal, intrarectal, vaginal, by gene gun, dermal patch or in eye drop or mouthwash form. Administration of the therapeutic compositions of oligonucleotide-based compounds according to the invention can be carried out using known procedures using an effective amount and for periods of time effective to reduce symptoms or surrogate markers of the disease. For example, an effective amount of an oligonucleotide-based compound according to the invention for treating a disease and/or disorder could be that amount necessary to alleviate or reduce the symptoms, or delay or ameliorate a tumor, cancer, or bacterial, viral or fungal infection. In the context of administering a composition that modulates gene expression, an effective amount of an oligonucleotide-based compound according to the invention is an amount sufficient to achieve the desired modulation as compared to the gene expression in the absence of the oligonucleotide-based compound according to the invention. The effective amount for any particular application can vary depending on such factors as the disease or condition being treated, the particular oligonucleotide being administered, the size of the subject, or the severity of the disease or condition. One of ordinary skill in the art can empirically determine the effective amount of a particular oligonucleotide without necessitating undue experimentation.
  • When administered systemically, the therapeutic composition is preferably administered at a sufficient dosage to attain a blood level of oligonucleotide-based compound according to the invention from about 0.0001 micromolar to about 10 micromolar. For localized administration, much lower concentrations than this may be effective, and much higher concentrations may be tolerated. Preferably, a total dosage of oligonucleotide-based compound according to the invention ranges from about 0.001 mg per patient per day to about 200 mg per kg body weight per day. In certain embodiments, the total dosage may be 0.08, 0.16, 0.32, 0.48, 0.32, 0.64, 1, 10 or 30 mg/kg body weight administered daily, twice weekly or weekly. It may be desirable to administer simultaneously, or sequentially a therapeutically effective amount of one or more of the therapeutic compositions of the invention to an individual as a single treatment episode.
  • The methods according to this aspect of the invention are useful for model studies of gene expression. The methods are also useful for the prophylactic or therapeutic treatment of human or animal disease. For example, the methods are useful for pediatric and veterinary inhibition of gene expression applications.
  • The examples below are intended to further illustrate certain preferred embodiments of the invention, and are not intended to limit the scope of the invention.
    • EXAMPLE 1 Preparation of Oligonucleotide-based Compounds
  • The oligonucleotide-based compounds of the invention were chemically synthesized using phosphoramidite chemistry on automated DNA/RNA synthesizer. TAC protected (Except U) 2′-O-TBDMS RNA monomers, A, G, C and U, were purchased from Sigma-Aldrich. 7-deaza-G, inosine and loxoribine monomers were purchased from ChemGenes Corporation. 0.25M 5-ethylthio-1H-tetrazole, PAC-anhydride Cap A and Cap B were purchased from Glen Research. 3% trichloroacetic acid (TCA) in dichloromethane (DCM) and 5% 3H-1,2-Benzodithiole-3-one-1,1-dioxide (Beaucage reagent) were made in house.
  • Oligonucleotide-based compounds of the invention were synthesized at 1-2 μM scale using a standard RNA synthesis protocol.
    • Cleavage and Base Deprotection
  • Oligonucleotide-based compounds of the invention were cleaved from solid support and the solution was further heated at 65° C. to removing protecting groups of exo cyclic-amines. The resulting solution was dried completely in a SpeedVac.
    • IE HPLC Purification
  • Oligonucleotide-based compounds of the invention were purified by ion exchange HPLC.
  • Column: Dionex DNAPac 100 column (22X250)
  • Column Heater: ChromTech TL-105 HPLC column heater, temperature is set to 80° C.
  • Buffer A: 20 mM Tris-HCl, pH 7.0, 20% acetinitrile
  • Buffer B: 3.0 M NaCl, 20 mM Tris-HCl, pH 7.0, 20% acetonitrile
  • Flow rate: 10 ml/min
  • Gradient:
      • 0-2 min: 0% B
      • 2-11 min: 0% B to 35% B
      • 11-41 min: 35% B to 90% B
      • 41-45 min: 100% B
  • Crude solution of oligonucleotide-based compounds of the invention was injected into HPLC. Above gradient is performed and the fractions were collected. All fractions containing more than 90% desired product were mixed, and then the solution was concentrated to almost dry by RotoVap. RNAse-free water was added to make final volume of 10 ml.
    • C-18 Reversed Phase Desalting
  • CC-18 Sep-Pak cartridge purchased from Waters was first conditioned with 10m1 of acetonitrile followed by 10 ml of 0.5 M sodium acetate. 10 ml of the solution of oligonucleotide-based compounds of the invention was loaded. 15 ml of water was then used to wash out the salt. The oligonucleotide-based compounds of the invention was eluted out by 1 ml of 50% acetonitrile in water.
  • The solution is placed in SpeedVac for 30 minutes. The remaining solution was filter through a 0.2 micro filter and then was lyophilized to dryness. The solid was then re-dissolved in water to make the desired concentration.
  • The final solution was stored below 0° C.
    • Capillary Electrophoresis
  • Oligonucleotide-based compounds of the invention were analyzed by capillary electrophoresis according to the following conditions.
      • Instrument: Beckman 5010
      • Capillary: 62 cm ssDNA capillary
      • Sample preparation: 0.2 OD of oligonucleotide-based composition according to the invention was dissolved in 200 ul of RNAse-free water.
      • Injection: electro-kinetic injection at 5 KV for 5 seconds.
      • Running condition: 14 KV for 50 minutes at 30° C.
        Ion Exchange HPLC analysis
  • Oligonucleotide-based compounds of the invention were analyzed by ion exchange HPLC according to the following conditions
  • Column: Dionex DNAPac guard column (22X250)
  • Column Heater: ChromTech TL-105 HPLC column heater, temperature is set to 80° C.
  • Buffer A: 100 mM Tris-HCl, pH 8.0, 20% acetinitrile
  • Buffer B: 2.0 M LiCl, 100 mM Tris-HCl, pH 8.0, 20% acetonitrile
  • Flow rate: 2 ml/min
  • Gradient:
      • 0-2 min: 0% B
      • 2-10 min: 0% B to 100% B
      • 10-15 min: 100% B
    PAGE Analysis
  • 0.3 OD of oligonucleotide-based compounds of the invention was loaded on 20% polyacrylamide gel and was running at constant power of 4 watts for approximately 5 hours. The gel was viewed under short wavelength UV light.
    • EXAMPLE 2 Human PBMC Isolation
  • Peripheral blood mononuclear cells (PBMCs) from freshly drawn healthy volunteer blood (CBR Laboratories, Boston, Mass.) were isolated by Ficoll density gradient centrifugation method (Histopaque-1077, Sigma).
    • Human pDC Isolation
  • Human plasmacytoid dendritic cells (pDCs) were isolated from freshly obtained healthy human volunteer's blood PBMCs by positive selection using the BDCA4 cell isolation kits (Miltenyi Biotec) according to the manufacturer's instructions.
  • Treatment of PBMCs and pDCs
  • Human PBMCs were plated in 48-well plates using 5×106 cells/ml. Human pDCs were plated in 96-well dishes using 1×106 cells/ml. The exemplary oligonucleotide-based compounds of the invention, dissolved in DPBS (pH 7.4; Mediatech), were added to the cell cultures at doses of 0, 0.01, 1.0 or 10.0 μg/ml. The cells were then incubated at 37° C. for 24 hours and subsequently stimulated with 10 μg/ml TLR9 agonist for 24 h. After treatment and stimulation, the supernatants were collected for luminex multiplex or ELISA assays. In certain experiments, the levels of IFN-α, IL-6, and/or IL-12 were measured by sandwich ELISA. The required reagents, including cytokine antibodies and standards, were purchased from PharMingen.
    • Human B Cell Assay for TLR9 Antisense Activity
  • Human B cells were isolated from PBMCs by positive selection using the CD19 Cell Isolation Kit (Miltenyi Biotec, Auburn, Calif.) according to the manufacturer's instructions.
  • The culture medium used for the assay consisted of RPMI 1640 medium supplemented with 1.5 mM glutamine, 1 mM sodium pyruvate, 0.1 mM non-essential amino acids, 50 μM 2-mercaptoethanol, 100 IU/ml penicillin-streptomycin mix and 10% heat-inactivated fetal bovine serum.
  • A total of 0.5×106B cells per ml (i.e.1×105/200 μl/well) were incubated in 96 well flat bottom plates with 50 μg/ml of exemplary oligonucleotide-based compounds of the invention for 24 hours. After 24 hours, cells were stimulated with 10 μg/ml TLR9 agonist for 24 h. Following treatment and stimulation, cell extracts were prepared and analyzed for the amount of TLR9 mRNA.
    • HEK293 Cell Culture Assays for TLR9 or TLR7 Antisense Activity
  • HEK293 cells stably expressing mouse TLR9 or TLR7 (Invivogen, San Diego, Calif.), were plated in 48-well plates in 250 μL/well DMEM supplemented with 10% heat-inactivated FBS in a 5% CO2 incubator. At 80% confluence, cultures were transiently transfected with 400 ng/mL of the secreted form of human embryonic alkaline phosphatase (SEAP) reporter plasmid (pNifty2-Seap) (Invivogen) in the presence of 4 μL/mL of lipofectamine (Invitrogen, Carlsbad, Calif.) in culture medium. Plasmid DNA and lipofectamine were diluted separately in serum-free medium and incubated at room emperature for 5 min. After incubation, the diluted DNA and lipofectamine were mixed and the mixtures were incubated further at room temperature for 20 min. Aliquots of 25 μL of the DNA/lipofectamine mixture containing 100 ng of plasmid DNA and 1 μL of lipofectamine were added to each well of the cell culture plate, and the cells were transfected for 6 h. After transfection, medium was replaced with fresh culture medium (no antibiotics) and 0, 0.01, 1 or 10 μg/ml of TLR9 or TLR7 specific oligonucleotide-based compounds of the invention were added to the wells, and incubation continued for 24 h. Following antisense treatment, cells were then stimulated with the 10 μg/ml TLR9 or TLR7 agonist for 24 h.
  • At the end of the treatment and stimulation, 20 μL of culture supematant was taken from each well and assayed for SEAP assay by the Quanti Blue method according to the manufacturer's protocol (Invivogen). The data are shown as fold increase in NF-κB activity over PBS control.
    • HEK293 Cell Culture Assays for TLR7, TLR8 or Other Specific RNA Target Antisense Activity
  • For determining the activity of antisense oligonucleotides according to the invention to inhibit TLR7 or TLR8 or any other specific RNA target, the following procedure would be followed: HEK293 cells stably expressing mouse TLR7 or TLR8 or another specific RNA target (Invivogen, San Diego, Calif.), would be plated in 48-well plates in 250 μL/well DMEM supplemented with 10% heat-inactivated FBS in a 5% CO2 incubator. At 80% confluence, cultures would be transiently transfected with 400 ng/mL of the secreted form of human embryonic alkaline phosphatase (SEAP) reporter plasmid (pNifty2-Seap) (Invivogen) in the presence of 4 μL/mL of lipofectamine (Invitrogen, Carlsbad, Calif.) in culture medium. Plasmid DNA and lipofectamine would be diluted separately in serum-free medium and incubated at room temperature for 5 min. After incubation, the diluted DNA and lipofectamine would be mixed and the mixtures would be incubated further at room temperature for 20 min. Aliquots of 25 μL of the DNA/lipofectamine mixture containing 100 ng of plasmid DNA and 1 μL of lipofectamine would be added to each well of the cell culture plate, and the cells would be transfected for 6 h. After transfection, medium would be replaced with fresh culture medium (no antibiotics) and 0, 0.01, 1 or 10 μg/ml of specific antisense oligonucleotides according to the invention would be added to the wells, and incubation continued for 24 h. Following antisense treatment, the cells would be stimulated with the target's agonist for up to 24 h.
  • At the end of the treatment and stimulation, 20 μL of culture supernatant would be taken from each well and assayed for SEAP assay by the Quanti Blue method according to the manufacturer's protocol (Invivogen). The data would be shown as fold increase in NF-κB activity over PBS control.
    • Murine J774 Cell Assay for TLR9 Antisense Activity
  • Murine J774 macrophage cells (American Type Culture Collection, Rockville, Md.) were cultured in Dulbecco's modified Eagle's medium supplemented with 10% (v/v) fetal bovine serum (FBS) and antibiotics (100 IU/ml penicillin G/100 μg/ml streptomycin). J774 cells were plated at a density of 5×106 cells/well in six-well plates. For dose dependent experiments, the J774 cells were then treated with 0,1, 10, 50 or 100 μg/ml of TLR9 specific oligonucleotide-based compounds of the invention and incubation continued for 24 h. For experiments determining the effects on mRNA, the J774 cells were then treated with 0, 1 or 3 μg/ml of TLR9 specific oligonucleotide-based compounds of the invention or control oligonucleotides and incubation continued for 48 h. For experiments determining the effects on protein, the J774 cells were then treated with 0, or 50 μg/ml of TLR9 specific oligonucleotide-based compounds of the invention or control oligonucleotides and incubation continued for 48 h. Following antisense treatment, cellular extracts were prepared and analyzed for the amount of TLR9 mRNA or TLR9 protein.
    • HeLa Cell Assay for VEGF Antisense Activity
  • 5×106 HeLa cells (ATCC, Manassas, Va.) were plated in a 12-well culture plate in Dulbecco's Modified Eagle Medium (DMEM, Mediatech, Manassas, Va.) supplemented with 10% fetal bovine serum (FBS, Mediatch, Manassas, Va.). For cell transfection, 5 μl Lipofectamine® 2000 (Invitrogen, Carlsbad, Calif.) and 5 μg antisense oligonucleotides were mixed in 100 μl DMEM without serum and incubated at room temperature for 15 minutes. Cells were washed once with DMEM without serum and 100 μl lipofectamine/oligonucleotide complexes were added to 900 μl DMEM without serum followed by 2 hour incubation at 37° C. with 5% CO2. A lipofectamine only group served as a control. Medium was then changed to DMEM with 10% FBS. and incubated for 24 hours. Following the 24 hour incubation, total RNA was isolated using a QIAGEN RNeasy mini kit (QIAGEN, Valencia, Calif.) according to manufacturer's suggestion. 1 μg RNA was used to reverse transcribe to cDNA using a High Capacity cDNA Reverse Transcription kit (Appliedbiosystems, Carlsbad, Calif.) according to manufacturer's recommendation. For quantitative real-time PCR (qPCR), primers and probes for VEGF (catalog no. Hs00900057_ml) and GAPDH (Hs99999905_ml) were purchased from Applied Biosystems. 50 ng cDNA was used in the qPCR with Taqman® Fast Universal PCR Master Mix (Applied Biosystems) and reactions were run on an Applied Biosystems StepOnePlus™ Real-Time PCR System according to manufacturer's instructions. Data is depicted in FIG. 8D as relative quantity of mRNA to lipofectamine treated cells using the ΔΔCT method, where ΔCT=CTVEGF−CTGAPDH and ΔΔCT=ACToligonucleotide−ΔCTlipofectamine. Each bar represents 2-3 separate experiments.
    • C57BL/6 Mouse Splenocyte Cell Assay for TLR9 Antisense Activity
  • Spleen cells from 4- to 8-week old C57BL/6 mice were cultured in RPMI complete medium. Mouse spleen cells were plated in 24-well dishes using 5×106 cells/ml, treated with TLR9 specific oligonucleotide-based compounds of the invention dissolved in TE buffer (10 mM Tris-HCl, pH 7.5, 1 mM EDTA), and incubated at 37° C. for 24 hrs. Following antisense treatment, cells were then stimulated with 10 μg/ml TLR9 agonist for 24 hrs. After treatment and stimulation, the supernatants were collected and the secretion of IL-12 and IL-6 in cell culture supernatants was measured by sandwich ELISA.
    • EXAMPLE 3 In Vivo Activity of Oligonucleotide-Based Compositions
  • To assess the in vivo activity of antisense oligonucleotides according to the invention, Female C57BL/6 mice of 5-6 weeks age (N=3/group) were injected with exemplary oligonucleotide-based compositions according to the invention at 0.25, 2, or 5 mg/kg, or PBS, subcutaneously in the left flank. Twenty-four hours after administration of the oligonucleotide-based compositions, mice were injected with 0.25 mg/kg of a TLR agonist subcutaneously in the right flank. Two hours after administration of the TLR agonist, blood was collected and serum IL-12 concentration was determined by ELISA. Data are shown as absolute IL-12 concentrations or as a percentage of IL-12 production.
    • Duration of In Vivo Activity of Oligonucleotide-Based Compositions
  • To assess the duration of in vivo activity of antisense oligonucleotides according to the invention, Female C57BL/6 mice of 5-6 weeks age (N=3/group) were injected with exemplary oligonucleotide-based compositions according to the invention at 5 mg/kg, or PBS, subcutaneously in the left flank. Twenty-four hours after administration of the oligonucleotide-based compositions, mice were injected with 0.25 mg/kg of a TLR agonist subcutaneously in the right flank on days 1, 3, 5, 7, 10 or 14. Two hours after each administration of the TLR agonist, blood was collected and serum IL-12 concentration was determined by ELISA. Data are shown as absolute IL-12 concentrations or as a percentage of IL-12 production.
    • EXAMPLE 4 Selective Binding and Cleavage of Oligonucleotide-Based Compounds by Antisense-Associated Proteins and Enzymes.
  • To assess the specificity for antisense-associated proteins and enzymes to bind and cleave oligonucleotide-based compounds according to the invention or control oligonucleotides, were treated as follows: The 5′-end [γ-32P] labeled target mRNA (e.g. SED ID NO. 21; 10 nM human/mouse TLR7) and complementary RNA or DNA (10 nM; human/mouse TLR7) in 30 ml of Buffer (10× buffer, Invitrogen) were heated at 85° C. for 5 min, and then cooled down to room temperature for 20 min to allow annealing of the two strands. The human dicer enzyme (0.025 U, Invitrogen) was added to reaction solution, and then incubated at 37° C. for 1 hr. 1 ml of stop solution (Invitrogen) and 10 ml of gel loading dye were added to sample solution and mixed well. The sample was frozen immediately at −80° C. RNA digestion products were analyzed on 16% denaturing PAGE and the gel was exposed to x-ray film and the autoradiogram was developed. Results are shown in FIG. 13.
    • Equivalents
  • Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific substances and procedures described herein. For example, antisense oligonucleotides that overlap with the oligonucleotides may be used. Such equivalents are considered to be within the scope of this invention, and are covered by the following claims.

Claims (20)

1. A synthetic oligonucleotide-based compound comprising two or more oligonucleotides that are complementary to one or more single-stranded RNA sequence, wherein the oligonucleotide forms a sufficient number of hydrogen bonds through Watson-Crick interactions of its nucleobases with nucelobases of the single-stranded RNA sequence to form a double helix with the single-stranded RNA sequence under physiological conditions, wherein the oligonucleotides are linked at their 5′-ends, such that the oligonucleotide-based compound has two or more accessible 3′-ends and the oligonucleotide-based compound specifically hybridize to and inhibit the expression of the one or more single-stranded RNA sequence.
2. The oligonucleotide-based compound of claim 1, wherein the oligonucleotides are independently 15 to 40 nucleotides in length.
3. The oligonucleotide-based compound of claim 1, wherein the oligonucleotides are linked to each other through a nucleotide linkage.
4. The oligonucleotide-based compound of claim 1, wherein the oligonucleotides are linked to each other through a linker.
5. The oligonucleotide-based compound of claim 4, wherein the linker is a non-nucleotide linker.
6. The oligonucleotide-based compound of claim 1, wherein the oligonucleotides comprise one or more ribonucleotides, deoxyribonucleotides, locked nucleic acids, arabino sugar nucleotides or a combination thereof.
7. The oligonucleotide-based compound of claim 1, wherein at least one of the oligonucleotides is modified.
8. The oligonucleotide-based compound of claim 7, wherein the modified oligonucleotide has at least one intemucleotide linkage selected from the group consisting of alkylphosphonate, phosphorothioate, phosphorodithioate, methylphosphonate, and non-nucleotide linker.
9. The oligonucleotide-based compound of claim 7, wherein the modified oligonucleotide comprises at least one 2′-O-substituted nucleotide.
10. The oligonucleotide-based compound of claim 9, wherein the 2′-O-substitution is selected from 2′-O-methyl, 2′ -O-methoxy, 2′-O-ethoxy, 2′-O-methoxyethyl, 2′-O-aryl, and 2′-O-allyl.
11. The oligonucleotide-based compound according to claim 1, wherein the oligonucleotide-based compound is selectively bound and/or cleaved by a protein involved in RNAi-mediated inhibition of gene expression.
12. The oligonucleotide-based compound according to claim 11, wherein the protein involved in RNAi-mediated inhibition of gene expression is selected from Dicer, Argonaut, and RISC.
13. The oligonucleotide-based compound according to claim 1, wherein the oligonucleotide-based compound is selectively bound and/or cleaved by a protein involved in RNaseH-mediated inhibition of gene expression.
14. A composition comprising an oligonucleotide-based compound according to claim 1 and a physiologically acceptable carrier.
15. An oligonucleotide-based compound comprising two oligonucleotides that are complementary to one or more single-stranded RNA sequence, wherein the oligonucleotide forms a sufficient number of hydrogen bonds through Watson-Crick interactions of its nucleobases with nucelobases of the single-stranded RNA sequence to form a double helix with the single-stranded RNA sequence under physiological conditions, wherein the oligonucleotides are linked at their 5′-ends, such that the oligonucleotide-based compound has two accessible 3′-ends and the oligonucleotide-based compound specifically hybridizes to and inhibit the expression of the one or more single-stranded RNA sequence, the oligonucleotide-based compound having the structure:
Figure US20120016004A1-20120119-C00056
wherein at least one of Domain A or Domain B is an oligoribonucelotide that is hybridized to a complementary oligoribonucleotide to form an siRNA.
16. An oligonucleotide-based compound comprising three oligonucleotides that are complementary to one or more single-stranded RNA sequence, wherein the oligonucleotide forms a sufficient number of hydrogen bonds through Watson-Crick interactions of its nucleobases with nucelobases of the single-stranded RNA sequence to form a double helix with the single-stranded RNA sequence under physiological conditions, wherein the oligonucleotides are linked at their 5′-ends, such that the oligonucleotide-based compound has two or more accessible 3′-ends and the oligonucleotide-based compound specifically hybridizes to and inhibit the expression of the one or more single-stranded RNA sequence, the oligonucleotide-based compound having the structure:
Figure US20120016004A1-20120119-C00057
wherein at least one of Domain A, Domain B, or Domain C is an oligoribonucleotide that is hybridized to a complementary oligoribonucleotide to form an siRNA molecule.
17. An oligonucleotide-based compound comprising three oligonucleotides that are complementary to one or more single-stranded RNA sequence, wherein the oligonucleotide forms a sufficient number of hydrogen bonds through Watson-Crick interactions of its nucleobases with nucelobases of the single-stranded RNA sequence to form a double helix with the single-stranded RNA sequence under physiological conditions, wherein two of the oligonucleotides are linked at their 5′-ends, such that the oligonucleotide-based compound has two accessible 3′-ends and the oligonucleotide-based compound specifically hybridizes to and inhibit the expression of the one or more single-stranded RNA sequence, the oligonucleotide-based compound having the structure:
Figure US20120016004A1-20120119-C00058
wherein at least one of Domain A, Domain B, or Domain C is an oligoribonucleotide that is hybridized to a complementary oligoribonucleotide to form an siRNA molecule.
18. An oligonucleotide-based compound comprising four oligonucleotides that are complementary to one or more single-stranded RNA sequence, wherein the oligonucleotide forms a sufficient number of hydrogen bonds through Watson-Crick interactions of its nucleobases with nucelobases of the single-stranded RNA sequence to form a double helix with the single-stranded RNA sequence under physiological conditions, wherein the oligonucleotides are linked at their 5′-ends, such that the oligonucleotide-based compound has two accessible 3′-ends and the oligonucleotide-based compound specifically hybridizes to and inhibits the expression of the one or more single-stranded RNA sequence, the oligonucleotide-based cnmnnund having the structure:
Figure US20120016004A1-20120119-C00059
wherein at least one of Domain A or Domain B or Domain C or Domain D is an oligoribonucleotide that is hybridized to a complementary oligoribonucleotide to form an siRNA molecule.
19. An oligonucleotide-based compound comprising three oligonucleotides, wherein the oligonucleotide forms a sufficient number of hydrogen bonds through Watson-Crick interactions of its nucleobases with nucelobases of the single-stranded RNA sequence to form a double helix with the single-stranded RNA sequence under physiological conditions, wherein two of the oligonucleotides are linked at their 5′-ends, such that the oligonucleotide-based compound has two accessible 3′-ends, the oligonucleotide-based compound having the structure:
Figure US20120016004A1-20120119-C00060
wherein at least one of Domain A, Domain B, or Domain C is an oligonucleotide that is complementary to a single-stranded RNA sequence such that the oligonucleotide-based compound specifically hybridizes to and inhibit the expression of at least one single-stranded RNA sequence, and wherein at least one of Domain A, Domain B, or Domain C is an oligonucleotide that is an antagonist of an intracellular or extracellular receptor.
20. The oligonucleotide-based compound according to claim 19, wherein the receptor is a TLR.
US13/038,924 2009-08-27 2011-03-02 Compositions for inhibiting gene expression and uses thereof Abandoned US20120016004A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/038,924 US20120016004A1 (en) 2009-08-27 2011-03-02 Compositions for inhibiting gene expression and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US27525209P 2009-08-27 2009-08-27
US24055309P 2009-09-08 2009-09-08
US12/869,185 US20110082186A1 (en) 2009-08-27 2010-08-26 Compositions for inhibiting gene expression and uses thereof
US13/038,924 US20120016004A1 (en) 2009-08-27 2011-03-02 Compositions for inhibiting gene expression and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US12/869,185 Continuation US20110082186A1 (en) 2009-08-27 2010-08-26 Compositions for inhibiting gene expression and uses thereof

Publications (1)

Publication Number Publication Date
US20120016004A1 true US20120016004A1 (en) 2012-01-19

Family

ID=43446697

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/869,209 Active US8431544B1 (en) 2009-08-27 2010-08-26 Compositions for inhibiting gene expression and uses thereof
US12/869,185 Abandoned US20110082186A1 (en) 2009-08-27 2010-08-26 Compositions for inhibiting gene expression and uses thereof
US13/038,924 Abandoned US20120016004A1 (en) 2009-08-27 2011-03-02 Compositions for inhibiting gene expression and uses thereof

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US12/869,209 Active US8431544B1 (en) 2009-08-27 2010-08-26 Compositions for inhibiting gene expression and uses thereof
US12/869,185 Abandoned US20110082186A1 (en) 2009-08-27 2010-08-26 Compositions for inhibiting gene expression and uses thereof

Country Status (15)

Country Link
US (3) US8431544B1 (en)
EP (3) EP3272870A1 (en)
JP (1) JP5805088B2 (en)
CN (2) CN102712926B (en)
CA (1) CA2772352A1 (en)
DK (1) DK2470656T3 (en)
ES (2) ES2646097T3 (en)
HK (1) HK1210223A1 (en)
HR (1) HRP20150566T1 (en)
HU (1) HUE026020T2 (en)
PL (1) PL2470656T3 (en)
PT (1) PT2470656E (en)
SI (1) SI2470656T1 (en)
SM (1) SMT201500140B (en)
WO (1) WO2011031520A1 (en)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
KR101141544B1 (en) 2009-03-13 2012-05-03 한국과학기술원 Multi-conjugate of siRNA and preparing method thereof
WO2011117353A1 (en) * 2010-03-24 2011-09-29 Mirrx Therapeutics A/S Bivalent antisense oligonucleotides
WO2012027206A1 (en) 2010-08-24 2012-03-01 Merck Sharp & Dohme Corp. SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER
US8877722B2 (en) * 2011-03-25 2014-11-04 Idera Pharmaceuticals, Inc. Compositions for inhibiting gene expression and uses thereof
JP6129844B2 (en) 2011-09-14 2017-05-17 ラナ セラピューティクス インコーポレイテッド Multimeric oligonucleotide compounds
HRP20220908T8 (en) 2011-11-18 2023-02-03 Alnylam Pharmaceuticals, Inc. Modified rnai agents
SG11201402392QA (en) 2011-11-18 2014-06-27 Alnylam Pharmaceuticals Inc Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
EP2847215A1 (en) * 2012-05-07 2015-03-18 Synthes GmbH Methods and devices for treating intervertebral disc disease
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
ITNA20120046A1 (en) 2012-08-02 2014-02-03 No Self S R L USE OF NUCLEIC ACIDS OF PARASITIC BIOLOGICAL SYSTEMS, PATOGENES AND WEATHER FOR THE INHIBITION AND / OR CONTROL OF THE SAME SYSTEMS
AU2013296321B2 (en) 2012-08-03 2019-05-16 Alnylam Pharmaceuticals, Inc. Modified RNAi agents
US20150247141A1 (en) 2012-09-14 2015-09-03 Rana Therapeutics, Inc. Multimeric oligonucleotide compounds
JP6574383B2 (en) 2012-12-05 2019-09-11 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． PCSK9 iRNA composition and method of use thereof
DK2970970T3 (en) * 2013-03-14 2019-02-11 Andes Biotechnologies Global Inc Antisense oligonucleotides for the treatment of cancer stem cells
KR20230162998A (en) 2013-03-14 2023-11-29 알닐람 파마슈티칼스 인코포레이티드 Complement component c5 irna compositions and methods of use thereof
HUE038146T2 (en) 2013-05-22 2018-09-28 Alnylam Pharmaceuticals Inc Serpina1 irna compositions and methods of use thereof
KR102365809B1 (en) 2013-05-22 2022-02-23 알닐람 파마슈티칼스 인코포레이티드 Tmprss6 compositions and methods of use thereof
TW201610151A (en) 2013-09-23 2016-03-16 阿尼拉製藥公司 Methods for treating or preventing transthyretin (TTR) associated diseases
AU2014362262B2 (en) 2013-12-12 2021-05-13 Alnylam Pharmaceuticals, Inc. Complement component iRNA compositions and methods of use thereof
WO2015106128A2 (en) 2014-01-09 2015-07-16 Alnylam Pharmaceuticals, Inc. MODIFIED RNAi AGENTS
CA2938857A1 (en) 2014-02-11 2015-08-20 Alnylam Pharmaceuticals, Inc. Ketohexokinase (khk) irna compositions and methods of use thereof
WO2015175510A1 (en) 2014-05-12 2015-11-19 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating a serpinc1-associated disorder
JP6811094B2 (en) 2014-05-22 2021-01-13 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Angiotensinogen (AGT) iRNA composition and its use
TR201908550T4 (en) 2014-06-04 2019-07-22 Exicure Inc Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications.
EP3812462A1 (en) 2014-08-20 2021-04-28 Alnylam Pharmaceuticals, Inc. Modified double-stranded rna agents
JOP20200115A1 (en) 2014-10-10 2017-06-16 Alnylam Pharmaceuticals Inc Compositions And Methods For Inhibition Of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression
JOP20200092A1 (en) 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc HEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
CN113846101A (en) 2014-11-17 2021-12-28 阿尔尼拉姆医药品有限公司 Apolipoprotein C3(APOC3) iRNA compositions and methods of use thereof
CN107106493A (en) 2014-11-21 2017-08-29 西北大学 The sequence-specific cellular uptake of spherical nucleic acid nano particle conjugate
CA2970795A1 (en) 2014-12-18 2016-06-23 Alnylam Pharmaceuticals, Inc. Reversir compounds
US10704043B2 (en) 2015-01-14 2020-07-07 Exicure, Inc. Nucleic acid nanostructures with core motifs
WO2016130806A2 (en) 2015-02-13 2016-08-18 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
US9828601B2 (en) 2015-02-27 2017-11-28 Idera Pharmaceuticals, Inc. Compositions for inhibiting checkpoint gene expression and uses thereof
PT3277815T (en) 2015-04-03 2021-11-11 Beth Israel Deaconess Medical Ct Inc Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
EP3277811B1 (en) 2015-04-03 2020-12-23 University of Massachusetts Fully stabilized asymmetric sirna
ES2808750T3 (en) 2015-04-03 2021-03-01 Univ Massachusetts Oligonucleotide compounds targeting huntingtin mRNA
EP3307316A1 (en) 2015-06-12 2018-04-18 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
AU2016280709B2 (en) 2015-06-15 2022-09-15 Mpeg La, Llc Defined multi-conjugate oligonucleotides
DE102015008536A1 (en) * 2015-07-02 2017-01-05 Rheinische Friedrich-Wilhelms-Universität Bonn Discontinuous oligonucleotide ligands
US20170009230A1 (en) * 2015-07-08 2017-01-12 Idera Pharmaceuticals, Inc. Compositions for inhibiting dux4 gene expression and uses thereof
WO2017011286A1 (en) 2015-07-10 2017-01-19 Alnylam Pharmaceuticals, Inc. Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
CA2995110A1 (en) 2015-08-14 2017-02-23 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
SG10202007937SA (en) 2015-09-02 2020-09-29 Alnylam Pharmaceuticals Inc PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
SK500652015A3 (en) 2015-10-15 2017-05-03 Ústav Polymérov Sav A method for altering the functional state of mRNA allowing its selective and specific recognition
US20170145412A1 (en) * 2015-11-04 2017-05-25 Idera Pharmaceuticals, Inc. Compositions for inhibiting nlrp3 gene expression and uses thereof
CA3011894A1 (en) 2016-01-31 2017-08-03 University Of Massachusetts Branched oligonucleotides
KR102617833B1 (en) 2016-05-06 2023-12-27 엑시큐어 오퍼레이팅 컴퍼니 Liposomal spherical nucleic acid (SNA) construct presenting antisense oligonucleotides (ASO) for specific knockdown of interleukin 17 receptor mRNA
WO2017205384A1 (en) * 2016-05-23 2017-11-30 Idera Pharmaceuticals, Inc. Compositions and methods for inhibiting target rna expression
JP2019518028A (en) 2016-06-10 2019-06-27 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Complement component C5i RNA composition and its use for treating paroxysmal nocturnal hemoglobinuria (PNH)
EP3496758A4 (en) 2016-08-12 2020-11-11 University of Massachusetts Conjugated oligonucleotides
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
TW202313978A (en) 2016-11-23 2023-04-01 美商阿尼拉製藥公司 Serpina1 irna compositions and methods of use thereof
EP3555292A1 (en) 2016-12-16 2019-10-23 Alnylam Pharmaceuticals, Inc. Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
WO2018201090A1 (en) 2017-04-28 2018-11-01 Exicure, Inc. Synthesis of spherical nucleic acids using lipophilic moieties
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
AU2018301477A1 (en) 2017-07-13 2020-02-27 Alnylam Pharmaceuticals Inc. Lactate dehydrogenase a (LDHA) iRNA compositions and methods of use thereof
EP3710587A1 (en) 2017-11-16 2020-09-23 Alnylam Pharmaceuticals, Inc. Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
EP3714054A1 (en) 2017-11-20 2020-09-30 Alnylam Pharmaceuticals, Inc. Serum amyloid p component (apcs) irna compositions and methods of use thereof
KR20200110655A (en) 2017-12-18 2020-09-24 알닐람 파마슈티칼스 인코포레이티드 High mobility group box-1 (HMGB1) IRNA composition and method of use thereof
MX2020011570A (en) 2018-05-07 2020-11-24 Alnylam Pharmaceuticals Inc Extrahepatic delivery.
TW202016304A (en) 2018-05-14 2020-05-01 美商阿尼拉製藥公司 Angiotensinogen (agt) irna compositions and methods of use thereof
BR112020021266A2 (en) * 2018-05-31 2021-01-26 Daiichi Sankyo Company, Limited human anti-tlr7 antibody
KR20210093227A (en) 2018-08-10 2021-07-27 유니버시티 오브 매사추세츠 Modified oligonucleotides targeting SNPs
AU2019344776A1 (en) 2018-09-18 2021-01-21 Alnylam Pharmaceuticals, Inc. Ketohexokinase (KHK) iRNA compositions and methods of use thereof
TW202028465A (en) 2018-09-28 2020-08-01 美商阿尼拉製藥公司 Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
AU2020239987A1 (en) * 2019-03-15 2021-11-04 University Of Massachusetts Oligonucleotides for tissue specific ApoE modulation
WO2020227395A2 (en) 2019-05-06 2020-11-12 University Of Massachusetts Anti-c9orf72 oligonucleotides and related methods
CA3138915A1 (en) 2019-05-17 2020-11-26 Alnylam Pharmaceuticals, Inc. Oral delivery of oligonucleotides
WO2021022108A2 (en) 2019-08-01 2021-02-04 Alnylam Pharmaceuticals, Inc. CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2021022109A1 (en) 2019-08-01 2021-02-04 Alnylam Pharmaceuticals, Inc. SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
EP4013870A1 (en) 2019-08-13 2022-06-22 Alnylam Pharmaceuticals, Inc. Small ribosomal protein subunit 25 (rps25) irna agent compositions and methods of use thereof
WO2021067747A1 (en) 2019-10-04 2021-04-08 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing ugt1a1 gene expression
WO2021076828A1 (en) 2019-10-18 2021-04-22 Alnylam Pharmaceuticals, Inc. Solute carrier family member irna compositions and methods of use thereof
WO2021081026A1 (en) 2019-10-22 2021-04-29 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof
US20230040920A1 (en) 2019-11-01 2023-02-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing dnajb1-prkaca fusion gene expression
JP2023500661A (en) 2019-11-01 2023-01-10 アルナイラム ファーマシューティカルズ， インコーポレイテッド HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
WO2021092145A1 (en) 2019-11-06 2021-05-14 Alnylam Pharmaceuticals, Inc. Transthyretin (ttr) irna composition and methods of use thereof for treating or preventing ttr-associated ocular diseases
KR20220110749A (en) 2019-11-06 2022-08-09 알닐람 파마슈티칼스 인코포레이티드 extrahepatic transmission
MX2022005692A (en) 2019-11-13 2022-06-08 Alnylam Pharmaceuticals Inc Methods and compositions for treating an angiotensinogen- (agt-) associated disorder.
US20230056569A1 (en) 2019-11-22 2023-02-23 Alnylam Pharmaceuticals, Inc. Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
IL293824A (en) 2019-12-13 2022-08-01 Alnylam Pharmaceuticals Inc Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof
TW202138559A (en) 2019-12-16 2021-10-16 美商阿尼拉製藥公司 Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
WO2021154941A1 (en) 2020-01-31 2021-08-05 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
IL295445A (en) 2020-02-10 2022-10-01 Alnylam Pharmaceuticals Inc Compositions and methods for silencing vegf-a expression
WO2021167841A1 (en) 2020-02-18 2021-08-26 Alnylam Pharmaceuticals, Inc. Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
EP4114947A1 (en) 2020-03-05 2023-01-11 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
CA3174725A1 (en) 2020-03-06 2021-09-10 Alnylam Pharmaceuticals, Inc. Ketohexokinase (khk) irna compositions and methods of use thereof
EP4121534A1 (en) 2020-03-18 2023-01-25 Alnylam Pharmaceuticals, Inc. Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
JP2023519274A (en) 2020-03-26 2023-05-10 アルナイラム ファーマシューティカルズ， インコーポレイテッド CORONAVIRUS iRNA COMPOSITIONS AND METHODS OF USE THEREOF
US20230190785A1 (en) 2020-03-30 2023-06-22 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing dnajc15 gene expression
CA3179411A1 (en) 2020-04-06 2021-10-14 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing myoc expression
WO2021206922A1 (en) 2020-04-07 2021-10-14 Alnylam Pharmaceuticals, Inc. Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
WO2021206917A1 (en) 2020-04-07 2021-10-14 Alnylam Pharmaceuticals, Inc. ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
MX2022012561A (en) 2020-04-07 2022-11-07 Alnylam Pharmaceuticals Inc Compositions and methods for silencing scn9a expression.
MX2022013525A (en) 2020-04-27 2023-01-24 Alnylam Pharmaceuticals Inc Apolipoprotein e (apoe) irna agent compositions and methods of use thereof.
BR112022021136A2 (en) 2020-04-30 2022-11-29 Alnylam Pharmaceuticals Inc COMPLEMENT FACTOR B IRNA COMPOSITIONS (CFB) AND METHODS OF USE THEREOF
EP4153746A1 (en) 2020-05-21 2023-03-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting marc1 gene expression
EP4162050A1 (en) 2020-06-09 2023-04-12 Alnylam Pharmaceuticals, Inc. Rnai compositions and methods of use thereof for delivery by inhalation
IL299063A (en) 2020-06-18 2023-02-01 Alnylam Pharmaceuticals Inc XANTHINE DEHYDROGENASE (XDH) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
US20230257745A1 (en) 2020-07-10 2023-08-17 Alnylam Pharmaceuticals, Inc. Circular siRNAs
WO2022066847A1 (en) 2020-09-24 2022-03-31 Alnylam Pharmaceuticals, Inc. Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
EP4225917A1 (en) 2020-10-05 2023-08-16 Alnylam Pharmaceuticals, Inc. G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof
CA3198823A1 (en) 2020-10-21 2022-04-28 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating primary hyperoxaluria
EP4232582A1 (en) 2020-10-23 2023-08-30 Alnylam Pharmaceuticals, Inc. Mucin 5b (muc5b) irna compositions and methods of use thereof
WO2022103999A1 (en) 2020-11-13 2022-05-19 Alnylam Pharmaceuticals, Inc. COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
EP4256053A1 (en) 2020-12-01 2023-10-11 Alnylam Pharmaceuticals, Inc. Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
WO2022125490A1 (en) 2020-12-08 2022-06-16 Alnylam Pharmaceuticals, Inc. Coagulation factor x (f10) irna compositions and methods of use thereof
WO2022147214A2 (en) 2020-12-31 2022-07-07 Alnylam Pharmaceuticals, Inc. Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
WO2022147223A2 (en) 2020-12-31 2022-07-07 Alnylam Pharmaceuticals, Inc. 2'-modified nucleoside based oligonucleotide prodrugs
EP4274896A1 (en) 2021-01-05 2023-11-15 Alnylam Pharmaceuticals, Inc. Complement component 9 (c9) irna compositions and methods of use thereof
KR20230146048A (en) 2021-02-12 2023-10-18 알닐람 파마슈티칼스 인코포레이티드 Superoxide dismutase 1 (SOD1) IRNA compositions and methods of using them to treat or prevent superoxide dismutase 1- (SOD1-)-related neurodegenerative diseases
EP4298220A1 (en) 2021-02-25 2024-01-03 Alnylam Pharmaceuticals, Inc. Prion protein (prnp) irna compositions and methods of use thereof
BR112023016645A2 (en) 2021-02-26 2023-11-14 Alnylam Pharmaceuticals Inc KETOHEXOKINASE (KHK) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
BR112023017737A2 (en) 2021-03-04 2023-10-03 Alnylam Pharmaceuticals Inc ANGIOPOIETIN-SIMILAR IRNA COMPOSITIONS 3 (ANGPTL3) AND METHODS OF USE THEREOF
EP4305169A1 (en) 2021-03-12 2024-01-17 Alnylam Pharmaceuticals, Inc. Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
IL307239A (en) 2021-03-29 2023-11-01 Alnylam Pharmaceuticals Inc Huntingtin (htt) irna agent compositions and methods of use thereof
EP4314293A1 (en) 2021-04-01 2024-02-07 Alnylam Pharmaceuticals, Inc. Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
IL307926A (en) 2021-04-26 2023-12-01 Alnylam Pharmaceuticals Inc Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof
EP4330396A1 (en) 2021-04-29 2024-03-06 Alnylam Pharmaceuticals, Inc. Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof
WO2022245583A1 (en) 2021-05-18 2022-11-24 Alnylam Pharmaceuticals, Inc. Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
WO2022256395A1 (en) 2021-06-02 2022-12-08 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
KR20240017911A (en) 2021-06-04 2024-02-08 알닐람 파마슈티칼스 인코포레이티드 Human chromosome 9 open reading frame 72 (C9orf72) iRNA preparation composition and method of using the same
AR126070A1 (en) 2021-06-08 2023-09-06 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING STARGARDT DISEASE AND/OR DISORDERS ASSOCIATED WITH RETINOL BORDER PROTEIN 4 (RBP4)
TW202315943A (en) 2021-06-23 2023-04-16 麻薩諸塞大學 Optimized anti-flt1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
KR20240026203A (en) 2021-06-30 2024-02-27 알닐람 파마슈티칼스 인코포레이티드 Methods and compositions for treating angiotensinogen (AGT)-related disorders
WO2023283403A2 (en) 2021-07-09 2023-01-12 Alnylam Pharmaceuticals, Inc. Bis-rnai compounds for cns delivery
TW202333748A (en) 2021-07-19 2023-09-01 美商艾拉倫製藥股份有限公司 Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder
KR20240036041A (en) 2021-07-21 2024-03-19 알닐람 파마슈티칼스 인코포레이티드 Metabolic Disorder-Associated Target Gene iRNA Composition and Methods of Using Same
WO2023003995A1 (en) 2021-07-23 2023-01-26 Alnylam Pharmaceuticals, Inc. Beta-catenin (ctnnb1) irna compositions and methods of use thereof
WO2023009687A1 (en) 2021-07-29 2023-02-02 Alnylam Pharmaceuticals, Inc. 3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof
AU2022323090A1 (en) 2021-08-03 2024-02-01 Alnylam Pharmaceuticals, Inc. Transthyretin (ttr) irna compositions and methods of use thereof
TW202337474A (en) 2021-08-04 2023-10-01 美商艾拉倫製藥股份有限公司 Irna compositions and methods for silencing angiotensinogen (agt)
CA3228733A1 (en) 2021-08-13 2023-02-16 Alnylam Pharmaceuticals, Inc. Factor xii (f12) irna compositions and methods of use thereof
WO2023044370A2 (en) 2021-09-17 2023-03-23 Alnylam Pharmaceuticals, Inc. Irna compositions and methods for silencing complement component 3 (c3)
CA3232420A1 (en) 2021-09-20 2023-03-23 Alnylam Pharmaceuticals, Inc. Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
WO2023064530A1 (en) 2021-10-15 2023-04-20 Alnylam Pharmaceuticals, Inc. Extra-hepatic delivery irna compositions and methods of use thereof
WO2023076450A2 (en) 2021-10-29 2023-05-04 Alnylam Pharmaceuticals, Inc. HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
AU2022378567A1 (en) 2021-10-29 2024-04-11 Alnylam Pharmaceuticals, Inc. Complement factor b (cfb) irna compositions and methods of use thereof
WO2023141314A2 (en) 2022-01-24 2023-07-27 Alnylam Pharmaceuticals, Inc. Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
WO2024006999A2 (en) 2022-06-30 2024-01-04 Alnylam Pharmaceuticals, Inc. Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
WO2024059165A1 (en) 2022-09-15 2024-03-21 Alnylam Pharmaceuticals, Inc. 17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
WO2024073732A1 (en) 2022-09-30 2024-04-04 Alnylam Pharmaceuticals, Inc. Modified double-stranded rna agents

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232074A1 (en) * 2002-04-04 2003-12-18 Coley Pharmaceutical Gmbh Immunostimulatory G, U-containing oligoribonucleotides
US20080171712A1 (en) * 2006-04-07 2008-07-17 Idera Pharmaceuticals, Inc. Stabilized immune modulatory rna (simra) compounds for tlr7 and tlr8
US20090060898A1 (en) * 2005-10-12 2009-03-05 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
US20100215642A1 (en) * 2009-02-10 2010-08-26 Idera Pharmaceuticals, Inc. Synthetic rna-based agonists of tlr7

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721218A (en) 1989-10-23 1998-02-24 Gilead Sciences, Inc. Oligonucleotides with inverted polarity
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US6204027B1 (en) 1992-02-26 2001-03-20 University Of Massachusetts Worcester Ribozymes having 2′-O substituted nucleotides in the flanking sequences
US6346614B1 (en) 1992-07-23 2002-02-12 Hybridon, Inc. Hybrid oligonucleotide phosphorothioates
TW244371B (en) 1992-07-23 1995-04-01 Tri Clover Inc
US5652355A (en) * 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
KR970703357A (en) 1994-06-01 1997-07-03 다알렌 반스톤 BRANCHED OLIGONU-CLEOTIDES AS PATHOGEN-INHIBITORY AGENTS As Pathogen-Inhibitor
US5652356A (en) 1995-08-17 1997-07-29 Hybridon, Inc. Inverted chimeric and hybrid oligonucleotides
US5912332A (en) 1996-07-26 1999-06-15 Hybridon, Inc. Affinity-based purification of oligonucleotides using soluble multimeric oligonucleotides
AU3465599A (en) 1998-04-01 1999-10-18 Hybridon, Inc. Mixed-backbone oligonucleotides containing pops blocks to obtain reduced phosphorothioate content
AU770615B2 (en) * 1999-03-31 2004-02-26 Hybridon, Inc. Pseudo-cyclic oligonucleobases
WO2003035836A2 (en) * 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
JP2005527219A (en) * 2002-05-24 2005-09-15 シジェン インコーポレイテッド Parallel double strands of deoxyribonucleic acid and methods of use thereof
US7851453B2 (en) * 2003-01-16 2010-12-14 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
KR101126030B1 (en) * 2003-07-15 2012-03-19 이데라 파마슈티칼즈, 인코포레이티드 Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy
CN101094594B (en) * 2003-12-08 2012-08-15 海布里顿公司 Modulation of immunostimulatory properties by small oligonucleotide-based compounds
WO2005083084A1 (en) * 2004-02-25 2005-09-09 Syddansk Universitet Intercalating triplex forming oligonucleotide derivatives and process for the preparation thereof
CN101821412A (en) * 2007-08-15 2010-09-01 艾德拉药物股份有限公司 TOLL sample receptor modulators

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232074A1 (en) * 2002-04-04 2003-12-18 Coley Pharmaceutical Gmbh Immunostimulatory G, U-containing oligoribonucleotides
US20090060898A1 (en) * 2005-10-12 2009-03-05 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
US20080171712A1 (en) * 2006-04-07 2008-07-17 Idera Pharmaceuticals, Inc. Stabilized immune modulatory rna (simra) compounds for tlr7 and tlr8
US20100215642A1 (en) * 2009-02-10 2010-08-26 Idera Pharmaceuticals, Inc. Synthetic rna-based agonists of tlr7

Also Published As

Publication number Publication date
HRP20150566T1 (en) 2015-07-17
HUE026020T2 (en) 2016-05-30
DK2470656T3 (en) 2015-06-22
US8431544B1 (en) 2013-04-30
PL2470656T3 (en) 2015-08-31
EP3272870A1 (en) 2018-01-24
CN102712926A (en) 2012-10-03
CN102712926B (en) 2015-04-29
US20110082186A1 (en) 2011-04-07
SMT201500140B (en) 2015-09-07
EP2470656B1 (en) 2015-05-06
HK1210223A1 (en) 2016-04-15
JP2013507905A (en) 2013-03-07
CN104673795A (en) 2015-06-03
EP2960333A1 (en) 2015-12-30
EP2960333B1 (en) 2017-10-04
EP2470656A1 (en) 2012-07-04
ES2538347T3 (en) 2015-06-19
PT2470656E (en) 2015-07-16
SI2470656T1 (en) 2015-07-31
JP5805088B2 (en) 2015-11-04
WO2011031520A1 (en) 2011-03-17
CA2772352A1 (en) 2011-03-17
ES2646097T3 (en) 2017-12-12

Similar Documents

Publication Publication Date Title
US8431544B1 (en) Compositions for inhibiting gene expression and uses thereof
AU2008279509B2 (en) Stabilized immune modulatory RNA (SIMRA) compounds
EP2021008B1 (en) Stabilized immune modulatory rna (simra) compounds for tlr7 and tlr8
US20100092486A1 (en) Modulation of myeloid differentation primary response gene 88 (myd88) expression by antisense oligonucleotides
AU2010213795A1 (en) Synthetic RNA-based agonists of TLR7
MX2011001050A (en) Modulation of toll-like receptor 9 expression by antisense oligonucleotides.
US20170009230A1 (en) Compositions for inhibiting dux4 gene expression and uses thereof
US8877722B2 (en) Compositions for inhibiting gene expression and uses thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: IDERA PHARMACEUTICALS, INC, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:AGRAWAL, SUDHIR;KANDIMALLA, EKAMBAR;PUTTA, MALLIKARJUNA;AND OTHERS;SIGNING DATES FROM 20110325 TO 20110406;REEL/FRAME:027026/0348

AS Assignment

Owner name: IDERA PHARMACEUTICALS, INC, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:AGRAWAL, SUDHIR;KANDIMALLA, EKAMBAR;PUTTA, MALLIKARJUNA;AND OTHERS;SIGNING DATES FROM 20110325 TO 20110406;REEL/FRAME:027031/0628

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION